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Abstract 
Tolerogenic dendritic cells are monocyte-derived dendritic cells (DC) cultured 
such that they adopt an immunoregulatory phenotype. In vitro, these cells are 
able to induce and maintain T cell tolerance through deviation of naive T cells to 
an anti-inflammatory phenotype and induction of anergy in memory T cells. 
Equivalent cells suppress established arthritis in murine models and tolerogenic 
DC are presently the subject of a phase I safety and efficacy trial at Newcastle 
University as part of the AutoDeCRA study. However, in spite of these 
promising data, we are yet to rigorously explore the basis of the phenotype of 
tolerogenic DC and lack markers to unequivocally distinguish them from other 
types of DC. 
This body of work is concerned with the development of a workflow to enable 
these questions to be addressed using mass spectrometry-based quantitative 
proteomics. Specifically, methods have been optimized and validated to enable 
a) enrichment and proteolytic digestion of membrane proteins, favouring their 
detection over more abundant cytoplasmic and nuclear proteins in LC/MS; b) 
differential stable isotope labelling of peptide N- and C-termini, enabling 
‘isobaric peptide termini labelling’-based relative quantitation at the MS2 level; 
c) pipette-tip based anion exchange fractionation of IPTL-labelled peptides prior 
to LC/MS analysis, broadening depth of proteome coverage. Efforts to apply 
aspects of the workflow to perform quantitative comparisons of the whole cell 
proteomes and qualitative profiling of the membrane proteomes of mature and 
tolerogenic DC are also documented. 
It is envisaged that future application of this optimized workflow as a whole will 
enable the identification and relative quantitation of significant numbers of 
mature and tolerogenic DC plasma membrane proteins. Differentially expressed 
proteins of interest identified through this approach may then be further 
investigated for putative roles in tolerance induction. 
  
iii 
 
Contents 
  
iv 
 
Abstract  ......................................................................................................... ii 
Figures and Tables ............................................................................................ xi 
Abbreviations ................................................................................................... xxii 
 
Chapter 1. Introduction ...................................................................................... 1 
 
1.1. Proteomics ............................................................................................. 2 
1.1.1. Top-down or bottom-up? ................................................................ 3 
1.1.2. The Bottom-up Proteomics Workflow............................................. 4 
1.1.2.1. Protein Extraction and Isolation ............................................... 6 
1.1.2.2. Protein Fractionation ............................................................... 6 
1.1.2.3. Protein Digestion ..................................................................... 7 
1.1.2.4. Peptide Fractionation ............................................................... 8 
1.1.2.5. Mass Spectrometry .................................................................. 9 
1.1.2.5.1. Ion Sources ..................................................................... 9 
1.1.2.5.2. Mass Analysers ............................................................. 10 
1.1.2.6. Mass Spectrometric Peptide Analysis ................................... 12 
1.1.2.6.1. Peptide mass fingerprinting ........................................... 12 
1.1.2.6.2. Accurate mass and time tag .......................................... 12 
1.1.2.6.3. Tandem mass spectrometry .......................................... 13 
1.1.2.6.3.1. Precursor Ion Selection .......................................... 15 
1.1.2.6.3.2. Precursor Ion Fragmentation .................................. 15 
1.1.2.6.3.3. Precursor Ion Identification ..................................... 16 
1.1.2.6.3.4. Protein Identification ............................................... 18 
1.1.3. Plasma Membrane Proteomics .................................................... 19 
1.1.3.1. Types of Membrane Protein .................................................. 19 
1.1.3.2. Challenges of Plasma Membrane Proteomics ....................... 20 
1.1.3.3. Plasma Membrane Protein Enrichment ................................. 21 
1.1.3.4. Plasma Membrane Protein Solubilization and Digestion ....... 23 
1.1.3.4.1. Detergents .................................................................... 23 
1.1.3.4.2. Chaotropes ................................................................... 25 
1.1.3.4.3. Solvents and Acids........................................................ 25 
1.1.3.4.4. Integrated Workflows .................................................... 25 
1.1.4. Quantitative Proteomics ............................................................... 27 
1.1.4.1. Label-based Quantitative Proteomics (MS1) ......................... 29 
v 
 
1.1.4.1.1. Chemical Labelling ........................................................ 29 
1.1.4.1.2. Enzymatic Labelling ...................................................... 29 
1.1.4.1.3. Metabolic Labelling ....................................................... 30 
1.1.4.2. Label-based Quantitative Proteomics (MS2) ......................... 31 
1.1.4.3. Absolute Quantitation ............................................................ 32 
1.1.4.4. Label Free Quantitative Proteomics ...................................... 32 
1.1.4.5. Quantitation Software ............................................................ 33 
 
1.2. Dendritic Cells ...................................................................................... 35 
1.2.1. Dendritic cells and immunological tolerance ................................ 35 
1.2.2. Functional specialization of dendritic cell subsets ........................ 36 
1.2.3. Dendritic cells in immunity and tolerance ..................................... 37 
1.2.3.1. Dendritic cells in immunity ..................................................... 37 
1.2.3.2. Dendritic cells in tolerance ..................................................... 38 
1.2.4. Mechanisms of tolerance induction .............................................. 41 
1.2.5. Molecules of tolerance induction .................................................. 42 
1.2.6. Using tolerogenic dendritic cells to treat autoimmune disease .... 43 
1.2.7. Autologous Dendritic Cells for Rheumatoid Arthritis - the 
AuToDeCRA study at Newcastle University ................................ 45 
1.2.8. Exploring the cell surface phenotype of tolerogenic dendritic cells48 
1.2.9. Previous dendritic cell proteomic studies ..................................... 48 
1.2.9.1. Proteomics of DC maturation ................................................ 49 
1.2.9.2. Proteomics of differentially matured DC ................................ 50 
 
Chapter 2. Aims and Objectives ...................................................................... 53 
 
Chapter 3. Methods ......................................................................................... 55 
 
3.1. Cell culture ........................................................................................... 56 
3.1.1. Jurkat T cells ................................................................................ 56 
3.1.2. Isolation of cells from peripheral blood ........................................ 56 
3.1.3. Generation of dendritic cell populations ....................................... 56 
3.2. Protein extraction and isolation ............................................................ 57 
3.2.1. Whole cell lysate preparation (in-solution digestion) .................... 57 
3.2.2. Whole cell lysate preparation (FASP) .......................................... 57 
vi 
 
3.2.3. Cell surface protein isolation with EZ-Link® Sulfo-NHS-SS Biotin 
and RevAmine ............................................................................. 58 
3.2.4. Membrane preparation using ‘stepwise depletion’ ....................... 59 
3.3. Protein Digestion .................................................................................. 61 
3.3.1. Detergent removal from whole cell lysates for in-solution 
digestion ................................................................................ 61 
3.3.2. In-solution digestion of BSA / whole cell lysates .......................... 61 
3.3.3. In-solution digestion of ‘stepwise depletion’ membrane 
preparations ................................................................................. 62 
3.3.4. FASP digestion of whole cell lysates and ‘stepwise depletion’ 
membrane preparations ............................................................... 63 
3.4. Peptide Labelling .................................................................................. 65 
3.4.1. Desalting of digests prior to peptide labelling ............................... 65 
3.4.2. C-terminal 18O labelling ................................................................ 65 
3.4.3. Lysine guanidination  N-terminal-specific succinylation ............ 66 
3.4.4. A novel isobaric peptide termini labelling protocol ....................... 69 
3.5. Peptide Fractionation ........................................................................... 70 
3.5.1. Isoelectric Focussing ................................................................... 70 
3.5.2. StageTip-based SAX fractionation ............................................... 71 
3.6. Desalting of peptides prior to LC-MS analysis ...................................... 72 
3.7. LC-MS/MS analysis .............................................................................. 73 
3.8. Data analysis ........................................................................................ 77 
3.9. Miscellaneous ...................................................................................... 79 
3.9.1. BSA labelling with EZ-Link® Sulfo-NHS-SS Biotin and RevAmine79 
3.9.2. MALDI-TOF-MS of EZ-Link® Sulfo-NHS-SS Biotin and RevAmine-
labelled BSA ................................................................................ 79 
3.9.3. Fluorescence confocal microscopy of EZ-Link® Sulfo-NHS-SS 
Biotin and RevAmine-labelled cells .............................................. 80 
 
Chapter 4. Development and validation of a membrane enrichment and 
digestion protocol to favour mass spectrometric identification of 
membrane proteins ........................................................................ 81 
 
4.1. Introduction .......................................................................................... 82 
4.1.1. Challenges of membrane proteomics .......................................... 82 
vii 
 
4.1.2. Criteria for evaluation of the effectiveness of a membrane protein 
enrichment and digestion strategy ............................................... 83 
4.1.3. Amine-directed biotinylation reagents .......................................... 85 
4.2. Results ................................................................................................. 89 
4.2.1. Characterisation of RevAmine - a novel amine-directed 
biotinylation reagent ..................................................................... 89 
4.2.1.1. MALDI-TOF analysis demonstrates facile conjugation of 
RevAmine tag to intact BSA .................................................. 89 
4.2.1.2. LC-MS analysis demonstrates facile conjugation and traceless 
removal of RevAmine tag to and from intact BSA prior to 
tryptic digestion...................................................................... 91 
4.2.1.3. Fluorescence confocal microscopy shows RevAmine and EZ-
LinkTM Sulfo-NHS-SS-Biotin are equally adept at biotinylating 
cell surface proteins in situ. ................................................... 97 
4.2.2. Evaluation of the suitability of amine-directed biotinylation 
reagents as tools for enrichment of cell surface proteins for 
analysis by mass spectrometry. ................................................... 99 
4.2.2.1. Filter-Aided Sample Preparation (FASP) performs as 
effectively as standard in-solution digestion for processing of 
whole cell lysates for LC-MS analysis. ................................ 100 
4.2.2.2. Use of ‘EZ-Link™’ Sulfo-NHS-SS-Biotin and RevAmine to 
enrich for plasma membrane proteins prior to LC-MS analysis 
produces only a small increase in percentage of plasma 
membrane protein IDs ......................................................... 103 
4.2.2.3. The limited enrichment of plasma membrane proteins in 
membrane fractions prepared using cell surface biotinylation-
based approaches is likely due to biotinylation of intracellular 
proteins ................................................................................ 110 
4.2.3. Evaluation of the suitability of subcellular fractionation protocols for 
enrichment of cell surface proteins for analysis by mass 
spectrometry. ............................................................................. 115 
4.2.3.1. Crude membrane preparations processed using sequential 
extraction in high salt, high pH and urea-containing buffers 
yield a more significant increase in percentage of membrane 
protein IDs ........................................................................... 115 
viii 
 
4.2.3.2. Filter-Aided Sample Preparation (FASP) performs more 
effectively than standard in-solution digestion for processing of 
crude membrane fractions prepared using ‘stepwise depletion’ 
for LC-MS analysis .............................................................. 120 
4.3. Discussion .......................................................................................... 122 
 
Chapter 5. Development and validation of an isobaric peptide termini labelling-
based method to facilitate relative quantitative proteomics between 
two samples ................................................................................. 131 
 
5.1. Introduction ........................................................................................ 132 
5.1.1. Requirement for development and validation of alternative stable 
isotope labelling methods .......................................................... 132 
5.1.2. Strategy for development and validation of alternative stable 
isotope labelling methods .......................................................... 133 
5.2. 18O Labelling ...................................................................................... 134 
5.2.1. ‘Optimal’ 18O Labelling ............................................................... 137 
5.2.2. Results and Discussion.............................................................. 139 
5.2.2.1. Development of a protocol for optimal C-terminal 18O-labelling 
of peptides ........................................................................... 139 
5.2.2.2. Decoupling the carboxyl oxygen exchange reaction from 
hydrolysis and performing it at pH4.5 with soluble trypsin 
facilitates labelling of all peptides with two 18O atoms. ........ 139 
5.2.2.3. Reducing and alkylating labelled samples with high 
concentrations of DTT and iodoacetamide prior to 
resuspension in 16O-based buffers completely abrogates 
trypsin-catalysed back exchange in labelled peptides. ........ 143 
5.2.2.4. Low pH causes small amounts of acid-catalysed back 
exchange in labelled peptides completely independently of 
trypsin. ................................................................................. 146 
5.2.2.5. Optimised protocol for C-terminal 18O labelling of peptides . 148 
5.2.2.6. Examination of the ability of C-terminal 18O-labelling to 
quantify differences between labelled and unlabelled 
proteomic peptides across a wide dynamic range. .............. 148 
5.3. Isobaric Peptide Termini Labelling ..................................................... 158 
ix 
 
5.3.1. ‘Optimal’ N-Terminal Labelling ................................................... 160 
5.3.2. Results and Discussion.............................................................. 161 
5.3.2.1. Development of a protocol for optimal N-terminal succinylation 
of peptides ........................................................................... 161 
5.3.2.2. Peptides cannot be N-terminally succinylated whilst bound to a 
solid phase extraction column without significant succinylation 
of lysine side chains. ........................................................... 162 
5.3.2.3. Peptides can be specifically guanidinated on lysine side 
chains whilst bound to a solid phase extraction column ...... 165 
5.3.2.4. Guanidination of lysine side chains renders subsequent 
succinylation N-terminal specific.......................................... 167 
5.3.2.5. Optimised protocol for N-terminal succinylation of peptides 170 
5.3.2.6. Examination of the ability of isobaric peptide termini labelling 
employing both N-terminal succinylation and C-terminal 18O 
labelling to quantify differences between labelled and 
unlabelled BSA and proteomic peptides across a wide 
dynamic range ..................................................................... 170 
 
Chapter 6. Evaluation of the suitability of OFFGEL fractionation and StageTip-
based SAX fractionation as the first dimension of separation for 
analysis of complex mixtures of proteomic peptides .................... 175 
 
6.1. Introduction ........................................................................................ 176 
6.2. OFFGEL Fractionation ....................................................................... 177 
6.2.1. Results ....................................................................................... 178 
6.2.1.1. OFFGEL Fractionation can be used as the first dimension of 
separation for 18O-based quantitative proteomic experiments.178 
6.2.1.2. OFFGEL Fractionation is less effective when used as the first 
dimension of separation for IPTL-based quantitative proteomic 
experiments. ........................................................................ 181 
6.3. StageTip-based SAX Fractionation .................................................... 186 
6.3.1. Results ....................................................................................... 187 
6.3.1.1. Evaluation of StageTip-based SAX fractionation as an 
alternative to OFFGEL Fractionation for first-dimensional 
separation of succinylated peptides ..................................... 187 
x 
 
6.3.1.2. StageTip-based SAX fractionation is an effective alternative to 
OFFGEL Fractionation for the first dimension of separation of 
unmodified and succinylated peptides ................................. 187 
6.3.1.3. Peptides bound to anion exchange resin in StageTip-based 
SAX fractionation appear to interact with the polystyrene 
sorbent of the resin in addition to the quaternary ammonium 
functional groups ................................................................. 191 
6.3.1.4. The ionic interactions of peptides with the resin in StageTip-
based SAX fractionation that appears to vary with successive 
decreases in pH is strongly affected by the presence of 
acetonitrile in the buffer ....................................................... 195 
6.4. Discussion .......................................................................................... 199 
 
Chapter 7. Application of optimized quantitative and membrane proteomics 
methods to mature and tolerogenic dendritic cells ....................... 201 
7.1. Introduction ........................................................................................ 202 
7.2. 18O-based quantitative profiling of the whole cell proteomes of mature 
and tolerogenic DC............................................................................. 203 
7.3. IPTL-based quantitative profiling of the whole cell proteomes of mature 
and tolerogenic DC............................................................................. 207 
7.4. Discussion (whole cell proteomes) ..................................................... 210 
7.5. Qualitative profiling of the membrane proteomes of mature and 
tolerogenic DC ................................................................................... 213 
7.6. Discussion (membrane proteomes) ................................................... 221 
 
Chapter 8. General Discussion ...................................................................... 225 
 
References  ................................................................................................... 2332 
 
  
xi 
 
Figures and Tables  
xii 
 
Figure 1: A general overview of the bottom-up proteomics workflow .................. 5 
 
Figure 2: MS/MS of a BSA-derived peptide with sequence HLVDEPQNLIK .... 14 
 
Figure 3: Fragmentation nomenclature for peptide ion cleavages along the 
polypeptide backbone ....................................................................................... 16 
 
Figure 4: Membrane protein nomenclature ....................................................... 20 
 
Figure 5: Quantitative proteomic strategies ...................................................... 28 
 
Figure 6: Dendritic cells in immunity and tolerance ........................................... 40 
 
Figure 7: Generation of mature and tolerogenic dendritic cells in the 
immunotherapy group at Newcastle University ................................................. 47 
 
Figure 8: SPE cartridge configuration for succinylation of bound peptides ....... 67 
 
Figure 9: SPE cartridge configuration for guanidination of bound peptides ...... 68 
 
Figure 10: Biotinylation of proteins using EZ-LinkTM Sulfo-NHS-SS-Biotin ........ 86 
 
Figure 11: Biotinylation of proteins using RevAmine ......................................... 88 
 
Figure 12: MALDI mass spectra showing intact mass measurements of a) 
unmodified  BSA; b) BSA modified with EZ-LinkTM Sulfo-NHS-SS Biotin; c) BSA 
modified with RevAmine ................................................................................... 90 
 
Figure 13: Unmodified and modified BSA peptides detected by LC-MS after 
tryptic digestion of EZ-LinkTM-modified BSA ..................................................... 93 
 
Figure 14: Unmodified and modified BSA peptides detected by LC-MS after 
tryptic digestion of RevAmine-modified BSA ..................................................... 94 
xiii 
 
Figure 15: Unmodified and modified BSA peptides detected by LC-MS after 
tryptic digestion followed by treatment with 0.1% (v/v) NH3 of EZ-Link
TM-
modified BSA .................................................................................................... 95 
 
Figure 16: Unmodified and modified BSA peptides detected by LC-MS after 
tryptic digestion followed by treatment with 0.1% (v/v) NH3 of RevAmine-
modified BSA .................................................................................................... 96 
 
Figure 17: In situ biotinylation of cell surface-exposed primary amine residues 
on Jurkat cells detected through staining with a Streptavidin – Alexa Fluor 568 
conjugate followed by fluorescence confocal microscopy ................................. 98 
 
Figure 18: Pie charts illustrating the distribution of cellular component ontologies 
of proteins identified from LC-MS analysis of a Jurkat whole cell lysate digested 
using a) in-solution digestion; b) FASP ........................................................... 102 
 
Figure 19: Pie charts illustrating the distribution of cellular component ontologies 
of proteins identified from LC-MS analysis of Jurkat membrane fractions 
prepared using the Pierce Cell Surface Isolation Kit as per supplied protocol but 
with Pierce Lysis and Wash Buffers substituted for 0.1 M TRIS-HCl (pH 7.4) 
supplemented with a) 1% (w/v) SDS; b) 2% (w/v) SDS; c) 4% (w/v) SDS ...... 105 
 
Figure 20: Pie charts illustrating the distribution of cellular component ontologies 
of proteins identified from LC-MS analysis of a) unlabelled; b) EZ-LinkTM- 
labelled; c) RevAmine-labelled Jurkat membrane fractions prepared using the 
Pierce Cell Surface Isolation Kit as per supplied protocol (using Pierce Lysis 
and Wash Buffers) ......................................................................................... 108 
 
Figure 21: Pie charts illustrating the distribution of cellular component ontologies 
of proteins identified from LC-MS analysis of a) unlabelled; b) EZ-LinkTM- 
labelled; c) RevAmine-labelled Jurkat membrane fractions prepared using the 
Pierce Cell Surface Isolation Kit with Pierce Lysis and Wash Buffers substituted 
for 0.1 M TRIS-HCl (pH 7.4) supplemented with 4% (w/v) SDS and increased 
incubation time for formation of the avidin-biotin interaction ........................... 109 
xiv 
 
Figure 22: Polyacrylamide gel electrophoresis of unprocessed, flow-through and 
eluate fractions of a) unlabelled Jurkat cell lysate; b) EZ-LinkTM-labelled Jurkat 
cell lysate processed using the Pierce Cell Surface Isolation Kit as per supplied 
protocol. .......................................................................................................... 112 
 
Figure 23: In situ biotinylation of cell surface-exposed primary amine residues 
on Jurkat cells detected through staining with a Streptavidin – Alexa Fluor 568 
conjugate followed by fluorescence confocal microscopy. a) EZ-LinkTM-labelled 
cells. b) RevAmine-labelled cells. All cells were also stained with DAPI prior to 
imaging ........................................................................................................... 114 
 
Figure 24: Pie charts illustrating the distribution of cellular component ontologies 
of proteins identified from LC-MS analysis of Jurkat membrane fractions 
prepared using three iterations of the ‘stepwise depletion’ procedure originally 
described by Wisniewski et al. a) cells lysed using Dounce homogenization and 
procedure performed in standard microcentrifuge tubes; b) cells lysed using 
Dounce homogenization and procedure performed in siliconized microcentrifuge 
tubes; c) cells lysed using freeze-thaw lysis and lysates homogenized using 
QiaShredder spin columns, procedure performed in siliconized microcentrifuge 
tubes ............................................................................................................... 119 
 
Figure 25: Pie charts illustrating the distribution of cellular component ontologies 
of proteins identified from LC-MS analysis of Jurkat membrane fractions 
prepared using the ‘stepwise depletion’ procedure and digested using a) FASP; 
b) In-solution digestion. ................................................................................... 121 
 
Figure 26: The two reactions which occur during trypsin-catalysed digestion of 
proteins to peptides in H2
18O water ................................................................. 134 
 
Figure 27: 18O-labelling of a BSA-derived peptide with sequence 
HLVDEPQNLIK ............................................................................................... 136 
 
Figure 28: Extent of incorporation of 18O atoms at the carboxyl termini of 10 
BSA peptides after a) 0 hours; b) 2 hours; c) 24 hours when the carboxyl 
xv 
 
oxygen exchange reaction is carried out in 50 mM ammonium bicarbonate (18O, 
pH 8) ............................................................................................................... 141 
 
Figure 29: Extent of incorporation of 18O atoms at the carboxyl termini of 10 
BSA peptides after a) 0 hours; b) 2 hours; c) 24 hours when the carboxyl 
oxygen exchange reaction is carried out in 50 mM ammonium bicarbonate (18O, 
pH 4.5) ............................................................................................................ 142 
 
Figure 30: Extent of trypsin-catalysed back exchange of 18O atoms for 16O 
atoms at the carboxyl termini of 10 fully 18O-labelled BSA peptides when 
vacuum-dried and resuspended in 50mM ammonium bicarbonate (16O, pH 4.5) 
and left at room temperature for 24 hours after a) no treatment; b) incubation at 
100ºC for 30 minutes; c) reduction with 20 mM DTT at 95ºC for 1 hour followed 
by alkylation with 40 mM iodoacetamide for 30 minutes ................................. 145 
 
Figure 31: Extent of trypsin-catalysed back exchange of 18O atoms for 16O 
atoms at the carboxyl termini of 10 fully 18O-labelled BSA peptides when 
vacuum-dried and resuspended in 50mM ammonium bicarbonate (16O, pH 4.5), 
acidified with 1% TFA and left at room temperature for 24 hours after a) no 
treatment; b) incubation at 100ºC for 30 minutes; c) reduction with 20mM DTT 
at 95ºC for 1 hour followed by alkylation with 40 mM iodoacetamide for 30 
minutes ........................................................................................................... 147 
 
Figure 32: Box and whisker plot showing distribution of protein ratios reported 
by Mascot Distiller when 18O-labelled and unlabelled proteomic peptides derived 
from mature DC whole cell lysate are combined in ratios ranging from 5 parts 
labelled : 1 part unlabelled through to 1 part labelled : 5 parts unlabelled ...... 150 
 
Figure 33: Relative quantitation of a proteomic peptide with sequence 
SLYASSPGGVYATR derived from unlabelled and 18O-labelled mature DC 
whole cell lysate combined in a 1:1 ratio ......................................................... 152 
 
Figure 34: Box and whisker plot showing distribution of unfiltered peptide ratios 
for a) all peptides assigned to proteins; b) all peptides with MS1 signal intensity 
greater than 104 assigned to proteins; c) all peptides with MS1 signal intensity 
xvi 
 
greater than 105 assigned to proteins; reported by Mascot Distiller when 18O-
labelled and unlabelled proteomic peptides derived from mature DC whole cell 
lysate are combined in ratios ranging from 5 parts labelled : 1 part unlabelled 
through to 1 part labelled : 5 parts unlabelled ................................................. 153 
 
Figure 35: Box and whisker plot showing distribution of filtered peptide ratios for 
a) all peptides assigned to proteins; b) all peptides with MS1 signal intensity 
greater than 104 assigned to proteins; c) all peptides with MS1 signal intensity 
greater than 105 assigned to proteins; reported by Mascot Distiller when 18O-
labelled and unlabelled proteomic peptides derived from mature DC whole cell 
lysate are combined in ratios ranging from 5 parts labelled : 1 part unlabelled 
through to 1 part labelled : 5 parts unlabelled ................................................. 154 
 
Figure 36: Isobaric peptide termini labelling of a BSA-derived peptide with 
sequence HLVDEPQNLIK .............................................................................. 159 
 
Figure 37: Succinylation of 10 BSA peptides when reacted with 20 mM succinic 
anhydride in 200 mM sodium acetate / 20 mM sodium hydroxide (pH 7.6) for a) 
5 minutes; b) 10 minutes; c) 15 minutes ......................................................... 163 
 
Figure 38: Guanidination of 10 BSA peptides when reacted with ~1 M O-
Methylisourea in 6.67% ammonia (pH ~11) at 65ºC for a) 10 minutes; b) 20 
minutes; c) 30 minutes .......................................................................................... 
 ........................................................................................................................ 166 
 
Figure 39: Modification states of 10 BSA peptides when reacted with ~1 M O-
Methylisourea in 6.67% ammonia (pH ~11) at 65ºC for 30 minutes and 
subsequently reacted with 20 mM succinic anhydride in 200 mM sodium acetate 
/ 20 mM sodium hydroxide (pH 7.6) for 15 minutes ........................................ 169 
 
Figure 40: Mascot fragmentation data of the peptide with sequence YLYEIAR 
and a mass consistent with a) single succinylation; b) double succinylation ... 169 
 
Figure 41: Box and whisker plot showing distribution of a) protein ratios; b) 
peptide ratios reported by Mascot when 13C4-succinylated and 
12C4-succinylated 
xvii 
 
/ 18O-labelled proteomic peptides derived from Jurkat whole cell lysate are 
combined in ratios ranging from 20:1 through to 1:20 ..................................... 172 
 
Figure 42: OFFGEL fractionation of ~50 µg peptides derived from an unlabelled 
mature DC whole cell lysate combined 1:1 with ~50 µg peptides from an 18O-
labelled tolerogenic DC whole cell lysate and fractionated on a pH 3-10 IEF 
strip. a) Total and total unique peptides identified in each well; b) & c) 
Redundancy of unique peptide identification across all 12 wells represented as 
a bar graph and a pie chart respectively ......................................................... 180 
 
Figure 43: OFFGEL fractionation of peptides derived from a 13C4-succinylated 
mature DC whole cell lysate combined 1:1 with a 12C4-succinylated / 
18O-
labelled tolerogenic DC whole cell lysate and fractionated on a pH 3-10 IEF 
strip. a) Total and total unique peptides identified in each well; b) & c) 
Redundancy of unique peptide identification across all 12 wells represented as 
a bar graph and a pie chart respectively ......................................................... 182 
 
Figure 44: OFFGEL fractionation of peptides derived from a 13C4-succinylated 
mature DC whole cell lysate combined 1:1 with a 12C4-succinylated / 
18O-
labelled tolerogenic DC whole cell lysate and fractionated on a pH 3-6 IEF strip. 
a) Total and total unique peptides identified in each well; b) & c) Redundancy of 
unique peptide identification across all 10 wells represented as a bar graph and 
a pie chart respectively ................................................................................... 185 
 
Figure 45: First StageTip-based SAX fractionation of 25 µg unlabelled peptides 
derived from a Jurkat whole-cell lysate. a) Total and total unique peptides 
identified in each fraction; b) & c) Redundancy of unique peptide identification 
across all 7 fractions represented as a bar graph and a pie chart respectively
 ........................................................................................................................ 189 
 
Figure 46: First StageTip-based SAX fractionation of 25 µg succinylated 
peptides derived from a Jurkat whole-cell lysate. a) Total and total unique 
peptides identified in each fraction; b) & c) Redundancy of unique peptide 
identification across all 7 fractions represented as a bar graph and a pie chart 
respectively ..................................................................................................... 190 
xviii 
 
Figure 47: Second StageTip-based SAX fractionation of 25 µg unlabelled 
peptides derived from a Jurkat whole-cell lysate. a) Total and total unique 
peptides identified in each fraction and in an equivalent amount of 
unfractionated material; b) & c) Redundancy of unique peptide identification 
across all 8 fractions represented as a bar graph and a pie chart respectively
 ........................................................................................................................ 193 
 
Figure 48: Second StageTip-based SAX fractionation of 25 µg succinylated 
peptides derived from a Jurkat whole-cell lysate. a) Total and total unique 
peptides identified in each fraction and in an equivalent amount of 
unfractionated material; b) & c) Redundancy of unique peptide identification 
across all 8 fractions represented as a bar graph and a pie chart respectively
 ........................................................................................................................ 194 
 
Figure 49: Third StageTip-based SAX fractionation of 25 µg unlabelled peptides 
derived from a Jurkat whole-cell lysate. a) Total and total unique peptides 
identified in each fraction and in an equivalent amount of unfractionated 
material; b) & c) Redundancy of unique peptide identification across all 13 
fractions represented as a bar graph and a pie chart respectively .................. 197 
 
Figure 50: Third StageTip-based SAX fractionation of 25 µg succinylated 
peptides derived from a Jurkat whole-cell lysate. a) Total and total unique 
peptides identified in each fraction and in an equivalent amount of 
unfractionated material; b) & c) Redundancy of unique peptide identification 
across all 13 fractions represented as a bar graph and a pie chart respectively
 ........................................................................................................................ 198 
 
Figure 51: Box and whisker plot showing distribution of a) protein ratios; b) 
peptide ratios reported by Mascot when 13C4-succinylated mature DC proteomic 
peptides and 12C4-succinylated / 
18O-labelled tolerogenic DC proteomic peptides 
are combined in a 1:1 ratio ............................................................................. 209 
 
Figure 52: Pie charts illustrating the distribution of cellular component ontologies 
of proteins identified from LC-MS analysis of a) mature DC membranes and b) 
xix 
 
tolerogenic DC membranes prepared using the optimized stepwise depletion 
enrichment method described in Chapter 4 and digested using FASP ........... 214 
 
Figure 53: Total ion chromatograms from LC-MS analysis of a) mature DC 
membranes and b) tolerogenic DC membranes ............................................. 215 
 
Figure 54: Extracted ion chromatograms (XICs) and MS/MS spectra for the 
CD32-derived peptide of interest with sequence VTFFQNGK. a) Mature DC 
XIC, b) tolerogenic DC XIC; c) mature DC MS/MS spectrum; d) tolerogenic DC 
MS/MS spectrum ............................................................................................ 224 
 
  
xx 
 
Table 1: Properties of mass analysers used for peptide analysis in bottom-up 
proteomics ........................................................................................................ 11 
 
Table 2: LC-MS settings used for experiments described in Chapters 4 - 7 ..... 75 
 
Table 3: Number of unique CAMthiopropanoylated peptides and proteins 
detected from membrane fractions prepared using EZ-LinkTM Sulfo-NHS-SS-
Biotin and processed with Pierce lysis and wash buffers and 4% (w/v) SDS 
respectively ..................................................................................................... 110 
 
Table 4: Comparison of reported percentages of membrane protein 
identifications with percentages of membrane protein identifications computed 
from STRAP GO annotation and TMHMM transmembrane helix predication of 
protein lists supplied in supplementary data  in publications citing high levels of 
membrane protein enrichment through various strategies .............................. 126 
 
Table 5: Reaction conditions used in previously published 18O-labelling 
proteomics papers .......................................................................................... 138 
 
Table 6: Scheme for combining labelled and unlabelled proteomic peptides to 
examine whether 18O-labelling is suitable for performing quantitative proteomic 
analyses .......................................................................................................... 148 
 
Table 7: Scheme for combining differentially labelled proteomic peptides to 
examine whether isobaric peptide termini labelling is suitable for performing 
quantitative proteomic analyses ...................................................................... 170 
 
Table 8: Proteins identified in 18O-based quantitative profiling of whole cell 
proteomes of mature and tolerogenic DCs with twofold or greater expression in 
mature DCs ..................................................................................................... 205 
 
Table 9: Proteins identified in 18O-based quantitative profiling of whole cell 
proteomes of mature and tolerogenic DCs with twofold or greater expression in 
tolerogenic DCs .............................................................................................. 206 
xxi 
 
Table 10: Proteins identified in IPTL-based quantitative profiling of whole cell 
proteomes of mature and tolerogenic DCs with twofold or greater expression in 
one cell type relative to the other .................................................................... 209 
 
Table 11: Proteins identified exclusively in mature DC membrane-enriched 
fraction ............................................................................................................ 217 
 
Table 12: Proteins identified exclusively in tolerogenic DC membrane-enriched 
fraction ............................................................................................................ 218 
 
Table 13: Proteins identified in both mature and tolerogenic DC membrane-
enriched fractions with emPAI scores suggesting differential expression ....... 219 
 
Table 14: Proteins identified in both mature and tolerogenic DC membrane-
enriched fractions with emPAI scores suggesting commensurate expression 220 
 
  
xxii 
 
Abbreviations 
(16)BAC/SDS-
PAGE 
Benzyldimethyl-n-hexadecylammonium Chloride/SDS-
PAGE 
AA Ammonium acetate 
ABC Ammonium bicarbonate 
AMT Accurate mass and time tag 
AuToDeCRA 
Autologous Tolerogenic Dendritic Cells for Rheumatoid 
Arthritis 
BN/SDS-
PAGE 
Blue native SDS PAGE 
BR Britton-Robinson 
BSA Bovine serum albumin 
BVR Biliverdin reductase 
C18 Octadecyl carbon chain 
CAD Collision-activated dissociation 
CCL19 Chemokine (C-C motif) ligand 19 
CCR7 Chemokine (C-C motif) receptor 7 
CD103 Cluster of differentiation 103 
CD14 Cluster of differentiation 14 
CD150 Cluster of differentiation 150 
CD154 Cluster of differentiation 154 
CD163 Cluster of differentiation 163 
CD1c Cluster of differentiation 1c 
CD25 Cluster of differentiation 25 
CD29 Cluster of differentiation 29 
CD299 Cluster of differentiation 299 
CD303 Cluster of differentiation 303 
CD317 Cluster of differentiation 317 
CD32a Cluster of differentiation 32a 
CD32b Cluster of differentiation 32b 
CD4 Cluster of differentiation 4 
CD40 Cluster of differentiation 40 
CD44 Cluster of differentiation 44 
CD45 Cluster of differentiation 45 
CD49c Cluster of differentiation 49c 
CD50 Cluster of differentiation 50 
CD63 Cluster of differentiation 63 
xxiii 
 
CD74 Cluster of differentiation 74 
CD8 Cluster of differentiation 8 
CD80 Cluster of differentiation 80 
CD83 Cluster of differentiation 83 
CD86 Cluster of differentiation 86 
cGMP Current good manufacturing practice 
CHAPS 
3-[(3-cholamidopropanyl)dimethylammonio]-1-
propanesulphonate 
CIA Collagen-induced arthritis 
CID Collision-induced dissociation 
CLR C-type lectin receptor 
CMC Critical micelle concentration 
CTLA4 Cytotoxic T lymphocyte antigen 4 
CXCR4 Chemokine (C-X-C motif) receptor 4 
DAMP Danger-associated molecular pattern 
DAPI 4',6-diamidino-2-phenylindole 
DC Dendritic cell 
DIGE Difference gel electrophoresis 
DMSO Dimethyl sulfoxide 
DTT Dithiothreitol 
EAE Experimental autoimmune encephalitis 
ECD Electron capture dissociation 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme-linked immunsorbent assay 
emPAI Exponentially modified protein abundance index 
ESI Electrospray ionization 
ETD Electron transfer dissociation 
FA Formic acid 
FACS Fluorescence-activated cell sorting 
FASP Filter-aided sample preparation 
FBS Fetal bovine serum 
FcγRI High affinity immunoglobulin gamma Fc receptor I 
FcγRIIA Low affinity immunoglobulin gamma Fc receptor II-a  
FcγRIIB Low affinity immunoglobulin gamma Fc receptor II-b 
FcγRIII Low affinity immunoglobulin gamma Fc receptor III 
FcεRIγ 
Fc fragment of IgE, high affinity I, receptor for gamma 
polypeptide 
xxiv 
 
FHA Filamentous haemagglutinin 
FoxP3 Forkhead box P3 
FSL-1 Mycoplasmal diacylated LPT, S-(2,3-bispalmitoyloxypropyl) 
FT-ICR Fourier transform ion cyclotron resonance 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GeLC-MS 1D SDS-PAGE followed by LC-MS 
GM-CSF Granulocyte macrophage colony-stimulating factor 
GO Gene Ontology 
GPI Glycosylphosphatidylinositol 
HA Haemagglutinin 
HBSS Hank’s balanced salt solution 
HEPES-NaOH 
4-(-2-hydroxyethyl)-1-piperazineethanesulfonic acid sodium 
hydroxide 
hESC Human embryonic stem cell 
HILIC Hydrophilic interaction liquid chromatography 
HIV-1 Human immunodeficiency virus type 1 
HPLC High performance liquid chromatography 
ICAT Isotope-coded affinity tag 
ICR Ion cyclotron resonance 
IDO Indoleamine 2,3-dioxygenase 
IEF Isoelectric focussing 
IFNγ Interferon gamma 
IgE Immunoglobulin E 
IgG Immunoglobulin G 
IL-10 Interleukin 10 
IL-12 Interleukin 12 
IL-23 Interleukin 23 
IL-27 Interleukin 27 
IL-4 Interleukin 4 
ILT Immunoglobulin-like transcript 
IMP Integral membrane protein 
IPG Immobilized pH gradient 
IPI International protein index 
IPTL Isobaric peptide termini labelling 
IT Ion trap 
iTRAQ Isobaric tags for relative and absolute quantification 
xxv 
 
iTreg ‘Adaptive’ regulatory T cell 
LC Liquid Chromatography 
LC-MS Liquid chromatography – mass spectrometry  
LCMV Lymphocytic choriomeningitis virus 
LPS Lipopolysaccharide 
LRS Leukocyte reduction system 
MALDI Matrix-assisted laser desorption/ionization 
MeOH Methanol 
MHC Major histocompatibility complex 
MLR Mixed lymphocyte reaction 
moDC Monocyte-derived dendritic cell 
MS Mass spectrometry 
MS/MS Tandem mass spectrometry 
MuDPIT Multi-dimensional protein identification technology 
MW Molecular weight 
MWCO Molecular weight cut off 
NF-κB Nuclear factor-kappa B 
NHS N-Hydroxysuccinimide 
NLR NOD-like receptor 
nTreg ‘Naturally-occurring’ regulatory T cell 
PAGE Polyacrylamide gel electrophoresis 
PAMP Pathogen-associated molecule pattern 
PBMC Peripheral blood mononuclear cell 
PBS Phosphate buffered saline 
PEG Polyethylene glycol 
PMF Peptide mass fingerprinting 
PPAR Peroxisome-proliferator activated receptor 
PRR Pattern recognition receptor 
PS Lysophosphatidylserine 
PSAQ Protein standard absolute quantification 
PSM Peptide-to-spectrum match 
Q Quadrupole 
QconCAT Quantification concatemer 
RA Retinoic acid 
RALDH Retinaldehyde dehydrogenase 
Rf Radiofrequency 
xxvi 
 
RLR Rig-I-like receptor 
RPLC Reversed phase liquid chromatography 
SAX Strong anion exchange chromatography 
SCX Strong cation exchange chromatography 
SD Standard deviation 
SDC Sodium deoxycholate 
SDS Sodium dodecyl sulphate 
shRNA Small hairpin RNA 
SILAC Stable isotope labelling by amino acids in cell culture 
siRNA Small interfering RNA 
SIRP-β-1 Signal regulatory protein beta-1 
SISCAPA 
Stable isotope standards and capture by anti-peptide 
antibodies 
SLAM Selected lymphocyte antibody method 
SOCS3 Suppressor of cytokine signalling 3 
SPE Solid phase extraction 
SRM Selected reaction monitoring 
STAT-3 Signal transducer and activator of transcription 3 
STAT-4 Signal transducer and activator of transcription 4 
Sulfo-NHS-SS-
Biotin 
Sulfosuccinimidyl-2-(biotinamido)ethyl-1,2-dithiopropionate 
TBS Tris buffered saline 
TCEP-HCl Tris(2-carboxyethyl)phosphine hydrochloride 
TcR T cell receptor 
TFA Trifluoroacetic acid 
TGF-β Transforming growth factor beta 
Th1 Type 1 helper T cell 
Th2 Type 2 helper T cell 
Th17 T helper 17 cell 
TIC Total ion chromatogram 
TLR Toll-like receptor 
TMD Transmembrane domain 
TMT Tandem mass tags 
TNFα Tumour necrosis factor alpha 
ToF Time-of-flight 
TRAIL TNF-related apoptosis-inducing ligand 
TRIS-HCl Trs(hydroxymethyl)aminomethane hydrochloride 
xxvii 
 
TRITC Tetramethyl rhodamine isothiocyanate 
WGA Wheat germ agglutinin 
XIC Extracted ion chromatogram 
 
  
1 
 
Chapter 1. Introduction  
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1.1. Proteomics 
The phrases ‘proteome’ and ‘proteomics’ first entered the scientific lexicon in 
1996 (Wilkins et al., 1996) and 1997 (James, 1997) respectively by way of 
analogy with the existing terms ‘genome’ and ‘genomics’. Each ‘omics’ is 
concerned with the study of a particular group of biological macromolecules and 
the ‘omics’ disciplines collectively share in common their conceptual approach 
of looking at these macromolecules through a holistic lens rather than a 
reductionist one (Kraj and Silberring, 2008). Thus genomics is the sequencing 
and analysis of genomes, whilst transcriptomics is the study of the transcription 
and post-transcriptional regulation of all mRNAs produced from a given 
genome. By extension, proteomics encompasses the study of the translation, 
function and post-translational regulation of all proteins produced from a given 
cellular complement of mRNAs.  
With each successive transfer of information from DNA through RNA to protein 
comes a concurrent expansion in complexity of the nature of the subsequent 
class of macromolecules and an increased degree of difficulty in scrutinizing 
said class of macromolecules as a whole. Genomics, concerned solely with 
DNA sequencing, is now a mature and well-established discipline, with 
complete genome sequences available for 1153 organisms as of February 16th 
2012 (Howald et al., 2012). Proteomics, on the other hand, must account for 
alternative splicing (which in itself has been suggested to produce 
approximately 100000 protein isoforms from approximately 20000 genes of the 
human genome (Gstaiger and Aebersold, 2009)), post translational 
modifications (predicted to increase the number of mature protein species by a 
further order of magnitude (Jensen, 2004)) and dynamic ranges of expression 
which may span up to ten orders of magnitude (Hortin and Sviridov, 2010); not 
to mention subcellular localization, protein-protein interactions and turnover. 
It is thus perhaps unsurprising that the comprehensive characterization of entire 
proteomes is a significantly more challenging proposition than the sequencing 
of entire genomes. In order to match up to this increased complexity, the 
development of proteomics-related techniques has had to move forward at an 
extraordinary rate. Advances in liquid chromatography (LC) and mass 
spectrometry (MS) over the past decade or so have invited comparison to 
Moore’s Law in some quarters (Mann, 2008). With the cutting edge 
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instrumentation available today it is possible to identify tens of thousands of 
peptides (many at sub-femtomole levels) (Thakur et al., 2011) and obtain near-
complete proteome coverage of simple model organisms (Nagaraj et al., 2012) 
in a matter of hours. Consequently, LC-MS is now firmly established as the 
major facilitating technology for proteomics. 
1.1.1. Top-down or bottom-up? 
In the broadest sense, mass spectrometry-based proteomics workflows can be 
defined as being either ‘bottom-up’ or ‘top-down’.  
 
Top-down proteomics (Ge et al., 2002) is concerned with the mass 
spectrometric analysis of intact proteins. It has proven possible to characterize 
intact proteins up to 200 kDa in size (Han et al., 2006) and this approach thus 
has applicability in the analysis of isoforms, post-translational modifications and 
protein complexes (Zhou et al., 2012a). Though identification of > 1000 proteins 
in a single study has previously been reported (Tran et al., 2011); technical 
constraints pertaining to separation, ionization and fragmentation of whole 
proteins generally render complex samples less amenable to analysis via this 
route (Zhang et al., 2013).  
 
In contrast, bottom-up proteomics entails the proteolysis of proteins to peptides 
prior to LC-MS analysis. When performed on complex samples, this is known as 
shotgun proteomics (Yates, 1998) (by way of analogy with shotgun DNA 
sequencing (Staden, 1979)). Very briefly, peptides are fragmented, sequenced 
and the protein content of a sample inferred through assigning the peptide 
sequences to proteins. The advantages of the top-down approach are 
relinquished, but the concomitant returns in increased sensitivity and proteome 
coverage make shotgun proteomics the approach of choice for analysis of 
complex protein mixtures. A bottom-up approach was adhered to in all work 
presented within this thesis and the specifics of this approach will be outlined in 
greater detail below. 
 
A recent addendum to the top-down / bottom-up paradigm is ‘middle-down’ 
proteomics (Wu et al., 2005), which seeks to strike a compromise between the 
two extremes through analysis of large peptide fragments. These larger 
4 
 
fragments can provide more information on isoforms and post-translational 
modifications than the short peptides analysed in bottom-up proteomics and are 
considerably more tractable than the whole proteins analysed in the top-down 
approach. 
1.1.2. The Bottom-up Proteomics Workflow 
There are numerous variations on the theme of a bottom-up proteomics 
workflow, but a few aspects are common to all. As aforementioned, ‘single-shot’ 
analyses of entire proteomes are achievable but these are currently confined to 
a select few specialist laboratories and are not yet conceivable for more 
complex organisms. The central principle is one of ‘divide and conquer’. The 
first step of any given workflow is thus extraction and isolation of a protein 
sample from the source of biological interest. The isolated protein sample is 
then digested to peptides, fractionated (though fractionation can also be 
performed at the protein level prior to digestion), ionized and subjected to mass 
spectrometric analysis. Bioinformatics tools are then employed to translate the 
information generated by the mass spectrometer into amino acid sequences of 
detected peptides and assign the peptides to proteins. These bottom-up 
workflows are outlined in Fig. 1 and each stage is subsequently detailed further. 
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1.1.2.1. Protein Extraction and Isolation 
The way in which a proteomic sample is extracted and isolated from the 
biological system under study can have important implications for stages further 
downstream in the workflow and its significance should not be underestimated. 
Even the most homogenous of biological systems (e.g. cells in culture) are still 
relatively complex with dynamic ranges of expression spanning many orders of 
magnitude. If certain sub-proteomes are of particular interest, subcellular 
fractionation techniques may be employed to decrease sample complexity. A 
case in point is the membrane proteome, whose low abundance and 
hydrophobic character relative to the rest of the proteome necessitates 
particular methodological considerations both at this stage and at the digestion 
stage. Since this body of work is concerned with characterization of the 
membrane proteomes of mature and tolerogenic dendritic cells, these 
considerations will be expanded upon in section 1.1.3.  
Secreted proteins represent something of a special case since the extracellular 
milieu into which they are secreted are not amenable to subcellular fractionation 
and are frequently even more complex than the cell from which the proteins 
originated. Accordingly, isolation approaches here are more geared towards 
depletion of highly abundant proteins (e.g. serum albumin), which alone 
constitutes over 50% of the total protein content of serum (Hortin and Sviridov, 
2010). 
1.1.2.2. Protein Fractionation 
The majority of bottom-up workflows incorporating a protein fractionation step 
are gel-based. Indeed, the majority of early proteomics experiments utilized 2D-
polyacrylamide gel electrophoresis (PAGE), a technique in which proteins are 
separated according to their isoelectric points in a first dimension pH gradient 
gel and their molecular masses in a second dimension PAGE (O'Farrell, 1975). 
The gel is then stained and imaged and spots of interest excised and analysed 
to confirm their identity. 2D-PAGE can therefore be used to look for differential 
protein expression in two (or more) samples run on two (or more) gels by 
examining differences in the protein spot profiles on the gel. However, the 
technique is hampered somewhat by low dynamic range, poor reproducibility, 
and a bias against both large and membrane proteins (Lopez, 2007); and is not 
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employed as regularly today as it once was. A more recent innovation is 
difference gel electrophoresis (DIGE), in which samples are differentially 
labelled with cyanine N-hydroxysuccinimide (NHS) esters prior to loading and 
quantified on a single gel, markedly alleviating the dynamic range and 
reproducibility issues (Alban et al., 2003).   
A simple and still commonly used protein fractionation method for proteomics is 
1D-SDS-PAGE (Laemmli, 1970). In the context of a shotgun workflow, complex 
proteomic samples are resolved by size alone on a PAGE gel and the gel is 
divided into a number of slices. Each slice is then treated as a separate fraction, 
digested in-gel (Shevchenko et al., 1996) and analysed by LC-MS. The entire 
workflow has thus been aptly termed GeLC-MS (Lundby and Olsen, 2011).   
Proteins may also be fractionated according to their isoelectric points in the 
liquid phase (Zuo and Speicher, 2000), circumventing some of the problems 
associated with performing this mode of separation in-gel. This liquid phase 
isoelectric focusing has been combined with GeLC-MS, yielding increased 
proteome coverage and reproducibility in comparison to repeated runs of 
fractions processed using GeLC-MS alone (Wang et al., 2010a). 
1.1.2.3. Protein Digestion 
Proteolytic digestion of proteins to peptides is a fundamental step central to all 
bottom-up workflows. Important considerations are the cleavage specificity of 
the enzyme/s used and the agent/s employed to aid solubilization and unfolding 
of proteins, affording the enzyme/s access to cleavage sites. These 
considerations are especially significant for membrane proteomics and will be 
discussed in greater detail in section 1.1.3. Trypsin is the protease of choice for 
the majority of bottom-up workflows and is frequently combined with an initial 
Endoproteinase-LysC digestion in denaturing conditions. 
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1.1.2.4. Peptide Fractionation 
Unfractionated  and 1D-PAGE-fractionated proteomic material contain a highly 
complex mixture of peptide species and fractionation at the peptide level is thus 
a necessary prerequisite for in-depth mass spectrometric detection of a 
significant proportion of the proteome. In this regard, 2D-PAGE does not really 
fall within the realm of what is understood today as shotgun proteomics, since 
an excised spot of interest corresponds at most to a few proteins (and ideally to 
a single protein!)  
Peptide separation can be performed off-line (whereby fractions are manually 
recovered prior to further analysis) or on-line (whereby fractionation is directly 
coupled to the mass spectrometer itself or a further dimension of downstream 
separation). All LC-MS workflows utilize at least one dimension of on-line 
chromatographic separation of peptides immediately prior to electrospray 
ionization (ESI). This allows large amounts of complex sample to be loaded 
onto the stationary phase of the chromatography column and continuously 
eluted over a pre-specified period of time by steadily increasing the 
concentration of the component in the mobile phase which favours 
displacement from the column. The specific physicochemical interaction of 
individual peptide species with the stationary phase determines the point at 
which they will be eluted. 
Reversed phase liquid chromatography (RPLC) uses a hydrophobic stationary 
phase and an aqueous to organic mobile phase gradient to separate peptides 
on the basis of hydrophobicity, with hydrophilic and shorter peptides eluting 
early and hydrophobic and longer peptides later in the gradient. Its high 
separation efficiency, high resolving capacity and the compatibility of solvent 
buffers with ESI render it the most important form of chromatography for 
shotgun proteomics and it is almost exclusively used as the final dimension of 
peptide separation in LC-MS (Shen and Smith, 2002). A less commonly used 
alternative is hydrophilic interaction liquid chromatography (HILIC) (Alpert, 
1990), which uses a hydrophilic stationary phase and an organic to aqueous 
mobile phase gradient and thus tends to invert the order in which peptides elute 
in RPLC.  
9 
 
These ESI-coupled chromatographic separations can be combined both on-line 
and off-line with many other forms of chromatography to further reduce sample 
complexity. The most common on-line separation upstream of RPLC is ion 
exchange chromatography, which uses a charged stationary phase and a 
mobile phase gradient of increasing ionic strength or changing pH; thereby 
separating peptides on the basis of charge. Strong cation exchange 
chromatography (SCX; negatively charged stationary phase, peptides loaded at 
low pH) is most frequently used, and the on-line coupling of SCX and RPLC has 
been dubbed Multi-dimensional Protein Identification Technology (MuDPIT) 
(Wolters et al., 2001). Strong anion exchange chromatography (SAX; positively 
charge stationary phase, peptides loaded at high pH) has also been used in an 
on-line format (Dai et al., 2009). Ion exchange chromatography can also be 
used for off-line separations by first collecting and then later analysing individual 
fractions with RPLC. 
Electrophoretic separations initially conceived for fractionation at the protein 
level may also be applied for peptide fractionation upstream of RPLC. Peptide 
isoelectric focusing can be performed in-gel (Essader et al., 2005) or in-solution 
(Heller et al., 2005). Free flow electrophoresis has also been used to this end 
(Malmstrom et al., 2006). 
1.1.2.5. Mass Spectrometry 
Mass spectrometry is the fundamental analytical technique underpinning 
proteomics and generates the raw data which will subsequently be used to 
identify proteins. All mass spectrometers consist of three basic components: an 
ion source which ionizes peptides and transfers them into the gas phase, a 
mass analyser which resolves sample components according to the mass-to-
charge ratio (m/z) of each ionized peptide and an ion detector which records the 
number of ions at each m/z. 
1.1.2.5.1. Ion Sources 
Though developments in proteomic sample separation have undoubtedly 
helped further mass spectrometry-based proteomics in the past few years, the 
field as we know it would not even exist had it not been for the development of 
MALDI (matrix-assisted laser desorption ionization (Karas and Hillenkamp, 
1988)) and ESI (electrospray ionization (Fenn et al., 1989)) around 25 years 
10 
 
ago. The importance of these breakthroughs was recognized with the award of 
the 2002 Nobel Prize in chemistry to Koichi Tanaka and John Fenn for their 
parts in pioneering the usage of MALDI and ESI respectively to analyse 
biological macromolecules. MALDI and ESI are ‘soft’ ionization methods, and 
their development allowed for the facile transfer of proteins and peptides into 
the gas phase with minimal degradation (Yates et al., 2009).  
In MALDI, the analyte is co-crystallized with a low molecular mass organic 
matrix on a metal plate. The matrix absorbs the energy from a laser fired at the 
sample and transfers it to the analyte, causing ionization, sublimation and 
desorption from the plate of both matrix and analyte ions (Karas and 
Hillenkamp, 1988). MALDI ionization predominantly results in the production of 
singly charged peptide ions.  
In ESI, samples are ionized as they elute from a chromatography capillary 
through the application of a high electric field generated via application of a 
voltage difference between the end of the capillary and the MS entrance. Liquid 
leaving the capillary is dispersed as an electrically charged aerosol. Positive 
ions accumulate at the surface of the droplets and as the solvent evaporates 
they are brought into closer and closer proximity with one another. When the 
surface tension of a droplet is exceeded by the forces of repulsion between the 
ions on its surface, the droplet ‘explodes’ into many smaller coulomb 
explosions. This occurs multiple times until all solvent has evaporated; leaving 
only ionized peptides in the gas phase (Fenn et al., 1989). ESI produces a 
range of charged peptide ions, though doubly and triply charged ions are most 
frequently observed.  
ESI is predominantly coupled to RPLC. Liquid chromatography has also 
previously been coupled to MALDI through automated deposition of column 
eluate onto MALDI plates (Miliotis et al., 2000; Rejtar et al., 2002; Wall et al., 
2002). 
1.1.2.5.2. Mass Analysers 
A variety of mass analysers are available. Time of flight (ToF) analysers 
compute m/z by accelerating the ions in a pulsed electric field and then 
measuring the time it takes for them to travel a fixed distance to the ion detector 
(Guilhaus, 1995). Quadrupole (Q) analysers are composed of two pairs of metal 
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rods and allow selectable ions of a particular m/z to reach the ion detector at 
any one time through application of oscillating radiofrequency (Rf) voltages to 
the rods such that all other ions are deflected (March, 1997). Ion trap (IT) 
analysers also utilize a quadrupolar field, but do so to ‘trap’ ions, such that ions 
of interest can be accumulated and then released from the trap according to 
their m/z value by varying the amplitude of the field (March, 1997). Finally, 
Fourier transform ion cyclotron resonance (FT-ICR) and Orbitrap analysers trap 
ions, measure ion oscillation frequencies and perform a Fourier transformation 
on the measured frequencies to derive m/z (Amster, 1996; Hu et al., 2005). 
Mass analysers vary in the resolution and mass accuracy of their m/z 
measurements, in the sensitivity and dynamic range of their detection 
thresholds and in the speed of their scan rates; and different mass analysers 
thus lend themselves to different applications. The resolution, mass accuracy 
and dynamic range capabilities of the mass analysers described above are 
summarized in Table 1 (adapted from (Zhang et al., 2013)) 
 
 
 
Two (or more) mass analysers are frequently interfaced with one another for 
tandem mass spectrometry (described in more detail below) in order to exploit 
distinct advantageous properties of each of them. Ion trap analysers have been 
interfaced with FT-ICR (Syka et al., 2004b) and Orbitrap (Yates et al., 2006) 
analysers and quadrupole analysers with ToF (Steen et al., 2001) and Orbitrap 
(Michalski et al., 2011) analysers; combinations which can be used to take 
advantage of the greater sensitivity of the former instruments in combination 
with the higher resolution and mass accuracy of the latter. 
Table 1: Properties of mass analysers used for peptide analysis in bottom-up 
proteomics 
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1.1.2.6. Mass Spectrometric Peptide Analysis 
The m/z of a peptide ion alone is insufficient information from which to 
determine its amino acid sequence. In order to identify individual peptide 
species present in a sample, the raw data must be searched against existing 
protein sequence databases. A number of approaches are available and the 
approach taken will depend upon the nature of the raw data generated. 
1.1.2.6.1. Peptide mass fingerprinting 
Peptide mass fingerprinting (PMF) was developed by a number of groups 
simultaneously in 1993 (Henzel et al., 1993; James et al., 1993; Mann et al., 
1993; Pappin et al., 1993; Yates et al., 1993). It identifies proteins by comparing 
the m/z values of the peptides detected in a given protein digest to databases of 
all theoretical peptide masses produced from an in silico digest. The principle 
behind this approach is that whilst a single m/z ratio may correspond to many 
peptide sequences, multiple m/z ratios corresponding to multiple peptide 
sequences known to be present in the same protein are increasingly unlikely to 
be observed by chance. This strategy can only identify proteins that are already 
in a database and rapidly becomes redundant as the number of proteins 
present in a sample increases. However, it is still a useful tool for analysis of 
single proteins and simple mixtures (differentially expressed spots on 2D gels 
for example).   
1.1.2.6.2. Accurate mass and time tag 
Accurate mass and time tag (AMT) identifies proteins in LC-MS by merit of both 
the m/z values of peptides and their retention time in liquid chromatography. 
The rationale here is that whilst multiple peptide species have the same m/z 
ratio, it is unlikely that they will also exhibit identical chromatographic behaviour. 
Retention time data thus constitutes an additional constraint, and it has been 
shown that when both constraints are used simultaneously, 88% of peaks on a 
mass spectrum can be matched to unique peptides (Lipton et al., 2002). This 
approach however requires a complex database containing m/z ratios and 
elution times of previously identified peptides. It also requires that peptides are 
detected consistently across multiple LC-MS runs and that the retention time of 
these peptides doesn’t drift from run to run. 
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1.1.2.6.3. Tandem mass spectrometry 
Tandem mass spectrometry (MS/MS) is by far the most widespread strategy for 
protein identification in shotgun experiments and enables high throughput 
sequencing of peptide ions detected by LC-MS. Precursor ions of interest 
(typically doubly- or triply-charged) detected in an MS1 scan are selected and 
isolated. Isolated precursor ions are then fragmented and product ion m/z ratios 
recorded in an MS2 scan. The m/z differences between product ions derived 
from the same parent ion are diagnostic of the mass differences imparted by the 
distinct residue masses of individual amino acids in the fragments. The tandem 
mass spectrum of a given peptide therefore contains ‘peptide sequence tags’ 
(Mann and Wilm, 1994) which can be searched against theoretical 
fragmentation patterns of peptides present in sequence databases. This is 
outlined graphically in Fig. 2. 
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H L V D E P Q N L I K 
a) 
b
)
c) 
Figure 2: MS/MS of a BSA-derived peptide with sequence HLVDEPQNLIK. a)
The precursor ion is selected and isolated owing to its intensity in the MS1 
spectrum. b) The precursor ion is fragmented and product ion masses recorded 
in the MS2 spectrum. The peptide is sequenced by merit of the close 
correlation of the observed fragmentation spectrum with the theoretical 
fragmentation spectrum shown in c).  
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1.1.2.6.3.1. Precursor Ion Selection 
Precursor ions are usually selected for fragmentation in a ‘data-dependent’ 
manner on the basis of their observed intensity in a given MS1 scan. Data-
dependent acquisition consists of repeated cycles of precursor ion scans 
followed by fragmentation of the n most intense ions in said scan. Highly 
abundant ions will generally be dynamically excluded from selection for a pre-
determined period of time if they are repeatedly selected for fragmentation to 
allow less abundant ions to be fragmented (Mallick and Kuster, 2010). 
Automated ‘exclusion lists’ have also been used to prevent highly abundant ions 
from being excessively selected for fragmentation across technical replicates 
(Zhang, 2012) and to preclude the selection of ions corresponding to 
contaminant proteins (Hodge et al., 2013). An alternative to the data-dependent 
paradigm is ‘data-independent’ acquisition, where the mass spectrometer is 
configured to sequentially cycle through small m/z ‘windows’ in the precursor 
ion scan; thus sampling lower abundance ions which would not otherwise be 
fragmented (Venable et al., 2004).  
1.1.2.6.3.2. Precursor Ion Fragmentation 
Tandem mass spectrometry can be performed ‘in space’ or ‘in time’. MS/MS ‘in 
space’ is carried out with two mass analysers separated by a collision chamber 
in which peptides are fragmented. The first analyser ‘selects’ ions of interest 
and enables them to pass into the collision chamber. Fragment m/z ratios are 
then recorded by the second analyser. MS/MS ‘in time’ is carried out with a 
single mass analyser able to isolate and fragment ions in a single chamber (e.g. 
quadrupole ion trap, FT-ICR and Orbitrap instruments).  
Either way, the principle requirement to enable sequencing of the peptide is for 
individual precursor ions to undergo a single cleavage along the polypeptide 
backbone between amino acid residues. A standard notation exists for 
indicating whether the product ion incorporates the N- or the C- terminus, where 
along the backbone the fragmentation occurred and the number of amino acid 
residues in the fragment (Roepstorff and Fohlman, 1984). This is shown in Fig. 
3.   
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The three most widely used means of inducing fragmentation in this manner are 
collision-induced/activated dissociation (CID/CAD), electron capture 
dissociation (ECD) and electron transfer dissociation (ETD). In CID/CAD, 
precursor ions of interest are accelerated to high kinetic energy and collided 
with an inert gas (usually helium, nitrogen or argon) (McLafferty and Bryce, 
1967; Jennings, 1968). These collisions produce predominantly b- and y-series 
product ions (Roepstorff and Fohlman, 1984). ECD (Zubarev et al., 1998) and 
ETD (Syka et al., 2004a) entail bombarding precursor ions with low energy 
electrons and radical anions respectively to induce fragmentation, favouring 
production of c- and z-series product ions. 
1.1.2.6.3.3. Precursor Ion Identification     
As stated, the fragmentation spectrum of a peptide is diagnostic of its 
sequence. However, an experimental MS/MS spectrum may exhibit some 
degree of homology with multiple theoretical MS/MS spectra. Furthermore, 
manual interpretation of experimental spectra is time-consuming and impractical 
for complex samples. A pivotal development in the field was the development of 
software tools enabling experimental MS/MS spectra to be searched against 
theoretical MS/MS spectra derived from protein sequence databases. The 
theoretical spectra queried are delineated by search-specific parameters 
Figure 3: Fragmentation nomenclature for peptide ion cleavages along the 
polypeptide backbone. N-terminal fragment ions are notated a, b and c; C-
terminal fragments are notated x, y and z. The numerical subscript indicates 
the number of amino acid residues present in the fragment ion.  
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pertaining to experimental and instrumentation-related constrains (e.g. enzyme 
used for digestion, fixed and variable peptide modifications, error window on 
experimental peptide m/z ratios). Experimental to theoretical spectral matches 
are ranked based on the probability that the match is genuine. A number of 
these tools are in use today; each differing slightly in the nature of the 
algorithm/s used to perform the ranking. A couple of the most widely used are 
described in more detail below.     
The first software tool developed for this purpose was SEQUEST (Eng et al., 
1994). SEQUEST compares experimental fragmentation spectra of a given 
precursor ion  to theoretical fragmentation spectra derived from precursor ions 
with similar m/z ratios and computes two statistics: XCorr (cross correlation of 
experimental and theoretical spectra) and ∆CN (difference between XCorr of 
highest ranking and second-highest ranking matches, assesses extent to which 
XCorr of highest ranking match deviates from stochastic matching).  
Mascot (Perkins et al., 1999) performs the same initial comparison but 
subsequently assigns all considered theoretical spectra a score dependent on 
the probability that the match between experimental and theoretical spectra is a 
random event, with low probability matches being assigned high scores and 
vice versa. The statistical significance of a match is ascertained by reference to 
a P > 0.05 threshold score determined from the data set and parameters under 
consideration. The probability of a peptide with a score identical to the threshold 
score being a random match is thus 1 in 20. The probability of a peptide with a 
score above the threshold score being a random match then decreases 
exponentially with increasing score. 
Given the nature of these software tools, it is invariable that some experimental 
to theoretical fragmentation spectra matches will be false. The prevalence of 
these ‘false positives’ can be estimated through the use of decoy database 
searching (Elias and Gygi, 2007), whereby the protein database from which 
theoretical spectra are derived is randomized or reversed. Since no genuine 
matches should be expected from searching the decoy database, the matches 
which are found can be used to approximate the false discovery rate of a given 
experiment, imparting additional validation to genuine matches.   
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1.1.2.6.3.4. Protein Identification 
The final stage in the bottom-up workflow is to assign all peptides identified in a 
given experiment to proteins. Mascot assigns all peptide matches to proteins 
regardless of their score. The scores of unique peptides assigned to each 
protein are then summed to arrive at a protein score. The output of a Mascot 
search is thus a list of proteins ranked on the basis of the summed scores of 
their peptides. The statistical significance of a protein hit is ascertained in a 
similar manner to that of peptide hits. The higher a protein score, the greater the 
confidence that that protein is present in the sample. 
It is worth noting briefly here that assigning peptides to proteins is in itself a far 
from trivial process. Certain peptide sequences are present in various isoforms 
of the same protein or in various proteins with redundant function. However, 
information pertaining to the proteinaceous origins of these ‘degenerate 
peptides’ (Nesvizhskii et al., 2003) is lost during the digestion step of a bottom-
up workflow. This is known as the ‘protein inference problem’ (Nesvizhskii and 
Aebersold, 2005). The problem can be confronted in the simplest sense by 
applying the principle of parsimony. In cases where a given set of peptides 
maps to multiple proteins, Mascot reports the minimum set of proteins to which 
all observed peptide matches can be assigned. Where identical sets of peptides 
map to multiple proteins; these proteins are grouped as a single hit.   
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1.1.3. Plasma Membrane Proteomics 
With regard to characterization of sub-proteomes, the plasma membrane 
proteome is frequently of considerable interest. Biological membranes 
demarcate intracellular compartments within cells and cells as a whole from 
their external environments. Since proteins are the principle mediators of all 
biological processes, it follows that membrane proteins govern the functionality 
of the membranes with which they are associated. Plasma membrane proteins 
act as receptors for propagation of signal transduction cascades; transporters 
and channels for movement of molecules and ions across the membrane; and 
adhesion molecules for contact-mediated cell-cell communication (Almen et al., 
2009). With 20% – 30% of genes in the majority of eukaryotic organisms 
encoding transmembrane proteins (Krogh et al., 2001) and 60% of all existing 
drug targets possessing cell surface-exposed domains (Overington et al., 
2006); the origins of this aforementioned interest are evident. 
1.1.3.1. Types of Membrane Protein 
Membrane-associated proteins can be broadly divided into integral membrane 
proteins (IMPs) and peripheral membrane proteins depending on whether or not 
they possess domains which span the breadth of the membrane. IMPs may 
possess either α-helical or β-barrel transmembrane domains (TMD); with the 
former constituting nearly all of the aforementioned 20% - 30% eukaryotic 
transmembrane proteins. α-helical IMPs can be further subdivided into Type 1 
(single TMD, cytoplasmic C-terminus), Type 2 (single TMD, cytoplasmic N-
terminus and multi-pass (more than one TMD) (Kanapin et al., 2003). Peripheral 
membrane proteins reside on either side of the membrane and interact with 
either IMPs themselves or with membrane lipids (Tan et al., 2008). This is 
shown graphically in Fig. 4.   
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1.1.3.2. Challenges of Plasma Membrane Proteomics 
Unfortunately, the characteristics of plasma membrane proteins which render 
them so interesting in theory also ensure that they are rather intractable to work 
with in practice. This is particularly true in bottom-up proteomic workflows; 
where their low abundance (approximately 2% relative to total cellular protein 
content (Rahbar and Fenselau, 2004)) and their comparative insolubility in the 
aqueous buffers which would typically be used throughout the workflow both 
pose significant obstacles to attaining comprehensive plasma membrane 
proteome coverage (Helbig et al., 2010). A wide array of techniques has been 
developed in an effort to circumvent these obstacles. In the context of the 
bottom-up workflow outlined in Fig. 1, these techniques are predominantly 
concerned with membrane protein enrichment during the extraction/isolation 
Type I Type II Multi-pass 
α-helical β-barrel 
Integral Membrane Proteins 
Peripheral 
Membrane 
Proteins 
Figure 4: Membrane protein nomenclature. Membrane proteins are classed as 
either integral (IMPs) or peripheral depending on whether they possess 
transmembrane domains (TMDs). TMDs may have either α-helical or β-barrel 
secondary structure. α-helical IMPs are categorized as Type I, Type II or multi-
pass depending on number of TMDs and orientation within the lipid bilayer. 
Peripheral membrane proteins do not span the bilayer but may be associated 
with IMPs or the membrane itself.  
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step and membrane protein solubilization to facilitate the continuation of the 
workflow thereafter. 
1.1.3.3. Plasma Membrane Protein Enrichment  
The rationale for performing membrane protein enrichment in plasma 
membrane-based proteomic studies is to increase the relative abundance of 
this particular class of proteins in a sample through depletion of proteins which 
would otherwise be present in far greater quantities (for instance cytoplasmic 
and nuclear proteins); thus increasing the probability that they are sampled 
during LC-MS. This can be achieved in a variety of ways, but the majority can 
be broadly divided into two categories: subcellular fractionation-based 
techniques which utilize some form of differential and/or density gradient 
centrifugation, and affinity purification-based techniques. 
Differential centrifugation partitioning a crude cell lysate into soluble and 
insoluble fractions is probably the most simple form of subcellular fractionation 
and has been used successfully for membrane proteomics of simple prokaryotic 
organisms (e.g. (Goo et al., 2003)) Sucrose density gradient centrifugation 
separates organelles on the basis of their buoyant density, is regarded as the 
classical subcellular fractionation technique and has previously been used for 
isolation of plasma membrane fractions of more complex organisms for 
proteomic analysis (e.g. (Zhang et al., 2005)). Coating cells with cationic 
colloidal silica and crosslinking with polyacrylic acid results in formation of a 
dense pellicle, allowing plasma membrane sheets to be pelleted by differential 
centrifugation after lysis (Chaney and Jacobson, 1983) and collected for MS 
analysis (e.g. (Rahbar and Fenselau, 2004)). Aqueous-polymer two-phase 
partitioning with polyethylene glycol (PEG) and dextran causes membranes to 
preferentially segregate into the more hydrophobic PEG phase, and subsequent 
treatment of plasma membranes with wheat germ agglutinin (WGA) specifically 
apportions them into a clean dextran phase upon repeated partitioning (e.g. 
(Schindler et al., 2006)). 
Affinity purification-based enrichment strategies centre around the tagging of 
surface-exposed protein domains on intact cells and subsequent pull-down of 
tagged proteins with appropriate reagents. Biotinylation reagents incorporating 
reactive groups which target primary amines and sulfhydryl groups can all be 
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used to this end (Macher and Yen, 2007). Amine-directed biotinylation reagents 
are explored in more detail in Chapter 4. Cell surface glycoproteins can also be 
targeted in this manner using lectin affinity chromatography (e.g. (Ghosh et al., 
2004)). Alternatively, the cis-diol groups of glycan carbohydrates can be 
derivatized to aldehydes, allowing affinity capture of glycoproteins on 
immobilized hydrazide (e.g. (Zhang et al., 2003)). Most recently, phospholipid 
coated superparamagnetic nanoparticles have been used to non-covalently 
coat the cell surface, enabling plasma membranes to be isolated magnetically 
after cell lysis (Thimiri Govinda Raj et al., 2011). 
A further consideration pertinent to both subcellular fractionation and affinity 
purification-based enrichment strategies is depletion of non-membrane proteins 
associated with proteins embedded within the membrane or the membrane 
itself. This can be achieved through washing membrane-enriched fractions with 
high salt buffers (disrupting interactions of membrane-associated proteins 
with phospholipid head groups (Hurwitz et al., 2006)) and high pH buffers 
(converting closed membrane vesicles to open sheets and releasing trapped 
non-membrane proteins (Fujiki et al., 1982)). Consecutive extractions of crude 
membrane extract in high salt, high pH and urea-containing buffers has been 
reported to provide effective membrane protein enrichment with no additional 
processing steps (Wisniewski et al., 2009a) and will be examined further in 
Chapter 4. 
Where the membrane fraction is recovered intact, depletion of membrane 
phospholipids themselves prevents their interference in downstream steps in 
the workflow. This is typically achieved by precipitating proteins whilst 
partitioning lipids into organic phases with, for instance, methanol/chloroform or 
acetone (Wessel and Flugge, 1984) .     
A distinct approach is cell surface ‘shaving’, where intact cells are incubated in 
the presence of proteases. Extracellular protein domains with protease-
accessible sites are cleaved and can be separated from cells and collected. 
Whilst conceptually attractive and somewhat fruitful for ‘surfaceome’ analysis of 
gram-positive bacteria (Rodriguez-Ortega et al., 2006), cell lysis in the presence 
of proteases and release of intracellular proteins into the surrounding medium 
has thus far proven problematic for eukaryotic cells (De Palma et al., 2010).  
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1.1.3.4. Plasma Membrane Protein Solubilization and Digestion 
There are also a wide range of published strategies for membrane protein 
solubilization and digestion. The hydrophobic domains of membrane proteins 
cause them to aggregate and precipitate in aqueous buffers, rendering some 
means of solubilization essential to prevent protein losses and facilitate 
proteolysis (Speers and Wu, 2007). However, a key consideration is the extent 
to which the means of solubilization impacts upon the efficiency of digestion and 
LC-MS analysis. The two processes are thus frequently considered collectively 
in shotgun workflows.  
Solubility issues are the underlying cause of the underrepresentation of 
membrane proteins in 2D-PAGE. A protein is at its least soluble in aqueous 
conditions at its isoelectric point and sparingly soluble membrane proteins thus 
tend to precipitate during first dimension isoelectric focussing (IEF), which 
prevents effective transfer into second dimension PAGE and severely hampers 
analysis (Klein et al., 2005). Alternative two-dimensional separation strategies 
such as blue native (BN)/SDS-PAGE (Schagger and von Jagow, 1991) and 
benzyldimethyl-n-hexadecylammonium chloride (16-BAC)/SDS-PAGE 
(Hartinger et al., 1996) alleviate these issues to some extent but 2D-PAGE is 
now rarely employed for membrane-based studies. 
1.1.3.4.1. Detergents 
The most effective way to solubilize membrane proteins is with the aid of 
detergents. Detergents are composed of a polar head group and a hydrophobic 
tail and these amphipathic characteristics enable them to self-associate and 
bind to hydrophobic surfaces, partially imitating the properties of the 
phospholipid bilayer (Garavito and Ferguson-Miller, 2001). At and above the 
critical micelle concentration (CMC) monomers will self-assemble into micelles; 
it is at this point that they can interact with and extract IMPs from the bilayer (le 
Maire et al., 2000). Detergents come in a wide range of shapes and sizes and 
the physicochemical properties of each determine the concentration at which 
micellar formation is favoured. They are generally classified as being ionic, non-
ionic or zwitterionic (Garavito and Ferguson-Miller, 2001), with bile acid salts 
being a class of ionic detergents with distinct structural properties (Seddon et 
al., 2004).   
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The archetypal example of an ionic detergent is sodium dodecyl sulphate 
(SDS), widely regarded as the most powerful detergent available for 
solubilization and denaturation of proteins. Unfortunately for shotgun 
proteomics, it is also only compatible with tryptic digestion at minute (< 0.1%) 
concentrations (Zhang and Li, 2004) and severely interferes with RPLC 
(Bosserhoff et al., 1989) and ESI (Loo et al., 1994), necessitating near-complete 
removal prior to LC-MS. This is a topic of much research in the field and a 
variety of methods have been proposed to enable SDS depletion without 
incurring concurrent sample loss; these include dialysis (Nagaraj et al., 2008), 
potassium chloride precipitation (Zhou et al., 2012b) and SCX chromatography 
(Sun et al., 2012). Commercially available resins which claim to quantitatively 
deplete SDS (amongst other detergents commonly used in shotgun workflows) 
have also been described (Antharavally et al., 2011).  
Non-ionic detergents (e.g. n-octyl glucoside), zwitterionic detergents (e.g. 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate – CHAPS) and bile 
acid salts (e.g. sodium deoxycholate – SDC)  do not possess the same 
solubilizing and denaturing power of SDS but compatibility with proteolytic 
enzymes at higher concentrations and/or increased ease of removal from 
samples mean they are also frequently employed in membrane-based 
proteomic workflows. For instance, n-octyl glucoside and CHAPS are both 
compatible with trypsin digestion at concentrations up to 1% (Zhang and Li, 
2004) and both have a relatively high CMC, enabling them to be effectively 
depleted from samples by dialysis (Lorber et al., 1990). Trypsin retains over 
three-quarters of its activity in concentrations of SDC up to 10% (Lin et al., 
2008), and SDC itself precipitates upon acidification with 0.1% trifluoroacetic 
acid (TFA), enabling removal by centrifugation (Zhou et al., 2006). 
Commercially available acid-labile detergents such as RapiGest™ (Yu et al., 
2003) (Waters)  and PPS Silent® Surfactant (Norris et al., 2003) (Protein 
Discovery) have been conceived specifically for mass spectrometric 
applications. They purport to exhibit solubilizing power on a par with SDS whilst 
being both compatible with proteolysis at higher concentrations and cleavable 
into non-surfactant breakdown products through sample acidification after 
digestion. However, it is acknowledged that hydrophobic peptides may co-
precipitate with one of the RapiGest™ breakdown products (Yu et al., 2003). 
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1.1.3.4.2. Chaotropes 
Chaotropes such as urea, thiourea and guanidium chloride stabilize unfolded 
protein states through interference with higher order protein structure (Moglich 
et al., 2005). Whilst chaotropes do not extract the majority of IMPs from the 
phospholipid bilayer itself (Wei et al., 2005), they have applicability in the 
denaturation of otherwise inaccessible protein domains to facilitate proteolysis 
and are frequently employed in tandem with the detergent solubilization 
strategies described above. Whilst trypsin is inhibited at chaotrope 
concentrations required to disrupt TMDs, endoproteinase Lys-C is far more 
robust, retaining activity in up to 8 M urea. This enables Lys-C to cleave at 
lysine residues which would be inaccessible to trypsin at lower chaotrope 
concentrations, augmenting subsequent tryptic digestion (Thingholm et al., 
2008). 
1.1.3.4.3. Solvents and Acids  
Aqueous-organic solvent systems (acetonitrile / methanol – water) can disrupt 
phospholipid bilayers (Patra et al., 2006) and denature proteins owing to their 
favourable interaction with nonpolar amino acid residues relative to purely 
aqueous buffers (Fink and Painter, 1987; Welinder, 1988); yet preserve 
sufficient trypsin activity to enable proteolysis to occur (Russell et al., 2001) and 
can simply be evaporated prior to LC-MS analysis. Organic acids such as 
formic acid (FA) (Washburn et al., 2001)  and TFA (Zhong et al., 2005) have 
also previously been used for the extraction and solubilization of IMPs. They 
have the advantage of complete compatibility with LC-MS but the disadvantage 
of incompatibility with tryptic digestion given the low pHs, necessitating the use 
of alternative modes of proteolysis (cyanogen bromide in (Washburn et al., 
2001) and acid-catalysed hydrolysis in (Zhong et al., 2005)). 
1.1.3.4.4. Integrated Workflows 
It is evident from the multitude of approaches described above that the 
proteomics community has yet to hit upon an optimal strategy for 
comprehensive solubilization, digestion and shotgun analysis of the membrane 
proteome, largely due to the aforementioned difficulties in integrating various 
stages of the workflow as a cohesive whole. One recently described technique 
which seeks to do so is filter-aided sample preparation (FASP) (Wisniewski et 
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al., 2009b). In FASP, the protein sample of interest is completely solubilized in 
high concentrations of SDS (typically 4% (w/v)). The sample is then diluted with 
an excess of 8 M urea, dissociating detergent micelles from proteins whilst 
maintaining them in solution (Nagaraj et al., 2008). The sample is then 
processed further in a molecular weight cut-off microcentrifuge spin column, 
enabling SDS monomers to be depleted whilst denatured proteins are retained 
and buffer exchanged into 8 M urea. Proteins are then digested first with Lys-C, 
then trypsin (after dilution) and released peptides pass through the molecular 
weight cut off (MWCO) filter and are then collected for LC-MS analysis. The 
applicability of the method to membrane-based studies has since been 
demonstrated with a crude membrane preparation extracted in high salt, high 
pH and urea-containing buffers as described in section 1.1.3.3. (Wisniewski et 
al., 2009a). FASP is explored further in Chapter 4.  
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1.1.4. Quantitative Proteomics 
A straightforward shotgun strategy is well-suited to qualitative proteome 
analysis, though whether this information is valuable from a biological 
perspective is another question entirely. If proteome profiling is to be used to 
address biological questions, a reference point is needed. This typically entails 
comparing and contrasting the proteins present in two (or more) physiologically 
related (but not identical) states of a biological system. Even with such a 
reference point, a list of proteins present in each sample is likely to be of limited 
use; there would be very few (if any) proteins present in one proteome which 
were completely absent in the other. However, if the reference point could be 
used to infer the abundances of proteins present in each sample, this 
information would be of far greater biological worth. Protein abundance changes 
upon application of given stimuli hint at roles for the protein in question in 
response to the stimuli and can be indicative of potential drug targets and 
biomarkers for diagnosis and treatment of disease. This is the rationale behind 
quantitative proteomics. There are many methods available for performing 
quantitative proteomic analyses; however they can be broadly categorized as 
being either label-based or label-free.  
Label-based approaches exploit the fact that proteins and peptides are able to 
incorporate stable isotopes into their amino acids which impart a measureable 
mass difference but do not significantly alter the physicochemical properties of 
the protein or peptide, such that both forms co-migrate or co-elute upon 
electrophoretic or chromatographic analysis respectively. This enables two or 
more samples to be labelled with differential mass tags and then combined prior 
to analysis. A peptide of given sequence present in differentially labelled forms 
in a single sample will produce discriminating peaks in a precursor or product 
ion scan. The relative intensities of the peaks can subsequently be compared to 
infer the relative quantities of differentially labelled peptide present in the 
sample. Label-based approaches can be further classified depending on 
whether quantitation is performed at the MS1 or MS2 level. In label-free 
approaches, quantitation is performed between samples rather than within them 
by comparing the ion intensity or the number of spectra acquired for a given 
peptide across all samples analysed. An overview of these various approaches 
is shown in Fig. 5.      
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Figure 5: Quantitative proteomic strategies. a) Label-based quantitation at the 
MS1 level. Peptides are differentially labelled and relative abundances of 
differentially labelled precursor ions compared. b) Label-based quantitation at 
the MS2 level. Peptides are isobarically labelled and thus differentially labelled 
precursor ions have the same mass. Quantitation is performed by comparing 
relative abundances of reporter group ions which preferentially fragment from 
the peptide in the product scan. c) Label-free quantitation. Samples to be 
quantitatively compared are analysed separately and quantitation performed on 
the basis of their response in the mass spectrometer (total ion intensity in this 
instance). The dashed green areas bound the ions being quantitated.    
a) 
b) 
c) 
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1.1.4.1. Label-based Quantitative Proteomics (MS1) 
1.1.4.1.1. Chemical Labelling 
The first mass spectrometry-based quantitative proteomic methods were 
chemical in nature, with isotope-coded labels conjugated to various chemicals 
which target the reactive sites present on peptides (typically the N-terminus and 
the side chains of lysine and cysteine residues).  
The first reagent developed with this purpose in mind was the isotope coded 
affinity tag (ICAT) (Gygi et al., 1999), which is composed of a biotin affinity tag 
containing either eight hydrogen atoms (light tag) or eight deuterium atoms 
(heavy tag) and a thiol specific reactive group to target the tag to cysteine 
residues. The major drawbacks of this method are twofold. Firstly, only 
cysteine-containing peptides are recovered after tagging and cysteine is a 
relatively rare amino acid. Secondly, deuterium is known to affect retention time 
in RPLC, causing light and heavy-labelled peptides to elute at different times 
and complicating quantitation (Zhang et al., 2001). This second issue has since 
been addressed by substituting the deuterated affinity tag with a 13C-labelled 
tag (Hansen et al., 2003; Li et al., 2003; Oda et al., 2003). 
An alternative MS1-based chemical labelling strategy targeting primary amine 
residues is differential dimethyl labelling (Hsu et al., 2003; Schmidt et al., 2005). 
The mass shift is imparted by reacting peptides with different isotope-coded 
forms of formaldehyde and cyanoborohydride. This theoretically allows for many 
different mass shifts, though in practice a maximum of three are used 
(formaldehyde – cyanoborohydride, formaldehyde-d2 – cyanoborohydride and 
formaldehyde-13c,d2 – cyanoborohydride-d3), allowing for triplex labelling with 
each labelled species separated by 4 Da. Amine-targeted tagging enables 
increased proteome coverage relative to cysteinyl-targeted tagging but the 
deuterium retention time issue must once again be taken into consideration. 
1.1.4.1.2. Enzymatic Labelling 
Enzymatic labelling utilizes the hydrolytic addition of oxygen atoms to the 
carboxyl termini of peptides produced during proteolysis. Schnölzer et al. were 
the first group to show that tryptic digestion in H218O water imparts a 2 – 4 Da 
mass shift to the peptides produced relative to tryptic digestion in H216O water 
30 
 
(Schnolzer et al., 1996). In practice, it is imperative to ensure that a 4 Da mass 
shift is imparted to all peptides as a 2 Da mass shift is insufficient to 
discriminate between the isotope envelopes of labelled and unlabelled peptides. 
18O labelling is examined in more detail in Chapter 5.  
1.1.4.1.3. Metabolic Labelling 
Metabolic labelling approaches exploit normal cell growth and division to 
introduce stable isotopes in vivo during protein synthesis. The most popular 
approach of this type is SILAC (stable isotope labelling by amino acids in cell 
culture) (Ong et al., 2002), in which cells are cultured in media containing heavy 
or light isotopes of certain essential amino acids (typically arginine and lysine as 
this ensures that all peptides other than the C-terminal peptide will incorporate 
at least one heavy amino acid if trypsin is used for digestion).  Near complete 
label incorporation can be achieved in as little as 5 cell cycles in replicative cell 
lines (Ong et al., 2002). An alternative approach is to culture cells in media 
supplemented with Nitrogen-15 (Oda et al., 1999); though this complicates data 
analysis considerably since different peptides will incorporate different amounts 
of isotope depending on the nitrogen content of their amino acid residues.  
A major advantage of metabolic labelling is that the labels can be introduced 
and the samples mixed prior to any sample-handling steps, minimizing the 
introduction of variation due to parallel processing. A significant shortcoming is 
that the nature of the method limits the types of sample which can be labelled. 
Mice have been labelled with both SILAC (Kruger et al., 2008) and 15N 
(McClatchy et al., 2007) by feeding with labelled diets for a number of 
generations but this is prohibitively expensive for large scale experiments. This 
can be overcome to some extent by using a labelled reference proteome as a 
‘spike-in’ standard for comparison with multiple experimental proteomes and 
then quantifying the differences between the experimental proteomes on the 
basis of the quantitative data obtained from individual comparisons with the 
reference proteome. This approach has previously been used for quantitative 
proteomics of primary cultured neurons through comparison with a 15N-labelled 
rat brain (Liao et al., 2012) and of human carcinoma tissue through comparison 
of a mixture of SILAC-labelled cell lines (‘super-SILAC’) (Geiger et al., 2010). 
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Metabolic labelling also has applications in investigations into rates of protein 
turnover. In ‘pulsed’ SILAC, cells are cultured in light SILAC media and then 
transferred to differentially-labelled heavy SILAC media upon the imposition of 
differential stimuli (Schwanhausser et al., 2009). Differences in protein turnover 
are ascertained by comparing the ratios of differential heavy labelling between 
samples. 
1.1.4.2. Label-based Quantitative Proteomics (MS2) 
MS2 level label-based quantitative proteomics differs from all of the approaches 
described above in that the quantitative measurement itself is performed in the 
product ion scan rather than the precursor ion scan. The best known MS2 level 
labelling reagents are the isobaric tags for relative and absolute quantification 
(iTRAQ) (Ross et al., 2004) and the tandem mass tags (TMT) (Thompson et al., 
2003). The main advantage of these reagents is that the tags themselves are 
isobaric but incorporate reporter groups which fragment during MS/MS to 
produce a series of diagnostic ‘signature’ ions that can be quantitated. This 
circumvents the inherent limitations of MS spectra complexity associated with 
mass difference tags and enables significantly more scope for multiplexing 
within a single experiment (up to 8-plex for iTRAQ (Ow et al., 2008) and 6-plex 
for TMT (Dayon et al., 2008)). However, the reagents cannot be used for 
quantitation with all ion trap mass spectrometers owing to the well-known ‘1/3 
cut-off rule’ limitation which prevents detection of fragment ion masses which 
are approximately less than a third that of the precursor ion mass (with tryptic 
peptides this often includes the iTRAQ and TMT reporter ions). In addition, 
quantitative accuracy can be compromised if multiple peptide species with 
similar m/z ratios and retention times are selected for fragmentation at the same 
time (Ow et al., 2009). 
A less well known MS2 level quantitation strategy is isobaric peptide termini 
labelling (IPTL) (Koehler et al., 2009), where two samples are rendered isobaric 
through incorporation of identical mass shifts to the N-termini of the peptides 
present in the first sample and the C-termini of the peptides present in the 
second sample. Quantitation is performed on the differentially N- and C- 
terminally labelled fragment ions themselves rather than with the aid of reporter 
ions. IPTL will be discussed in more detail in Chapter 5.    
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1.1.4.3. Absolute Quantitation 
The labelling methods described so far all facilitate relative quantitative 
inferences to be made within a single sample. Absolute quantitation is also 
possible in a manner similar to the ‘spike-in’ metabolic labelling approach by 
using limited numbers of stable isotope labelled peptides or proteins of known 
concentration. Absolute quantitative approaches usually make use of selected 
reaction monitoring (SRM), where pre-defined ‘transitions’ (m/z values 
corresponding to pairs of precursor and fragment ions of interest) are monitored 
throughout the course of the experiment irrespective of precursor ion intensity. 
This targeted approach permits considerable increases in sensitivity and 
dynamic range for chosen ions over standard data dependent acquisition 
(Gallien et al., 2011). 
The first reagents conceived for absolute quantitation were the AQUA peptides 
(Gerber et al., 2003), which are simply chemically synthesized stable isotope-
labelled peptides of known concentration corresponding to a protein of interest. 
This concept has since been extended with the QconCAT (quantification 
concatemer) peptides (Beynon et al., 2005), where an artificial protein 
comprised of a number of concatenated tryptic peptides corresponding to 
multiple proteins of interest is synthesized, affinity purified and introduced to the 
experimental sample prior to proteolysis. Design of AQUA and QconCAT 
constructs needs to be considered carefully to ensure optimal ionization and 
fragmentation behaviour of reference peptides within the mass spectrometer. In 
addition, neither technique is compatible with workflows incorporating protein 
fractionation steps owing to incomplete sample recovery for AQUA quantitation 
and the fact that the artificial protein construct does not correspond with any 
endogenously expressed protein for QconCAT quantitation (Havlis and 
Shevchenko, 2004). This shortcoming can be overcome using PSAQ (protein 
standard absolute quantification) stable isotope labelled proteins (Brun et al., 
2007), which can be spiked into samples at the beginning of the proteomics 
workflow and provide multiple peptide standards for a single protein of interest. 
1.1.4.4. Label Free Quantitative Proteomics  
Label-free approaches seek to use the mass spectrometer itself as a 
quantitative tool, alleviating the need to label and combine samples prior to 
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analysis and theoretically allowing an unlimited number of experiments to be 
compared. Peptide abundance can be inferred either directly or indirectly. Direct 
label free quantitation entails integrating the areas under the curves of extracted 
ion chromatograms (XICs) and comparing the signal responses of individual 
peptides (which are linear over around four orders of magnitude) between LC-
MS runs (Bondarenko et al., 2002; Chelius and Bondarenko, 2002). Indirect 
label free quantitation exploits the fact that the number of peptide-to-spectrum 
matches (PSMs) obtained for a given peptide consistently correlates with 
abundance over around two orders of magnitude (Liu et al., 2004a). This is 
routinely reported as emPAI (exponentially modified protein abundance index, 
the exponent of the number of peptide-to-spectrum matches for a given protein 
divided by the number of theoretically observable peptides that the protein could 
produce (Ishihama et al., 2005)).  
A few factors pertaining to instrumentation need to be considered if quantitative 
inferences are to be made between runs. In direct label free approaches, the 
identification and quantitation of a peptide are decoupled and it is thus vital that 
the two are correctly reconciled. A mass spectrometer with high resolution and 
mass accuracy is of considerable utility here (Bantscheff et al., 2012). Narrow 
peak widths aid in resolution of individual peptide species and retention time 
stability across runs can increase confidence that an XIC corresponds to a 
peptide in the absence of MS/MS data in all runs, thus a robust LC setup is also 
essential for accurate label free quantitation.          
1.1.4.5. Quantitation Software 
Whether label-based or label-free, intensity-based protein quantitation requires 
some degree of additional data processing on top of that used to for protein 
identification. For MS2 level label-based quantitation, the quantitative 
calculations are performed concurrently with peptide and protein identification 
and ratios are reported within the software tools themselves (where the 
quantitation method in question is supported). Mascot supports the commonly 
employed reporter ion chemistries (iTRAQ and TMT) and quantitation protocols 
are also customizable to allow for use of more exotic chemistries.  For other 
modes of intensity-based quantitation, a number of open-source (e.g. 
MaxQuant (Cox and Mann, 2008)) and commercial (e.g. Mascot Distiller) 
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software tools are available to detect, align, normalise and compare peptide 
features of interest both within and across LC-MS runs. 
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1.2. Dendritic Cells 
1.2.1. Dendritic cells and immunological tolerance 
The term immunological tolerance refers to “a state of indifference or non-
reactivity towards a substance that would normally be expected to elicit an 
immunological response” (Medawar, 1960). Such a state was first demonstrated 
in vivo in the transplantation immunology field using skin grafts between 
different strains of mice (Wood et al., 2010); work for which Sir Peter Medawar 
and Sir Frank McFarlane Burnett were jointly awarded the Nobel Prize in 
Medicine in 1960. Today, we have a much greater appreciation of the 
importance of immunological tolerance and a more comprehensive 
understanding of the mechanisms which bring it to pass. T cell receptor gene 
rearrangement is an extremely effective means of generating a sizeable and 
diverse repertoire of receptors (Arstila et al., 1999) but its stochastic nature 
inevitably ensures a significant percentage of productive rearrangements 
recognize endogenous antigens (van Meerwijk et al., 1997). The processes 
underpinning immunological tolerance serve to prevent these self-reactive T 
cells from contributing to autoimmunity. The vast majority of self-reactive cells 
are deleted during their development through negative selection in the thymus. 
This is known as central tolerance (Palmer, 2003). However, a small number of 
cells evade this process and migrate from the thymus; these cells must be kept 
in check in the periphery by a process known as peripheral tolerance (Walker 
and Abbas, 2002). 
Dendritic cells (referred to hereafter as DCs) are ‘professional’ antigen 
presenting cells, potent activators of other leukocytes and orchestrators of 
adaptive immunity (Trinchieri, 2007). Their presence as a constituent of murine 
peripheral lymphoid tissue (Steinman and Cohn, 1973) and purpose in 
performing the processes described above was first documented and defined 
by Ralph Steinman and collaborators; work which garnered a posthumous 
Nobel Prize in Medicine for Steinman in 2011. However, more recent work has 
shown that DCs are also important in the establishment and maintenance of 
central and peripheral tolerance. Their role in central tolerance was first 
established by Brocker et al., who targeted expression of major 
histocompatibility complex (MHC) class II I-E molecules specifically to DCs in a 
transgenic mouse model and showed that its expression on thymic DCs was 
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sufficient to negatively select cognate cluster of differentiation (CD)4+ T cells 
(Brocker et al., 1997). Their role in peripheral tolerance was demonstrated by 
Probst et al., who generated transgenic mice in which DC expression and 
presentation of lymphocytic choriomeningitis virus (LCMV) peptide epitopes to 
CD8+ T cells could be induced via Cre/Lox recombination in response to 
administration of Tamoxifen (Probst et al., 2003). Co-administration of 
Tamoxifen with an antibody against CD40 caused the epitopes to be presented 
in an immunogenic context and led to antigen-specific CD8+ T cell activation 
and expansion, whilst Tamoxifen alone caused the epitopes to presented in the 
steady state and led to antigen-specific CD8+ T cell tolerance which endured 
upon subsequent challenge with LCMV. An extensive discussion of central 
tolerance is not pertinent to this body of work and it will not be considered 
further. The capacity of DCs to induce and maintain peripheral tolerance is 
examined in more detail below.    
1.2.2. Functional specialization of dendritic cell subsets 
All human DCs express high levels of MHC Class II and can be distinguished 
from blood lymphocytes through the absence of lineage-specific markers (Collin 
et al., 2013). However, it is now clear that there are a number of DC subsets 
which differ in their locations throughout the body, their migratory pathways and 
their precise immunological function. Recent convention conceived to facilitate 
comparison of human and murine DC populations broadly divides human DCs 
into three subsets: CD1c+ myeloid DCs, CD141+ myeloid DCs and plasmacytoid 
DCs (Ziegler-Heitbrock et al., 2010). CD1c+ DCs comprise the major population 
of myeloid DCs. Present in peripheral tissues, lymphoid tissues and blood; they 
perform the processes of antigen uptake, transport and presentation to CD4+ T 
cells with which DCs are typically associated (Reis e Sousa, 2001). CD141+ 
DCs represent a small sub-population of myeloid DCs, distinguished by their 
considerably enhanced capacity to cross-present antigen to CD8+ T cells and 
initiate cytotoxic effector responses (Bachem et al., 2010; Crozat et al., 2010; 
Jongbloed et al., 2010; Poulin et al., 2010). Plasmacytoid DCs are primarily 
present in blood and are uniquely specialized in their ability to produce vast 
quantities of type I interferons in response to viral challenge (Siegal et al., 
1999).  
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Additional subsets of DCs with distinct functional specializations are also 
recognized. For instance, human dermal and epidermal tissue contains CD1a+ 
and CD14+ ‘dermal’ DCs and Langerhans cells with structural and functional 
features specific to the environment in which they reside (Klechevsky et al., 
2008). Novel populations of DC not present in steady state conditions also 
appear in response to inflammation and are thought to differentiate from CD14+ 
monocytes (Shortman and Naik, 2007). Derivation of these ‘inflammatory’ DCs 
is well characterized in vitro through culture of CD14+ monocytes in the 
presence of interleukin 4 (IL-4) and granulocyte macrophage colony stimulating 
factor (GM-CSF) followed by exposure to a variety of inflammatory stimuli (e.g. 
tumour necrosis factor alpha (TNFα) (Sallusto and Lanzavecchia, 1994)). There 
is also evidence that it occurs in vivo through experiments in which monocytes 
were adoptively transferred into recipient mice and their fates followed upon 
introduction of inflammatory stimuli (Geissmann et al., 2003; Serbina et al., 
2003).  
1.2.3. Dendritic cells in immunity and tolerance 
The molecular mechanisms which govern the function of myeloid DCs are now 
well known. In the steady state, peripheral tissue-resident DCs exist in an 
‘immature’ state and act as ‘immune sentinels’; surveying their surroundings 
through a variety of endocytic mechanisms and perpetually capturing, 
processing and presenting antigenic material to T cells (Sallusto et al., 1995). 
The seemingly diametrically opposed outcomes of immunity and tolerance are 
both initiated through T cell recognition of cognate antigen presented by DCs. 
The question of whether the T cell is subsequently activated or tolerised is 
context-specific and determined by cues emanating from the microenvironment 
in which the DC itself encounters the antigen. 
1.2.3.1. Dendritic cells in immunity 
If an infectious agent is present, antigen uptake is coupled with the detection of 
‘danger signals’ by pattern recognition receptors (PRRs). DCs are now known 
to express a number of PRRs (Takeuchi and Akira, 2010) (including Toll-like 
receptors (TLRs), C-type lectin receptors (CLRs), NOD-like receptors (NLRs) 
and RIG-I-like receptors (RLRs)) capable of recognizing exogenous pathogen-
associated molecular patterns (PAMPs) such as peptidoglycan and 
38 
 
lipopolysaccharide (LPS) (Kadowaki et al., 2001) and endogenous danger-
associated molecular patterns (DAMPs) derived from stressed, injured or 
necrotic cells, such as heat shock proteins (Gallucci and Matzinger, 2001). 
Detection of these danger signals can contribute to inducing DC maturation 
(Macagno et al., 2007). Maturing DCs cease to sample their extracellular 
environment (Garrett et al., 2000) whilst upregulating the expression of MHC 
class II molecule / peptide complexes (signal 1) (Cella et al., 1997), co-
stimulatory molecules such as CD80 and CD86 (signal 2) (Caux et al., 1994) 
and chemokine receptors CCR7 and CXCR4 (Sallusto et al., 1998); enabling 
them to migrate out of peripheral tissues and towards lymph nodes to activate 
naïve T cells. Concurrent with activation, DCs provide T cells with immune-
polarizing cues (signal 3) (Kalinski et al., 1999) which direct their differentiation 
into an appropriate subtype. For example, DC production of IL-12 concomitant 
with stimulation instructs T cells to adopt a Th1 phenotype (Macatonia et al., 
1995). 
1.2.3.2. Dendritic cells in tolerance 
If no infectious agent is present, antigen uptake is not coupled with the 
aforementioned danger signals and DCs remain immature. They continue to 
process and present self-antigens, but since uptake of these antigens is not 
(typically) coupled with danger signals, they express neither the chemokine 
receptors necessary to migrate from the periphery nor the co-stimulatory 
molecules necessary to activate T cells. This ensures that any potentially self-
reactive T cells encountered in the periphery are not activated. 
It was thus initially thought that mature DCs induce immunity and immature DCs 
induce tolerance (Probst et al., 2003). However, it has since become evident 
that the situation is a little more equivocal: there are a number of reported 
instances in which activated ‘mature’ DCs induce T cell tolerance. For instance, 
DCs matured in the presence of PAMPs such as filamentous haemagglutinin 
(FHA) from B. pertussis (McGuirk et al., 2002) or lysophosphatidylserine (PS) 
from S. mansoni (van der Kleij et al., 2002) adopt a mature surface phenotype 
but produce IL-10 and induce naïve T cells to adopt an IL-10-producing 
regulatory phenotype. DCs cultured in the presence of anti-inflammatory 
cytokines (IL-10 and transforming growth factor beta (TGF-β)) (Lan et al., 2006) 
or corticosteroids (de Jong et al., 1999) and matured with LPS exhibit a more 
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immature surface phenotype than would be expected upon LPS stimulation and 
expand regulatory T-cells and Th2-polarized T-cells respectively (though the 
authors of the second study concede that Th2 polarization can cause 
undesirable side effects due to elevated levels of Immunoglobulin E (IgE) and 
eosinophils). As touched upon above, it is now generally accepted that DCs can 
be ‘alternatively activated’ by certain signals they receive during maturation and 
subsequently exhibit similar T cell stimulatory capacity to that of mature DCs but 
generate tolerance in the same manner as immature DCs. This significant 
plasticity in the function of DCs is illustrated in Fig. 6 overleaf. 
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Figure 6: Dendritic cells in immunity and tolerance 
DCs integrate antigen uptake, processing and presentation with the signals 
which they receive from the extracellular milieu to determine whether they 
will activate or tolerise cognate T cells. If antigen uptake takes place in the 
presence of danger signals (pro-inflammatory cytokines and 
pathogen/danger-associated molecular patterns such as peptidoglycan and 
lipopolysaccharide), DCs mature and activate effector T cells. If antigen 
uptake takes place in the steady-state, DCs remain immature and tolerise T 
cells. If antigen uptake takes place in the presence of anti-inflammatory 
cytokines, immunosuppressive drugs or pathogen/danger-associated 
molecular patterns such as filamentous haemagglutinin and 
lysophophatidylserine; DCs may assume a mature-like phenotype but retain 
the ability to tolerise T cells.  
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1.2.4. Mechanisms of tolerance induction 
Several mechanisms have been outlined through which DCs mediate tolerance 
in the periphery. These include clonal anergy and clonal deletion of autoreactive 
T cells, polarization of autoreactive T cell cytokine profiles and induction and/or 
expansion of regulatory T cells (Hilkens et al., 2010).  
Clonal anergy is a hyporesponsive state assumed by T cells after recognizing 
their antigen in the absence of co-stimulation (Jenkins and Schwartz, 1987). 
Induction of clonal anergy upon stimulation with immature DCs has been 
demonstrated both in vivo and in vitro. Hawiger et al. injected mice with a 
monoclonal antibody to the DC endocytic receptor DEC-205 and engineered to 
contain a hen egg lysozyme peptide in steady-state conditions. T cells which 
recognized the peptide began to proliferate, but most of them were 
subsequently deleted. The small number which did remain did not respond to 
rechallenge with the same peptide (Hawiger et al., 2001). Waithman et al. 
reported DC-mediated clonal deletion of ovalbumin-specific T cells in steady-
state conditions in a transgenic mouse engineered to express membrane-bound 
ovalbumin on keratinocytes (Waithman et al., 2007). 
The Th1/Th2 paradigm postulates that Th1 CD4
+ T cells will tend to promote 
more immunogenic cell-mediated immune responses, whilst Th2 CD4
+ T cells 
will tend to promote more tolerogenic cell-mediated immune responses (Strom 
et al., 1996). This is exploited for immune evasion by a number of pathogens 
whose PAMPs signal through PRRs which program DCs to induce Th2 
responses. Examples include recognition of the bacterial lipopeptide Pam-3-cys 
by TLR-2 (Agrawal et al., 2003; Dillon et al., 2004); and recognition of 
Mycobacterial ManLAM (Geijtenbeek et al., 2003), H. pylori LPS Lewis antigens 
(Bergman et al., 2004) and L. acidophilus surface layer A protein (Konstantinov 
et al., 2008) by the CLR DC-SIGN. Skewing the effector T cell response has 
also been leveraged for therapeutic benefit. Li et al. transduced DCs with 
suppressor of cytokine signalling 3 (SOCS3) (a potent inhibitor of transcription 
of Th1-specific genes by signal transducer and activator of transcription (STAT) 
3 and 4). Transduced cells exhibited reduced MHC class II and CD86 
expression, produced low levels of IL-12 and interferon gamma (IFN-γ) but high 
levels of IL-10 and suppressed experimental autoimmune encephalitis (EAE), a 
Th1-mediated mouse model of multiple sclerosis in vivo (Li et al., 2006). 
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Induction and expansion of regulatory T cells is perhaps the most widely 
reported mechanism through which DCs maintain immune tolerance. There are 
two major groups of regulatory T cells; ‘naturally occurring’  forkhead box P3+ 
(FoxP3+) CD4+ CD25+ regulatory T cells (nTregs) which constitute around 5% of 
all T cells which survive negative selection in the thymus (Itoh et al., 1999) and 
‘adaptive’ FoxP3+ CD4+ CD25- regulatory T cells (iTregs) which can be induced 
through stimulation of naïve T cells in the periphery (Chen et al., 2003). Mature 
DCs are capable of expanding and sustaining antigen-specific populations of 
nTregs in a mixed lymphocyte reaction (MLR), though this seems to depend less 
on the phenotype of the DCs and more on the phenotype of the nTregs 
(Yamazaki et al., 2006). In a study similar to that described by Hawiger et al, 
Bruder et al. injected a T cell receptor (TcR) transgenic mouse model of 
diabetes with an α-DEC-205-HA conjugate (Bruder et al., 2005). The mice were 
engineered such that they expressed haemagglutinin (HA) under the control of 
the insulin promoter. Newborn mice injected with the conjugate did not develop 
disease and the induction of HA-specific FoxP3+ iTregs was observed. 
1.2.5. Molecules of tolerance induction 
Many studies documenting the induction of T cell tolerance by DCs identify 
certain molecules which appear to be important in both programming DCs 
themselves to a tolerogenic phenotype and enabling them to induce T cell 
tolerance. Expression of the tryptophan-catabolizing enzyme indoleamine 2,3-
dioxygenase (IDO) by DCs activated with CD40 ligand (CD40L) and IFNγ 
inhibits the proliferation of autologous T cells in co-culture experiments through 
tryptophan starvation (Hwu et al., 2000). IDO expression in DCs is coupled with 
upregulation of immunoglobin-like transcripts (ILTs) 3 and 4, resulting in 
impaired T cell stimulatory capacity (which can be rescued by ILT3 blockade) 
and enhanced induction of iTregs (Brenk et al., 2009). In vivo, treatment of mice 
with abatacept (cytotoxic T lymphocyte antigen 4 (CTLA4)-Ig) induces IDO 
expression in a subset of splenic DCs, which subsequently suppress the 
expansion of adoptively transferred T cells specific for murine MHC class I 
(Mellor et al., 2003). TGF-β and retinoic acid (RA) act in a synergistic manner to 
induce differentiation of naïve T cells into iTregs as opposed to Th17 cells (Mucida 
et al., 2007). Concurrent with this observation, CD103+ lamina propria-resident 
DCs express high levels of retinal dehydrogenase (RALDH, which converts 
43 
 
retinaldehyde to retinoic acid) and induce FoxP3+ Tregs in a RA and TGF-β-
dependent manner (Coombes et al., 2007; Sun et al., 2007), an important 
mechanism for the maintenance of oral tolerance in the face of constant 
exposure of gut-associated lymphoid tissue to oral antigens. High RALDH 
expression in these DCs may be maintained through constitutive signalling 
through the Wnt-β-catenin pathway (Manicassamy et al., 2010). Galectins may 
represent another important class of tolerogenic molecules. Exogenous and 
endogenous galectin-1 activates a STAT-3 mediated regulatory program in 
DCs, imparting a phenotype characterized by production of high levels of IL-27 
(Ilarregui et al., 2009). These DCs induce IL-10-producing Tregs and suppress 
inflammation in mice with EAE. Interestingly, it has been shown that galectin-1 
is highly expressed by Tregs themselves (Garin et al., 2007), alluding to cross-
talk between Tregs and tolerogenic DC as a potential mechanism to perpetuate 
tolerance. The balance between expression of and signalling through activating 
and inhibitory Fcγ receptors on DCs also appears important, with signalling 
through FcγRI and FcγRIII favouring DC activation and maturation and 
signalling through FcγRIIB curtailing it. As such, FcγRIIB knockout mice exhibit 
increased DC activation and autoimmune inflammation upon nasal challenge 
with ovalbumin (Samsom et al., 2005). A recent study has demonstrated that 
TLR-2 signalling in murine macrophages upregulates cell surface expression of 
FcγRIIB (Abdollahi-Roodsaz et al., 2013). It is worth noting that whilst these are 
all undoubtedly important tolerogenic molecules in the context in which they 
were studied, a ‘unifying theory’ of tolerance induction is yet to be elucidated.   
1.2.6. Using tolerogenic dendritic cells to treat autoimmune disease 
With the accumulating evidence that DCs could engender tolerance in 
autoreactive T cells came increasing excitement that it might be possible to 
harness these properties to treat allergic and autoimmune disorders and 
promote transplantation tolerance (Steinman and Banchereau, 2007). A clinical 
trial which utilized autologous mature DCs to stimulate immune responses 
against tumours in patients with B cell lymphoma had already hinted at the 
tremendous potential that DCs held as biological therapeutics (Hsu et al., 1996). 
Proof of principle that they could also be manipulated to induce tolerance in vivo 
in humans was provided in a similar manner through injection of a single dose 
of autologous immature DCs pulsed with influenza matrix peptide. This led to 
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the inhibition of CD8+ T cell-mediated cytotoxity and the appearance of IL-10 
producing T cells specific for the influenza matrix peptide (Dhodapkar et al., 
2001). These IL-10 producing cells were subsequently shown to be able to 
inhibit influenza matrix peptide-specific effector CD8+ T cells generated from 
peripheral blood mononuclear cells (PBMCs) isolated prior to DC injection 
(Dhodapkar and Steinman, 2002).  
Research groups all over the world have since dedicated a great deal of time 
and resources to developing means to manipulate DCs ex vivo such that they 
subsequently induce tolerance in vivo. Numerous studies have been conducted, 
differing in terms of the autoimmune diseases they are intended to treat and the 
manner in which the cells are manipulated. Tolerogenic DCs have previously 
been generated through: a) Inhibition of nuclear factor-kappa B (NF-κB)-
mediated transcription of genes necessary for DC maturation, with 
immunomodulatory agents such as dexamethasone (e.g. (Matasic et al., 1999)), 
1-Alpha,25-dihydroxyvitamin D3 (e.g. (Penna and Adorini, 2000)) and BAY 11-
7082 (e.g. (Martin et al., 2007)); or transfection with MicroRNA-23b (Zheng et 
al., 2012); b) genetic modification to upregulate expression of 
immunosuppressive molecules such as CTLA-4 (e.g. (Lu et al., 1999)), IL-4 
(e.g. (Kim et al., 2001)) and IL-10 (e.g. (Coates et al., 2001)); or apoptosis-
inducing molecules such as Fas ligand (e.g. (Min et al., 2000)) and TNF-related 
apoptosis-inducing ligand (TRAIL) (e.g. (Liu et al., 2003)); or to downregulate 
expression of immunostimulatory molecules such as CD80/86 (e.g. (Liang et al., 
2003))  and IL-12 (e.g. (Xu et al., 2006)); c) treatment with immunosuppressive 
cytokines or drugs such as IL-10 (e.g. (Steinbrink et al., 1997)), TGF-β (e.g. 
(Yarilin et al., 2002)) or rapamycin (e.g. (Turnquist et al., 2007)); d) treatment 
with Wnt ligands to increase Wnt signalling (Valencia et al., 2011); and finally e) 
short-term exposure to LPS (Salazar et al., 2008).  
An important consideration in ex vivo generation of tolerogenic DCs for 
treatment of autoimmune disease is that the cells must be maturation-resistant. 
In sites of autoimmune inflammation, endogenous danger signals are present in 
the absence of infection and there is an abundance of self-antigen for DCs to 
process and present. In these circumstances, mature DCs are at least as potent 
in perpetuating autoimmunity as tolerogenic DCs are in preventing it. ‘Semi-
mature’ DCs generated through treatment of immature DCs with TNF-α have 
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been shown to mature further and become immunogenic in vivo upon exposure 
to inflammatory stimuli in murine EAE (Voigtlander et al., 2006) and through 
increasing the inoculant number in murine collagen-induced arthritis (CIA) (Lim 
et al., 2009). 
1.2.7. Autologous Dendritic Cells for Rheumatoid Arthritis - the 
AuToDeCRA study at Newcastle University 
Prophylactic and therapeutic efficiency of tolerogenic DCs has now been 
established in a number of the models described above and two Phase I human 
studies in type I diabetes and rheumatoid arthritis have recently been conducted 
with no adverse effects of treatment reported (Hilkens and Isaacs, 2013). 
Here at Newcastle University, a robust method has been developed for the 
generation of human tolerogenic DCs from monocytes through treatment with 
dexamethasone and vitamin D3 and maturation with LPS (Fig. 7). These DCs 
exhibit a semi-mature phenotype relative to mature DCs characterized by: a) 
high MHC class II expression; b) intermediate expression of co-stimulatory 
molecules CD80 / CD86 and low expression of maturation markers CD40 / 
CD83; and c) an anti-inflammatory cytokine profile with high levels of IL-10 / 
TGF-β and low levels of IL-12, IL-23 and TNFα (Anderson et al., 2008; 
Anderson et al., 2009). They are limited in their capacity to activate naïve and 
memory CD4+ T cells and modulate naïve and memory responses in distinct 
ways. Naïve cells primed by these DCs retain proliferative capacity but are 
deviated to an anti-inflammatory phenotype characterized by high expression of 
IL-10 and low expression of IFN-γ (Anderson et al., 2008). Memory cells primed 
by these DCs do not exhibit a polarized cytokine profile but are rendered 
hyporesponsive to subsequent restimulation (Anderson et al., 2008). LPS 
maturation of these DCs increases both their migratory capacity in response to 
the CCR7 ligand CCL19 and their ability to present an antigenic peptide from 
type II collagen relative to equivalent cells which do not receive a maturation 
stimulus (but still in a tolerogenic context) (Anderson et al., 2009). Intravenous 
injection of equivalent mouse DCs pulsed with type II collagen significantly 
inhibits disease severity and progression in murine CIA (Stoop et al., 2010).  
Several translational issues have had to be addressed in order to bring these 
tolerogenic DCs into compliance with current good manufacturing practice 
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(cGMP) and enable the initiation of clinical trials. ‘Clinical grade’ DCs are 
cultured using CellGroDC (a cGMP compliant serum-free medium) (Napoletano 
et al., 2007) and matured using monophosphoryl lipid A (a low toxicity derivative 
of the lipid A portion of LPS) (Makkouk and Abdelnoor, 2009). Tolerogenic DCs 
generated from the monocytes of rheumatoid arthritis patients in this manner 
exhibit a comparable phenotype to the DCs described above and are resistant 
to maturation when placed in a pro-inflammatory environment (Harry et al., 
2010), an important consideration if they are to be used to treat established 
rheumatoid arthritis. 
These clinical grade tolerogenic DCs are presently the subject of a randomized, 
unblinded, placebo-controlled, dose-escalation Phase 1 safety trial as part of 
the Autologous Tolerogenic Dendritic Cells for Rheumatoid Arthritis 
(AuToDeCRA) study; in which RA patient monocytes are isolated, differentiated 
ex vivo, loaded with autologous synovial fluid and injected intra-articularly into 
an inflamed knee joint. Whilst the primary objective of the trial is to assess 
safety and acceptability, synovial biopsies are also collected to ascertain the 
effects of the treatment on local and systemic disease activity and to check for 
the presence of prospective response biomarkers (Hilkens and Isaacs, 2013). 
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Figure 7: Generation of mature and tolerogenic dendritic cells in the 
immunotherapy group at Newcastle University 
CD14+ monocytes are cultured for six days in the presence of IL-4 and GM-
CSF to induce differentiation into immature DC. These are matured for a 
further 24 hours with LPS. To generate tolerogenic dendritic cells, 
monocytes are additionally supplemented with dexamethasone on days 3 
and 6 and vitamin D3 on day 6. 
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1.2.8. Exploring the cell surface phenotype of tolerogenic dendritic cells 
The in vitro and in vivo evidence accumulated to date suggests that these 
tolerogenic DCs hold considerable immunotherapeutic promise. However, whilst 
it is known that they induce tolerance in part through a TGF-β dependent 
mechanism which inhibits T cell proliferation and IFN-γ production (Anderson 
and Hilkens; unpublished data), the basis of their phenotype and precisely what 
it is that makes them tolerogenic has yet to be systematically explored. This 
would be valuable information to possess in itself and the findings may also 
help to expedite their progression from bench to bedside. 
A hitherto imperfectly addressed requirement in advancing tolerogenic DC-
based therapy for the treatment of RA is the identification of ‘quality control’ 
(QC) markers which unambiguously exemplify the tolerogenic phenotype 
(Hilkens and Isaacs, 2013). Ideally, such markers need to be robust, readily 
assayable and indicative of tolerogenic function. With this in mind, the QC 
markers currently in use are low CD83 expression, indiscernible IL-12 
production and high IL-10 production (Hilkens and Isaacs, 2013). TLR-2 is 
known to exhibit 3-4 fold greater expression on tolerogenic DCs than on mature 
or immature DCs (Harry et al., 2010), though it is as yet unclear whether this 
correlates directly with their tolerogenic function. It is possible that as yet 
uncharacterized markers with more exclusive expression and/or more directly 
associated with function are yet to be discovered. The discipline of proteomics 
is well suited to pursue this particular line of enquiry. 
1.2.9. Previous dendritic cell proteomic studies 
The importance in fully comprehending the molecular processes underpinning 
the functional properties of human DCs in immunity and tolerance is reflected in 
the number of proteomic studies of which they have been the focus since the 
turn of the century (Ferreira et al., 2010). The earliest studies were largely gel-
based and focused largely on the differentiation and maturation process of 
monocyte-derived DCs (moDCs). Advances in the field have since facilitated 
comparative studies between different types of moDC and more in-depth 
investigation of individual organelles such as the plasma membrane. 
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1.2.9.1. Proteomics of DC maturation 
The first human DC proteomic studies employed 2D-PAGE in an effort to 
characterize proteome-wide changes in response to differentiation and 
maturation, frequently in tandem with array-based transcriptome profiling to 
enable comparison of the two.  
Angenieux et al. compared transcriptome and proteome profiles of monocytes 
and mature DCs (Angenieux et al., 2001). A significant proportion of genes 
induced by maturation corresponded to surface expressed proteins with known 
functions in antigen processing and presentation. Intracellular components of 
the antigen processing machinery were also upregulated at the protein level; 
together with proteins with roles in cytoskeletal remodelling and the 
mitochondrial oxidative stress response. Le Naour et al. performed a similar 
study (Le Naour et al., 2001), identifying 255 differentially expressed transcripts 
and 37 differentially expressed proteins. Differentially expressed genes 
corresponded largely to secreted proteins or proteins involved in cell adhesion 
and signalling; whilst differentially expressed proteins had roles in calcium and 
fatty acid-binding, chaperone activities associated with antigen processing and 
presentation, and cell motility. Pereira et al. used 2D-PAGE to examine 
differential protein expression during both differentiation and maturation (Pereira 
et al., 2005), identifying 56 differentially expressed spots in immature DCs and 
50 differentially expressed proteins in mature DCs. These spots corresponded 
to 36 proteins, 11 of which were present as 38 electrophoretic isoforms. As with 
the previously described studies, differentially expressed proteins corresponded 
predominantly to known biological alterations occurring during differentiation 
and maturation such as cytoskeletal remodelling, chaperone activities and 
intracellular antigen processing. Finally, Ferriera et al. used 2D-DIGE to 
examine differential protein expression during maturation (Ferreira et al., 2008), 
identifying 74 differentially expressed spots corresponding to 41 proteins; many 
of which were once again involved in cytoskeletal modelling, cell motility and 
antigen processing. 
A couple of trends emerge through collective consideration of these studies. 
Whilst differentially expressed genes and proteins in all of the studies can be 
broadly reconciled with the processes of DC differentiation and maturation, the 
two studies in which both transcriptome and proteome analysis were performed 
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note that little correlation was observed between the two datasets. Angenieux et 
al. attribute this to difficulties in analysing membrane proteins using 2D gels for 
the differentially expressed transcripts not identified by proteomics and to post-
transcriptional and post-translational control of protein expression for the 
upregulated proteins not identified by transcriptomics. The latter proposition 
would appear to fit with the identification of numerous differentially expressed 
isoforms of individual proteins by Pereira et al. and Ferriera et al. This is 
corroborated by a more recent shotgun study by Buschow et al. examining 
transcriptome and proteome changes during DC maturation (Buschow et al., 
2010). Little correlation was observed between differentially expressed 
transcripts and proteins per se, but correlation was considerably greater when 
the transcripts and proteins were mapped to maturation-related pathways. The 
five pathways identified with considerable overlap between mRNA and protein 
levels were cell adhesion, cell motility, cytokine receptor interaction and the 
peroxisome proliferator-activated receptor (PPAR) and TLR signalling 
pathways. It is also noted that whilst differentially expressed proteins can be 
broadly reconciled with the processes of DC differentiation and maturation, 
there are very few differentially expressed proteins identified in common across 
the gel-based studies. It is suggested that differences in gel-based platforms 
and differentiation/maturation stimuli used may be partly responsible for this 
variation. 
1.2.9.2. Proteomics of differentially matured DC 
More recent human DC proteomic studies have focused less on the maturation 
process itself and more on differentially expressed proteins in DC matured with 
distinct stimuli and exhibiting discrete mature phenotypes. 
Gundacker et al. compared differences in the cytoplasmic and secreted 
proteomes of immature DCs with DCs which had been either classically 
activated with LPS, alternatively activated with OxPAPC (an oxidized 
phospholipid) or tolerised with human rhinovirus (Gundacker et al., 2009). They 
identified significant cytoplasmic and secretome changes in LPS-matured DCs 
relative to the other two cell types, most notably upregulation of a significant 
number of interferon-induced proteins, proteins involved in cell motility and 
secreted cytokines and chemokines. Few changes were noted in alternatively 
activated or tolerised DCs. It is possible that this is due to alternatively activated 
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/ tolerised DCs more closely resembling immature DCs than LPS-matured DCs, 
though it is also worth noting that an unusual metabolic labelling strategy was 
used in which DCs were matured for 6 hours in media containing 35S-labelled 
methionine and cysteine.      
In a follow up study to that described in (Ferreira et al., 2008), Ferreira et al. 
examined the effects of  adding TX527 (a structural analogue of vitamin D) 
(Ferreira et al., 2009) on days 3 and 6 on the expression profiles of immature 
and mature DCs. The proteins differentially expressed between mature DCs 
and TX527-treated mature DCs could be categorized into three main groups. 
Proteins involved in cytoskeletal remodelling (e.g. fascin, actin polymerizing 
proteins) were downregulated, whilst proteins involved in mitochondrial 
oxidative metabolism (e.g. periredoxin, superoxide dismutase) were 
upregulated. TX527 treatment also had significant effects on antigen processing 
pathways. Proteins with a role in MHC class I antigen processing (e.g. 
cytosomal aminopeptidase, proteasome activator complex subunit 2) were 
downregulated, whilst proteins with a role in MHC class II antigen processing 
(e.g. cathepsins D and S) were upregulated.  
The group has since published a further study which examines the effects of 
dexamethasone, vitamin D3 and a combination of the two on the expression 
profiles of mature DCs (Ferreira et al., 2012). The culture protocol differs slightly 
from both that employed at Newcastle and that employed in the previous study: 
the group treats DCs with vitamin D3 from day 0 and matures through co-
culture on cells expressing CD154 for 48 hours. Nevertheless, the phenotype of 
DCs cultured in the presence of both reagents is broadly similar to that 
documented in the TX527 study, though the earlier supplementation of vitamin 
D3 seems to have an additional effect on a number of metabolic proteins, with 
fructose 1,6 biphosphate and carbonic anhydrase being particularly strongly 
induced.    
Most recently, Zimmer et al. performed a label-free proteome-wide comparison 
of immature DCs, LPS-matured DCs (DC1), PGN-matured DCs (DC2) and 
dexamethasone-treated DCs (DCreg) in an effort to identify candidate response 
biomarkers to allergen immunotherapy (Zimmer et al., 2012). Nine proteins 
were identified which were upregulated in DCreg relative to the other types of 
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DC; namely annexin A1, complement C1q subcomponent subunits B and C, 
dipeptidyl peptidase 1, coagulation factor XIII A chain, chloride intracellular 
channel protein 2, peptidyl-prolyl-cis-trans-isomerase, macrophage mannose 
receptor 1 and stabilin-1. Both complement C1q subcomponent subunits and 
stabilin-1 were subsequently validated as predictors of tolerogenic response to 
immunotherapy. Interestingly, none of the upregulated proteins identified in this 
study were also identified as upregulated in the dexamethasone-treated DCs in 
the study by Ferreira et al. Indeed, of the nine, only one (annexin A1) was 
detected in both studies at all. It is possible that this is again due to the different 
proteomic platforms utilized. It will be interesting to see if any of the differentially 
expressed proteins in either study are also detected in the current body of work. 
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Chapter 2. Aims and Objectives 
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The principle aim of this body of work entails the development of a mass 
spectrometry-based proteomics workflow to enable quantitative plasma 
membrane proteomics of mature and tolerogenic dendritic cells. This overall 
aim will be realised through the optimization and validation of several elements 
of the proteomics sample preparation process described in section 1.1.2. such 
that the biological questions at hand can be addressed effectively. These 
elements pertain primarily to two active areas of research within the field, each 
of which has been the subject of a great deal of research to date.  
• The first objective is to develop a technique to extract, isolate and digest the 
DC plasma membrane proteome which enables the detection of substantial 
numbers of this relatively scarce and biochemically recalcitrant class of 
proteins in LC-MS analysis. 
 
• The second objective is to develop a means of stable isotope labelling the 
proteomic peptides of mature and tolerogenic DC to enable their respective 
protein complements to be quantified relative to one another.  
The difficulties posed by these two considerations, in particular the latter, are in 
part imposed by the nature of the cells under study and the LC-MS 
instrumentation available and are detailed in the introductions of the respective 
chapters of which they are the focus. 
Upon completion, it is envisaged that future application of the optimized 
elements of the sample preparation workflow in sequence will enable the 
identification and relative quantitation of significant numbers of mature and 
tolerogenic DC plasma membrane proteins. However, individual elements of the 
workflow should also prove applicable to the examination of mature and 
tolerogenic DC biology (and beyond in general proteomics). 
• The third objective is thus to appropriate these elements as such for 
quantitative comparisons of their unfractionated proteomes in the absence 
of membrane enrichment, and qualitative profiling of their plasma 
membrane proteomes in the absence of stable isotope-based quantitation. 
These investigations will both inform development of the overall workflow and 
may also be of interest from a biological perspective in their own right. 
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Chapter 3. Methods 
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All reagents were sourced from Sigma-Aldrich (St. Louis, MO, USA) unless 
otherwise stated. 
3.1. Cell culture 
3.1.1. Jurkat T cells 
Jurkat T cells were cultured in RFI0 (RPMI 1640; Lonza, Basel, Switzerland) 
with 10% (v/v) fetal bovine serum (FBS; Lonza), 2 mM glutamine, 100 U/ml 
penicillin and 100 µg/ml streptomycin) at 37°C with 5% CO2. Cells were split 1 
in 10 twice a week and expanded as required.  
3.1.2. Isolation of cells from peripheral blood 
Human samples were obtained with informed consent and following a 
favourable ethical opinion from North Tyneside Research Ethics Committee 
(UK). PBMCs were isolated from leukocyte reduction system (LRS) cones 
through density gradient centrifugation on Lymphoprep (Axis-Shield 
Diagnostics, Dundee, UK). CD14+ monocytes were isolated from PBMCs 
through positive selection with anti-CD14 microbeads (Miltenyi Biotec, Bergisch 
Gladback, Germany).  
3.1.3. Generation of dendritic cell populations 
CD14+ monocytes were cultured in RF10 supplemented with 50 ng/ml IL-4 and 
50 ng/ml GM-CSF (Immunotools, Friesoythe, Germany). Cells were cultured at 
0.5×106 cells/ml for 6 days with fresh media and cytokines on day 3 to induce 
differentiation into immature DCs.  Immature DCs were matured through the 
addition of 0.1 µg/ml LPS (Sigma-Aldrich) for a further 24 hours on day 6. 
Tolerogenic DCs were additionally supplemented with 10-6 M dexamethasone 
(Sigma-Aldrich) on days 3 and 6 and 10-10 M 1α,25-dihydroxyvitamin D3 (Leo-
Pharma, Ballerup, Denmark) on day 6. All cells were cultured at 37°C with 5% 
CO2. 
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3.2. Protein extraction and isolation 
3.2.1. Whole cell lysate preparation (in-solution digestion) 
Jurkat T cells were harvested at approximately 95% confluence. Mature and 
tolerogenic DCs were harvested on day 7, 24 hours after addition of LPS. All 
cells were resuspended in Hank’s balanced salt solution (HBSS; Lonza) / 1% 
(v/v) FBS and washed three times; then resuspended in 1 ml phosphate 
buffered saline (PBS) / 1 mM ethylenediaminetetraacetic acid (EDTA), 
transferred to low binding microcentrifuge tubes (Sorensen Bioscience, Salt 
Lake City, UT, USA) and washed a further three times to remove residual 
serum proteins which would otherwise contaminate downstream LC-MS 
analysis. After washing, cells were resuspended in lysis buffer (1% (v/v) n-octyl-
β-D-glucoside, 0.1% (w/v) SDC, 150 mM sodium chloride (NaCl), 50 mM 
tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl, pH ~7.5), 1 mM 
EDTA; supplemented with complete mini EDTA-free protease inhibitor cocktail 
(Roche Applied Science, Penzburg, Germany). The volume of lysis buffer used 
was calculated such that protein concentration in the lysates would be 
approximately 2 µg/µl assuming a yield of 100 picograms of protein per cell. 
Samples were thoroughly vortexed and incubated on ice for 30 minutes. To 
ensure complete lysis, cells were then subjected to 3 freeze-thaw cycles 
consisting of a sequence of 2 minutes in liquid nitrogen, 2 minutes in a 37°C 
water bath and 1 minute of thorough vortexing. Lysates were cleared by 
centrifugation at 1000g for 10 minutes at 4°C. Total protein concentration in 
clarified lysates was assayed using a Micro BCA assay kit (Thermo Fisher 
Scientific, Waltham, MA, USA) as per user instructions. Lysates were 
subsequently transferred to fresh low binding tubes and stored as 100 µg 
aliquots at -80ºC if not required immediately. 
3.2.2. Whole cell lysate preparation (FASP) 
Jurkat T cells and mature/tolerogenic DCs were harvested and washed with 
HBSS / 1% (v/v) FCS and PBS / 1% (v/v) EDTA as described above. After 
washing, cells were resuspended in 4% (w/v) SDS / 0.1 M Tris-HCl (pH ~7.5) 
and incubated for 5 minutes at 95°C. The volume of lysis buffer used was 
calculated as before. Lysates were homogenized by passage through 
QiaSHREDDER microcentrifuge spin columns (Qiagen, Hilden, Germany) at 
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16000g for 2 minutes at room temperature, transferred to low binding 
microcentrifuge tubes and cleared by centrifugation at 16000g for 5 minutes at 
room temperature. Total protein concentration in clarified lysates was assayed 
using a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific). Lysates 
were subsequently transferred to new low binding tubes and stored as 100 µg 
aliquots at -80ºC if not required immediately. 
3.2.3. Cell surface protein isolation with EZ-Link® Sulfo-NHS-SS Biotin 
and RevAmine 
Jurkat T cells were harvested and washed with HBSS / 1% (v/v) FCS and PBS / 
1% (v/v) EDTA as described above. After washing, cells were resuspended in 1 
ml PBS at a volume of 1 × 107 cells/ml. 10 µl of EZ-Link® Sulfo-NHS-SS Biotin 
(Thermo Fisher Scientific) or RevAmine (25 µg/µl, reconstituted in dimethyl 
sulfoxide (DMSO)) was added. 10 µl of DMSO alone was added to cells which 
would serve as unbiotinylated controls. Tubes were incubated for 30 minutes at 
4ºC with end-over-end agitation. Biotinylation reactions were quenched through 
addition of 50 µl of ‘quenching solution’ (Thermo Fisher) and incubation for a 
further minute at 4ºC with end-over-end agitation. Biotinylated cells were spun 
down, resuspended in 25 mM Tris buffered saline (TBS) and washed three 
times.  
Biotinylated and unbiotinylated cells were subsequently resuspended in either 
100 µl of ‘Lysis Buffer’ (Thermo Fisher, proprietary formulation) or 100 µl of 1% 
(w/v), 2% (w/v) or 4% (w/v) SDS / 0.1 M Tris-HCl (pH ~7.5) supplemented with 
HALT EDTA-free protease inhibitor cocktail (Thermo Fisher Scientific) and 1 
mM EDTA. Cells resuspended in Lysis Buffer were sonicated for 1 minute in a 
sonicating water bath at 4ºC and incubated on ice for 30 minutes with vortexing 
for 5 seconds every 5 minutes. Lysates were cleared by centrifugation at 
10000g for 2 minutes at 4ºC. Clarified supernatant was transferred to new low 
binding tubes and stored at -80ºC if not required immediately. Cells 
resuspended in SDS / 0.1 M Tris-HCl were incubated for 5 minutes at 95ºC. 
Lysates were homogenized using a 25 gauge needle and syringe and cleared 
by centrifugation at 16000g for 5 minutes at room temperature. Clarified 
supernatant was processed and stored as described above if not required 
immediately. 
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For cell surface protein isolation, 100 µl of NeutrAvidinTM agarose resin (Thermo 
Fisher Scientific) was added to a 0.8 ml centrifuge column (Thermo Fisher 
Scientific) and washed three times. Resin which was to be used for isolation of 
cell surface proteins from cells lysed with Lysis Buffer was washed with 500 µl 
of ‘Wash Buffer’ (Thermo Fisher Scientific, proprietary formulation). Resin which 
was to be used for isolation of cell surface proteins from cells lysed with 1% 
(w/v), 2% (w/v) or 4% (w/v) SDS / 0.1 M Tris-HCl was washed with 500 µl of the 
corresponding SDS solution. Biotinylated and unbiotinylated lysates were added 
to the resin and incubated for 1 hour or overnight at room temperature with end-
over-end agitation. After incubation, resin was washed four times with 500 µl of 
the buffer which had been used to equilibrate the resin prior to addition of 
lysates, supplemented with HALT EDTA-free protease inhibitor cocktail and 1 
mM EDTA.  
Proteins biotinylated with EZ-Link® Sulfo-NHS-SS Biotin were liberated from the 
resin through addition of 100 µl of 4% (w/v) SDS / 0.1 M Tris-HCl / 0.1 M 
dithiothreitol (DTT) and incubation for 1 hour at room temperature with end-
over-end agitation. Proteins biotinylated with RevAmine were liberated from the 
resin through addition of 0.1% (v/v) ammonia solution and incubation for 1 hour 
at room temperature, followed by addition of 100 µl of 4% (w/v) SDS / 0.1 M 
Tris-HCl / 0.1 M DTT and incubation as described above. SDS eluates from EZ-
Link®-biotinylated samples were collected in low binding microcentrifuge tubes. 
Ammonia eluates from RevAmine-biotinylated samples were collected in low 
binding microcentrifuge tubes and evaporated under vacuum prior to addition of 
SDS solution. SDS eluates were subsequently collected in the same tubes. 
3.2.4. Membrane preparation using ‘stepwise depletion’ 
Jurkat T cells and mature/tolerogenic DCs were harvested and washed with 
HBSS / 1% (v/v) FCS and PBS / 1% (v/v) EDTA respectively as described 
above. After washing, cells were resuspended in 1 ml hypotonic lysis buffer (10 
mM NaCl, 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid – sodium 
hydroxide (HEPES-NaOH) (pH ~7.5), 1 mM EDTA; supplemented with HALT 
EDTA-free protease inhibitor cocktail) and allowed to swell on ice for 10 
minutes. Swollen cells were transferred to a pre-chilled Dounce homogenizer 
(2ml) and lysed using 50 strokes with a tight pestle. Lysates were cleared by 
centrifugation at 1000g for 10 minutes at 4ºC. Salt concentration in clarified 
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lysates was adjusted to 2 M NaCl. Alternatively, cells were resuspended in 200 
µl isotonic lysis buffer (150 mM NaCl, 10 mM HEPES-NaOH (pH ~7.5), 1 mM 
EDTA; supplemented with HALT EDTA-free protease inhibitor cocktail) and 
subjected to 3 freeze-thaw cycles as described in section 3.2.1. Volume and 
salt concentration of crude lysates was adjusted to 500 µl and 2 M NaCl 
respectively. Lysates were homogenized by three passages through 
QIAshredder microcentrifuge spin columns as described in section 3.2.2. The 
volume of the clarified lysates was adjusted to 1 ml through addition of 500 µl 
hypertonic buffer (2 M NaCl, 10 mM HEPES-NaOH (pH ~7.5), 1 mM EDTA; 
supplemented with HALT EDTA-free protease inhibitor cocktail). 
Crude membrane preparations were subsequently prepared using the ‘stepwise 
depletion of non-membrane molecules’ method described in (Wisniewski et al., 
2009a) with a few modifications. 1 ml volumes of clarified lysate prepared by 
either of the two methods described above were transferred to 1 ml siliconized 
microcentrifuge tubes (Sigma-Aldrich) and crude membranes pelleted by 
centrifugation at 21100g for 30 minutes at 4ºC. Supernatant was discarded and 
pellets extracted in 1 ml carbonate buffer (0.1 M Na2CO3 (pH 11.3), 1 mM 
EDTA; supplemented with HALT EDTA-free protease inhibitor cocktail). Pellet 
dispersal was aided by sonication for 1 minute in a sonicating water bath at 4ºC. 
Membranes were pelleted by centrifugation and extracted as described a further 
two times with carbonate buffer and one final time with urea-containing buffer (4 
M urea, 100 mM NaCl, 10 mM HEPES-NaOH (pH ~7.5), 1 mM EDTA). The 
supernatant was carefully removed and discarded and the membrane pellets 
stored at -80ºC if not required immediately. 
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3.3. Protein Digestion 
3.3.1. Detergent removal from whole cell lysates for in-solution digestion 
Detergent was removed from whole cell lysates generated as described in 
section 3.2.1. using detergent removal spin columns (Thermo Fisher) as per 
manufacturer instructions. Briefly, the columns were washed and equilibrated 3 
times with 50 mM Tris-HCl (pH ~7.5). 100 µg aliquots of whole cell lysate were 
made up to 50 µl with 50 mM Tris-HCl (pH ~7.5), transferred onto columns and 
incubated at room temperature for 2 minutes. Columns were then centrifuged at 
1500g for 2 minutes at room temperature and the eluate was collected in low 
binding microcentrifuge tubes. 
3.3.2. In-solution digestion of BSA / whole cell lysates 
50 µl volumes of bovine serum albumin (BSA) (Sigma-Aldrich) reconstituted in 
50 mM Tris-HCl (pH ~7.5) to a final concentration of 200 ng/µl or 50 µl volumes 
of whole cell lysate depleted of detergent as described above were transferred 
to PCR tubes (STARLAB, Hamburg, Germany). RapiGest™ SF (Waters, 
Manchester, UK) was reconstituted in 10 mM TRIS-HCl to a stock concentration 
of 2% (w/v) and added to samples at a final concentration of 0.1% (w/v) (for 
experiments described in sections 5.2., 6.2.1.1. and 7.2.)  Alternatively, 
ProteaseMAX™ (Promega, Fitchburg, WI, USA) was reconstituted in 10 mM 
TRIS-HCl (pH ~7.5) to a stock concentration of 1% (w/v) and added to samples 
at a final concentration of 0.03% (w/v) (for experiments described in sections 
4.2.2.1., 4.2.3.2., 6.2.1.2., 6.3. and 7.3.) All samples were reduced by addition 
of Tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCl) to 1 mM and 
incubation for 30 minutes at 56ºC. Cysteine residues were then alkylated by 
addition of iodoacetamide to 5 mM and incubation for 1 hour at room 
temperature in the dark. Excess iodoacetamide was scavenged by addition of 
DTT to 4 mM and incubation for 30 minutes at room temperature. All samples 
were digested overnight at 37ºC with sequencing grade modified trypsin 
(Promega) (enzyme-to-substrate ratio 1:50 (w/w)). Upon digestion completion, 
RapiGest™-containing samples were acidified with 1/20th volume 10% (v/v) 
TFA, incubated at 37ºC for a further 45 minutes and centrifuged at 13000g for 
10 minutes at room temperature to precipitate and pellet RapiGest™ 
breakdown products. ProteaseMAX™-containing samples were acidified with 
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1/20th volume 10% (v/v) TFA, incubated at room temperature for 5 minutes and 
centrifuged at 13000g for 10 minutes at room temperature to precipitate and 
pellet ProteaseMAX™ breakdown products. All supernatants were then 
transferred to new PCR tubes and stored at -20ºC if not required immediately. 
3.3.3. In-solution digestion of ‘stepwise depletion’ membrane 
preparations 
Crude membrane pellets were resuspended in 200 µl buffer (100 mM NaCl, 10 
mM HEPES-NaOH (pH ~7.5), 1 mM EDTA), to which four volumes of ice cold 
acetone were added. Samples were vortexed for 1 minute, incubated at -20ºC 
for 1 hour and centrifuged at 15000g for 10 minutes at 4ºC. Supernatant was 
carefully decanted and protein pellets left to air-dry for 30 minutes at room 
temperature. ProteaseMAX™ was reconstituted in 50 mM ammonium 
bicarbonate to a stock concentration of 1% (w/v). Protein pellets were 
solubilized with 15 µl 8 M urea / 20 µl 0.2% (v/v) ProteaseMAX™, vortexed for 2 
minutes, placed in a Thermomixer® (Eppendorf, Hamburg, Germany) set to 300 
rpm and agitated at room temperature for a further hour. 50 mM ammonium 
bicarbonate was added to a final volume of 93.5 µl. Samples were reduced by 
addition of 1 µl 0.5 M DTT and incubation for 20 minutes at 56ºC. Cysteine 
residues were alkylated by addition of 2.7 µl 0.55 M iodoacetamide and 
incubation for 15 minutes at room temperature in the dark. A further 1 µl of 1% 
(v/v) ProteaseMAX™ was added and samples were digested overnight at 25°C 
with sequencing grade modified trypsin (Promega) (enzyme-to-substrate ratio 
1:50 (w/w), added to make final sample volume up to 100 µl). Total protein 
concentration in the samples was not assayed directly but inferred from total 
protein concentration in crude membrane pellets prepared in the same way with 
the same number of cells which were solubilized in 4% (w/v) SDS / 0.1 M Tris-
HCl and assayed using a NanoDrop 1000 spectrophotometer by UV versus 
blank. Upon digestion completion, ProteaseMAX™ breakdown products were 
precipitated and pelleted as described above and supernatants transferred to 
new low binding tubes and stored at -20ºC if not required immediately.    
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3.3.4. FASP digestion of whole cell lysates and ‘stepwise depletion’ 
membrane preparations 
Crude membrane pellets were solubilized in 30 µl 4% (w/v) SDS / 0.1 M Tris-
HCl (pH ~7.4) and incubated for 5 minutes at 95ºC. 3 µl of solubilized 
membrane protein was removed and total protein concentration assayed using 
a NanoDrop 1000 spectrophotometer as before. 
Whole cell lysates and crude membrane pellets to be digested using FASP 
were reduced by addition of 1/10th volume 1 M DTT made up in 4% (w/v) SDS / 
0.1 M Tris-HCl (pH ~7.4) and incubated for a further 5 minutes at 95ºC. FASP 
was subsequently carried out as described in (Wisniewski et al., 2009b) with a 
few modifications. 30 µl volumes of reduced protein sample were diluted with 
200 µl UA buffer (8 M urea, 0.1 M Tris-HCl (pH ~8.5)); vortexed for 1 minute 
and transferred to Microcon® YM-30 MWCO spin filters (Merck-Millipore, 
Billerica, MA, USA). Columns were centrifuged at 14000g for 40 minutes at 
20ºC. A further 200 µl of UA buffer was added to the filters and centrifugation 
repeated as described above. Cysteine residues were alkylated through 
addition of 100 µl UA buffer containing 50 mM iodoacetamide. Filters were 
placed in a Thermomixer® set to 600 rpm and agitated at 20ºC for 1 minute, 
incubated at 20ºC without agitation for a further 20 minutes and then 
centrifuged at 14000g for 30 minutes at 20°C. Three 100 µl volumes of UB 
buffer (8 M urea, 0.1 M Tris-HCl (pH ~8)) were then passed through the filters 
by centrifugation at 14000g for 40 minutes at 20°C. 
Samples were digested on-filter by addition of 30 µl UB buffer containing 
endoproteinase Lys-C (Promega) (enzyme-to-substrate ratio 1:50 (w/w)). Filters 
were agitated in a Thermomixer® as described above and incubated overnight 
at 25°C in a wet chamber. The filters were subsequently transferred to new 
collection tubes and the 30 µl UB buffer diluted through addition of 120 µl 50 
mM ammonium bicarbonate (pH ~7.5) containing sequencing grade modified 
trypsin (Promega) (enzyme-to-substrate ratio 1:100 (w/w)). Filters were agitated 
in a Thermomixer® as described above and incubated over a second night at 
25°C. Upon digestion completion, filters were centrifuged at 14000g for 40 
minutes at 20°C. Finally, one volume of 50 µl 0.5 M NaCl was passed through 
the filters by centrifugation at 14000g for 20 minutes at 20°C. The combined 
eluates from the final two centrifugation steps were transferred to new low 
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binding tubes, acidified with 1/20th volume 10% (v/v) TFA and stored at -20ºC if 
not required immediately. 
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3.4. Peptide Labelling 
3.4.1. Desalting of digests prior to peptide labelling 
Digests performed using the methods described in sections 3.3.3. and 3.3.4. 
needed to be desalted prior to peptide stable isotope labelling. This was 
performed using Empore™ C18-SD solid phase extraction (SPE) cartridges 
(3M, St. Paul, MN, USA). Whole cell lysate digests were desalted with 3 ml 
cartridges (80 µg binding capacity) and membrane digests were desalted with 1 
ml cartridges (25 µg binding capacity). Cartridges were conditioned with 
acetonitrile and equilibrated with 0.1% (v/v) TFA (500 µl for 3 ml cartridges, 200 
µl for 1 ml cartridges). Acidified digests were passed through the cartridges. 
Bound peptides were washed with three volumes of 0.1% (v/v) TFA (3 ml for 3 
ml cartridges, 1 ml for 1 ml cartridges) and eluted with 80% (v/v) acetonitrile / 
0.1% (v/v) TFA (200 µl for 3 ml cartridges, 100 µl for 1 ml cartridges). Desalted 
peptides were stored at -20ºC if not required immediately.    
3.4.2. C-terminal 18O labelling 
C-terminal 18O labelling was initially optimized using in-solution BSA digests 
prepared in section 3.3.2. The optimization process itself is described in 
Chapter 5. Optimized conditions were subsequently used for C-terminal 
labelling of in-solution and FASP digests of whole cell lysates and membrane 
preparations. 
BSA peptides were dried under vacuum and reconstituted in either a) 50 µl of 
50 mM ammonium bicarbonate (pH 8.0) or b) 50 µl of 50 mM ammonium 
acetate (pH 4.5), both of which had been prepared in H2
18O water (Isotec / 
Sigma). Peptides were sonicated in an ultrasonic bath for 1 minute at room 
temperature and vortexed briefly to aid resuspension. Trypsin was reconstituted 
in 50 mM acetic acid (prepared using H2
18O water) such that addition of 5 µl to 
peptides resulted in an enzyme-to-substrate ratio of 1:20 (w/w). Labelling 
reactions were allowed to proceed for either a) 2 hours or b) 24 hours at 37°C in 
a thermal cycler. Reaction termination was tested by either a) no manipulation, 
b) incubating reactions at 100°C for 30 minutes and then rapidly cooling to -
20°C or c) performing reducing and alkylating reactions through addition of 1 M 
DTT to a final concentration of 20 mM and incubation at 95°C for 1 hour 
followed by addition of 1 M iodoacetamide to a final concentration of 40 mM and 
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incubation at 60°C for 30 minutes. Finally, labelled peptide storage conditions 
were tested by either: a) acidifying immediately through addition of 1/10th 
volume 10% (v/v) TFA or b) not acidifying the labelling reaction at all. 
Optimized 18O labelling conditions were subsequently established as: - 
• Reconstitution of vacuum-dried peptides in 50 µl of 50 mM ammonium 
acetate (pH 4.5) prepared in H2
18O water. 
• Incubation of peptides with trypsin (enzyme-to-substrate ratio of 1:20 
(w/w)) for 24 hours at 37°C in a thermal cycler. 
• Inactivation of trypsin by reducing and alkylating labelling reactions as 
described above. 
• Storage of reduced / alkylated labelling reactions without acidification at -
20°C until required for downstream processing or LC-MS analysis.  
These conditions were used for the subsequent C-terminal 18O labelling of all 
proteomic peptides. 
3.4.3. Lysine guanidination  N-terminal-specific succinylation 
As with C-terminal 18O labelling, N-succinylation and lysine guanidination were 
initially optimized using the in-solution BSA digests described in section 3.3.2. 
The two reactions were optimized separately and then consolidated as a single 
procedure; the net result rendering succinylation N-terminal-specific. The 
optimization process itself is described in Chapter 5. Optimized conditions were 
used for N-terminal labelling of in-solution and FASP digests of whole cell 
lysates and membrane preparations. 
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For non-specific succinylation, 1 ml Empore™ C18-SD SPE cartridges were 
conditioned and equilibrated as described in section 3.4.1. Acidified digests 
were made up to 200 µl with 1% (v/v) TFA and passed through the cartridges. 
Bound BSA peptides were washed with 1 ml of 0.1% (v/v) TFA, followed by 1 ml 
of water, followed by 1 ml 200 mM sodium acetate (pH 7.6). Peptides were 
succinylated through addition of 1 ml of 20 mM succinic anhydride made up in 
200 mM sodium acetate / 20 mM sodium hydroxide (pH 7.6). The SPE 
cartridges were attached to a ‘Visi-1’ SPE tube processor (3M) as shown below 
(Fig. 8), which was configured such that the reaction buffer passed through the 
cartridges at a uniform rate over the course of a) 5 minutes, b) 10 minutes or c) 
15 minutes. Upon completion, residual reaction buffer was expelled from the 
cartridge using the plunger on the processor. Peptides were washed with 1 ml 
of 200 mM sodium acetate (pH 7.6), followed by 1 ml of water, followed by 1 ml 
of 0.1% (v/v) TFA, followed by 1 ml of 0.2% (v/v) formic acid (FA), and eluted 
with 100 µl 80% (v/v) acetonitrile / 0.2% (v/v) FA. Succinylated peptides were 
dried under vacuum and stored at -20°C if not required immediately. 
  
Figure 8: SPE cartridge configuration for succinylation of bound peptides. 
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For lysine guanidination, 1 ml Empore™ C18-SD SPE cartridges were 
conditioned, equilibrated and acidified digests passed through as described 
above. Bound BSA peptides were washed with 0.1% (v/v) TFA and water as 
above, followed by 1 ml of 6.67% (v/v) ammonia solution. Peptides were 
guanidinated through addition of 1 ml of 1 M O-Methylisourea made up in of 
6.67% (v/v) ammonia solution. The end of the SPE cartridges were plugged 
using SPE tube adaptors attached to fully depressed 5 ml syringes as shown 
below (Fig. 9) and the cartridges were incubated at 65°C for a) 10 minutes, b) 
20 minutes or c) 30 minutes. Upon completion, residual reaction buffer that had 
not passed through the cartridges was removed by inverting the cartridges and 
discarded. Peptides were washed with 1 ml of 6.67% (v/v) ammonia solution 
followed by water, 0.1% (v/v) TFA and 0.2% (v/v) FA as above; and eluted with 
100 µl 80% (v/v) acetonitrile / 0.2% (v/v) FA. Guanidinated peptides were dried 
under vacuum and stored at -20°C if not required immediately. 
  
Figure 9: SPE cartridge configuration for guanidination of bound peptides. 
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For combined lysine guanidination followed by N-terminal-specific succinylation, 
the lysine guanidination procedure described above was followed for 30 
minutes. After removal of residual reaction buffer, peptides were washed with 1 
ml of 6.67% (v/v) ammonia solution, followed by 1 ml 0.1% (v/v) TFA, followed 
by 1 ml water, followed by 1 ml 200 mM sodium acetate (pH 7.6). The non-
specific succinylation procedure also described above was then followed, with 
the reaction allowed to proceed for 15 minutes. This was established as the 
optimized procedure for N-terminal-specific succinylation and used for N-
terminal labelling of all proteomic peptides.    
3.4.4. A novel isobaric peptide termini labelling protocol 
Finally, C-terminal 18O labelling and N-terminal-specific succinylation were 
consolidated as an integrated workflow, allowing two sets of proteomic peptides 
to be differentially isobarically labelled. C-terminal labelling was always carried 
out prior to N-terminal labelling. In the C-terminal labelling step, one set of 
peptides was 18O labelled as described in section 3.4.2. The other set of 
peptides was treated in exactly the same manner but all buffers used were 
made up using 16O water. In the N-terminal labelling step, the 18O-labelled set of 
peptides was guanidinated and succinylated with 12C4 succinic anhydride as 
described in section 3.4.3. The other set of peptides was treated in exactly the 
same manner but succinylated with 13C4 succinic anhydride (Cambridge Isotope 
Laboratories, Tewksbury, MA, USA).  
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3.5. Peptide Fractionation 
3.5.1. Isoelectric Focussing 
Total peptide concentration in samples to be focused was first assayed using a 
NanoDrop 1000 spectrophotometer. Approximately 50 µg of a differentially 
labelled mixture mature and tolerogenic DC peptides were combined in a 1:1 
ratio and separated into fractions using an Agilent 3100 OFFGEL Fractionator 
(Agilent, Santa Clara, CA, USA). For the experiments described in sections 
6.2.1.1., 6.2.1.2. (first experiment) and 7.2., 12 well frames and pH 3-10 
immobilized pH gradient (IPG) strips (13 cm) (GE Healthcare, Buckinghamshire, 
UK) were assembled as per manufacturer instructions. For the experiments 
described in sections 6.2.1.2. (second experiment) and 7.3., 12 well frames 
were converted into 11 well frames as described in (Berkelman et al., 2011) and 
used in tandem with pH 3-6 IPG strips (11 cm) (Bio-Rad, Hercules, CA, USA). 
GE strips were rehydrated for 15 minutes with 40 µl / well IPG buffer (water, 5% 
(v/v) glycerol, 0.5% (v/v) pH 3-10 IPG amphyolytes (GE)). Bio-Rad strips were 
rehydrated in the same manner using Bio-Rad ampholytes instead of GE 
ampholytes. Combined samples were made up to 360 µl with water and then to 
1.8 ml with 1.44 ml IPG buffer. For the experiments described in sections 
6.2.1.1., 6.2.1.2. (first experiment) and 7.2., 150 µl of sample was added to 
each of the 12 wells. For the experiments described in sections 6.2.1.2. (second 
experiment) and 7.3., 163 µl of sample was added to each of the 11 wells. The 
wells were sealed using the cover strips provided and 10 µl distilled water was 
applied to the electrode pads. 200 µl of mineral oil was applied to the anode 
end of the frame, 1 ml to the cathode end, and the electrodes were attached. 
Peptides were focused for 20 kVh with a maximum current of 50 mA and power 
of 200 mW. After 24 hours the upper electrode pads were replaced and a 
further 200 µl mineral oil was applied to both electrodes. Focusing typically 
completed in around 36 hours. Focussed peptides were recovered from the 
wells, concentrated to approximately 50 µl under vacuum and stored at -20°C if 
not required immediately. 
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3.5.2. StageTip-based SAX fractionation 
StageTip-based SAX fractionation was performed as described in (Wisniewski 
et al., 2009a) with a few modifications. Anion exchanger columns were 
constructed by stacking 6 × approx. 1 mm diameter disks of Empore™ Anion-
SR SPE resin (3M) in a 200 µl pipette tip (assuming a single disc had binding 
capacity of approx. 5 µg peptides). All steps were performed by passage of 
solutions through the tips using a room temperature microcentrifuge at 3000g. 
Equilibration, loading and elution steps were performed with Britton-Robinson 
(BR) buffer (20 mM acetic acid, 20 mM phosphoric acid, 20 mM boric acid; 
titrated to the desired pH with 1 N NaOH) Tips were conditioned with 50 µl 
acetone for 1 minute (spin time), followed by 50 µl methanol for 2 minutes, then 
50 µl water for 4 minutes, then 50 µl 1 N NaOH for 5 minutes, then 50 µl water 
for 5 minutes; and finally equilibrated with 50 µl BR buffer (pH 11) for 5 minutes. 
Peptides to be fractionated were reconstituted in a final volume of 50 µl BR 
buffer (pH 11). Peptides were loaded onto tips for 5 minutes. Flow-through was 
recovered and the loading repeated a further two times, then reserved as the 
pH 11 fraction. For the experiments described in section 6.3.1.1., bound 
peptides were subsequently eluted through sequential passage of 50 µl 
volumes of BR buffer solutions of pH 7, 6, 5, 4, 3 and 2 respectively. For the 
experiment described in section 6.3.1.2., an additional final elution was 
performed with BR buffer (pH 2) / 50% (v/v) acetonitrile. For the experiment 
described in section 6.3.1.3., additional elutions were performed before every 
pH decrement with BR buffer of the corresponding pH / 50% (v/v) acetonitrile. 
Fractionated peptides were stored at -20°C if not required immediately.     
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3.6. Desalting of peptides prior to LC-MS analysis 
All samples analysed by LC-MS other than those described in sections 5.3.2., 
6.2.1.2., 6.3.1. (succinylated samples) and 7.3. (all in which desalting was 
achieved concurrent with peptide guanidination and/or succinylation) were 
desalted using StageTips as described in (Rappsilber et al., 2003). Briefly, 
StageTips were constructed by stacking up to 5 × approx. 1 mm diameter discs 
of Empore™ C18-SR SPE resin (3M) in a 10 µl pipette tip (assuming a single 
disc had binding capacity of approx. 5 µg peptides). All steps were performed 
by passage of solutions through the tips using a syringe. Tips were wetted with 
20 µl acetonitrile and equilibrated with 20 µl 0.1% (v/v) TFA. Samples were 
acidified with 1/10th volume 10% (v/v) TFA and passed through the tips. Bound 
peptides were washed twice with 50 µl 0.1% (v/v) TFA, twice with 50 µl 0.2% 
(v/v) FA and eluted with 10 µl 80% (v/v) acetonitrile / 0.2% (v/v) FA. Desalted 
peptides were dried under vacuum and stored at -20°C if not required 
immediately.  
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3.7. LC-MS/MS analysis 
Peptides were reconstituted in 0.2% (v/v) FA and chromatographically resolved 
using a NanoACQUITY UltraPerformance LC® system (Waters, Manchester, 
UK). Buffer A was 0.1% (v/v) aqueous FA and buffer B was 0.1% (v/v) FA in 
acetonitrile. 
Approximately 100 ng of BSA peptides or 1 µg proteomic peptides were loaded 
onto a 0.18 X 20 mm C18 Symmetry (5 µm) trapping column (Waters) in buffer 
A. The trap was then switched in-line with a self-packed column (100 µm 
internal diameter) of Reprosil-Pur C18-AQ 3 µm resin (Dr Maisch, Ammerbuch, 
Baden-Württemberg, Germany). Peptides were eluted with segmented 
gradients of buffer B. Ion source, trapping duration, flow rate, column length and 
temperature, chromatographic gradient duration and flow rate were varied 
across multiple experiments and are summarized in Table 2.  
Peptides eluting from the capillary column were analysed by LC-MS using a 
Finnigan LTQ-FT mass spectrometer equipped with either a Finnigan 
Nanospray ion source (ThermoElectron, Bremen, Germany) or an Advance MS 
Source (Bruker, Billerica, MA, USA). All analysis was performed in positive ion 
mode. Eluate was sprayed using an uncoated 20 µm I.D. SilicaTip (New 
Objective, Woburn, MA, USA) at a spray voltage of 2 kV when using the 
Nanospray ion source and using an Advance Spraytip Assembly (Bruker) when 
using the Advance ion source. The ion source used varied across experiments 
and is summarized in Table 2. 
Top 5 data-dependent acquisition was performed as follows. Survey MS scans 
were performed over the mass range m/z = 300 – 1500 in data-dependent 
mode. Data was acquired with a FT-MS resolution setting of 100,000 at m/z = 
400 and a Penning trap injection target value of 1,000,000. The top five ions in 
the survey scan were automatically subject to collision-induced dissociation 
MS/MS in the linear ion trap region of the instrument at an injection target value 
of 100,000, using a normalized collision energy of 30% and an activation time of 
30 ms (activation Q = 0.25). Precursor ion charge state screening was enabled 
and singly charged; quadruple charged (or greater) and unassigned charge 
states were rejected. Dynamic exclusion was enabled and precursor masses 
were selected for MS/MS with a repeat count of 2 (within 15 s), then excluded 
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from further selection for a duration of 20 s. The maximum number of precursor 
masses allowed on the exclusion list at any one time was 500. Inspection of 
mass spectrum plots and MS/MS fragmentation data was performed using 
QualBrowser software (ThermoElectron).  
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Table 2: LC-MS settings used for experiments described in Chapters 4 - 7 
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Table 2 (cont.): LC-MS settings used for experiments described in Chapters 4 
- 7 
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3.8. Data analysis 
Protein identifications were performed using the Mascot search engine (Matrix 
Science Ltd, London, UK). The peptide mass tolerance was limited to 10 ppm, 
the fragment mass tolerance to 0.6 Da and searches were performed against 
the UniProt protein sequence database (sprot release 20-04-2010; 516603 
sequences; 181919312 residues). Searches were limited to human sequences 
for proteomic samples and sequences for all mammals other than primates and 
rodents for BSA samples. Cysteine carbamidomethylation was specified as a 
fixed modification, whilst methionine oxidation and pyroglutamate formation 
from N-terminal glutamine residues were taken into account as variable 
modifications. We routinely allow for potentially one missed trypsin cleavage 
and all proteins present in the database are taken into account without any pI or 
Mr restrictions. Proteins with scores in excess of the 95% confidence limit (P < 
0.05) are accepted as significant hits. 
Protein quantitation in 18O-labelled proteomic samples was carried out by 
performing Mascot searches as described above using the Mascot Distiller 
software package (Matrix Science) with C-terminal labelling with two 18O atoms 
specified as an additional variable modification. For quantitation itself, Distiller 
calculates the areas under the precursor peak elution traces for unlabelled and 
labelled peptide pairs identified in the Mascot search and reports this as the 
abundance ratio of heavy peptide to that of light peptide. Individual peptide peak 
area ratios are collated into groups which correspond to individual protein hits 
and an average ratio is calculated for each identified protein, weighted using the 
signal intensities of each peptide peak. A minimum of two unique peptide ratios 
was specified as a requirement to report an average ratio for a protein. Upon 
completion, protein quantitation reports were exported to Excel for sorting and 
filtering of matches. 
Protein quantitation in IPTL-labelled proteomic samples was carried out by 
performing Mascot searches as described above with lysine guanidination 
specified as an addition fixed modification and C-terminal labelling with two 18O 
atoms, N-terminal succinylation with 12C4-succinic anhydride and N-terminal 
succinylation with 13C4-succinic anhydride specified as additional variable 
modifications. For quantitation, Mascots in-built multiplex quantitation protocol 
calculates the relative intensities of both 12C4-labelled versus 
13C4-labelled b-
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series product ions and unlabelled versus 18O-labelled y-series product ions in a 
given product ion scan. Each peptide-to-spectrum match (PSM) is thus reported 
with an overall ratio derived from the summed ratios of each 12c4 / 
13c4 and 
unlabelled / 18O-labelled product ion pair. Individual PSM ratios are consolidated 
in instances where more than one PSM is obtained for a given peptide, and 
further consolidated as peptides are assigned to proteins. The final ratios are 
weighted using product ion signal intensities for all PSMs assigned to a given 
protein. A minimum of two unique peptide ratios was specified as a requirement 
to report an average ratio for a protein. Upon completion, protein and peptide 
reports were exported to Excel for sorting and filtering of matches. 
Protein gene annotation and transmembrane helix prediction in membrane-
enriched fractions was performed using the STRAP (Bhatia et al., 2009) 
(http://www.bumc.bu.edu/cardiovascularproteomics/cpctools/strap/) and 
TMHMM (Krogh et al., 2001) (http://www.cbs.dtu.dk/services/TMHMM/) 
algorithms respectively and described in more detail in Chapter 4. 
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3.9. Miscellaneous 
3.9.1. BSA labelling with EZ-Link® Sulfo-NHS-SS Biotin and RevAmine 
BSA (Sigma-Aldrich) was reconstituted in 1 ml PBS in low binding 
microcentrifuge tubes (Sorensen Bioscience) and reacted with 10 µl of either 
EZ-Link® Sulfo-NHS-SS Biotin (Thermo Fisher Scientific) or RevAmine, both at 
25µg/µl, in DMSO). The amount of BSA reconstituted was calculated such that 
addition of 10 µl of either reagent would result in a 20-fold molar excess of 
reagent over that of BSA. 10 µl of DMSO alone was also added to BSA to serve 
as an unbiotinylated control. Tubes were vortexed for 1 minute and incubated 
for 1 hour at room temperature. Biotinylation reactions were quenched through 
addition of 50 µl of ‘quenching solution’ (Thermo Fisher) with incubation for a 
further minute at room temperature. Biotinylated BSA was desalted using PD 
SpinTrap™ Sephadex™ G-25 microcentrifuge spin columns (GE Healthcare). 
Columns were equilibrated with four 500 µl volumes of water and centrifuged at 
800g for 1 minute at room temperature. 150 µl of BSA solution was applied to 
the resin, incubated at room temperature for 1 minute and then collected by 
centrifugation as described. 
3.9.2. MALDI-TOF-MS of EZ-Link® Sulfo-NHS-SS Biotin and RevAmine-
labelled BSA 
Samples of desalted biotinylated and unbiotinylated control BSA were acidified 
through addition of 1/10th volume 10% (v/v) TFA and 1 µl (approximately 1 µg) 
protein solution was spotted onto a MALDI plate and allowed to air dry. Sample 
spots were then overlaid with 1 µl of sinapinic acid matrix (10 mg/ml in 50% 
(v/v) acetonitrile containing 0.1% (v/v) TFA) and allowed to air dry once more. 
Analysis was performed by matrix-assisted laser desorption ionization-time of 
flight mass spectrometry (MALDI-TOF-MS) using a Voyager DE-STR (Applied 
Biosystems, Foster City, CA, USA). Spectra were acquired in positive ion linear 
mode (25 kV accelerating voltage, 250 ns delay time) over a mass range of 
40000 Da – 90000 Da with 50 laser shots per spectrum. External calibration 
was performed against the unbiotinylated BSA control.  
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3.9.3. Fluorescence confocal microscopy of EZ-Link® Sulfo-NHS-SS 
Biotin and RevAmine-labelled cells 
Jurkat T cells were harvested, washed and biotinylated as described in section 
3.2.3. After quenching of biotinylation reactions and washing with TBS, 
biotinylated and control cells were resuspended in fluorescence-activated cell 
sorting (FACS) buffer (PBS / 0.5% (v/v) BSA / 0.01% (v/v) sodium azide) 
containing a streptavidin - Alexa Fluor® 568 conjugate (Life Technologies, 
Carlsbad, CA, USA). Cells were incubated at 4°C in the dark for 1 hour, washed 
three times with FACS buffer and fixed with FACS buffer / 1% (v/v) 
paraformaldehyde. 1 × 105 fixed cells were transferred to microscope slides 
using a Cytospin for 3 minutes at 1000 rpm and mounted using VECTASHIELD 
mounting media with 4',6-diamidino-2-phenylindole (DAPI) counterstain (Vector 
Laboratories, Burlingame, CA, USA). Cells were visualized by 
immunofluorescence using a Leica TCS SP2 UV laser-scanning confocal 
microscope set up to detect tetramethyl rhodamine isothiocyanate (TRITC) 
(excitation 547 nm, emission 572 nm) and DAPI (excitation 345 nm, emission 
455 nm). Baseline TRITC emission levels were set using unlabelled cells and all 
labelled cells imaged using these settings. 
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Chapter 4. Development and validation of a membrane 
enrichment and digestion protocol to favour 
mass spectrometric identification of membrane 
proteins 
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4.1. Introduction 
4.1.1. Challenges of membrane proteomics 
As discussed in Chapter 1, bottom-up mass-spectrometry based proteomics of 
membrane proteins poses particular challenges owing to their low abundance 
relative to the rest of the proteome and their decreased solubility in the aqueous 
buffers typically used throughout the proteomic workflow prior to LC-MS 
analysis. The first of these challenges necessitates performing some form of 
membrane protein enrichment prior to analysis whilst the second requires the 
adoption of novel strategies to solubilize and digest membrane proteins whilst 
avoiding the use or retention of substances which negatively impact upon the 
activity of the protease/s used for digestion and the process of LC-MS analysis 
itself. 
Mass spectrometry is essentially a concentration-dependent technique and the 
probability of sampling membrane proteins during LC-MS is substantially 
increased if proteins present in far greater quantities (for instance cytoplasmic 
and nuclear proteins) are first depleted from the sample. There are a variety of 
ways to enrich membrane proteins relative to non-membrane proteins in a 
sample, with the majority either utilising differential or density gradient 
centrifugation or affinity purification with tagging reagents which target surface-
exposed protein domains on intact cells. It was initially intended that an 
enrichment strategy which fell into the second of these categories was pursued 
with a novel amine-directed biotinylation reagent (RevAmine), which will be 
discussed in more detail later. 
There are also a wide range of published strategies for membrane protein 
solubilization and digestion. A key consideration here is the extent to which the 
means of solubilization impacts upon the efficiency of digestion and subsequent 
analysis.  A case in point is SDS, which is widely regarded as the most powerful 
detergent available for solubilization of proteins, but is only compatible with 
tryptic digestion at minute (< 0.1% (w/v)) concentrations and must be 
completely removed prior to LC-MS. An ‘ideal’ strategy for solubilization and 
digestion would thus be one which employed a powerful solubilizing agent with 
negligible repercussions on downstream processing. FASP (Wisniewski et al., 
2009b) appears to be well-suited in this regard. In addition, the final elution step 
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of the affinity purification which would be required were a cell surface 
biotinylation strategy for membrane protein enrichment to be adopted would 
segue nicely into the initial solubilization step of FASP, and it was thus selected 
as the first-line digestion strategy to pursue. 
4.1.2. Criteria for evaluation of the effectiveness of a membrane protein 
enrichment and digestion strategy 
There exist a number of means for inferring which proteins identified in an LC-
MS run are likely to be membrane proteins. A commonly employed approach in 
the literature is to use Gene Ontology annotations. The Gene Ontology (GO) is 
a major bioinformatics initiative which seeks to annotate all genes and gene 
products with a controlled vocabulary of attributes pertaining to the ‘biological 
processes’ in which they partake, the ‘molecular functions’ which they possess 
and the ‘cellular components’ in which they reside (Ashburner et al., 2000). 
Membrane localization can thus be inferred through examining which of the 
identified proteins have a membrane-related cellular component annotation. 
That said, GO annotation is by no means an infallible system for determining 
whether a given protein is likely to be a bona fide membrane protein. The nature 
of the controlled vocabulary and the fact that many annotations are assigned via 
software through inference from sequence or structural similarity to other 
proteins means that membrane annotations are often assigned to proteins 
which would not typically be considered membrane proteins and would almost 
certainly not be considered of interest in the context of this particular project. 
For instance, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) has a 
plasma membrane annotation. The converse is also true, genuine membrane 
proteins which have not been annotated as such will clearly not be identified as 
such. This may occur with proteins that are poorly annotated. For instance, 
signal-regulatory protein beta-1 (SIRP-β-1) and SIRP-β-1 isoform 3 are both 
transcribed from the same gene and share 87% sequence identity but only the 
former has a plasma membrane GO annotation.  
An alternative approach is to examine the primary amino acid sequences of the 
proteins identified for structural motifs synonymous with membrane localization. 
Motifs of interest are stretches of sequence which assume a membrane-
spanning α-helical conformation, accumulation of amphiphilic residues at each 
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end of said α-helical stretches and cytoplasmic loop regions between helices. α-
Helices are a very common structural motif but transmembrane helices are 
composed largely of hydrophobic amino acids and must be at least 15 residues 
in length in order to span the lipid bilayer (Punta et al., 2007). The presence of 
amphiphilic amino acids at each end of a membrane-spanning helix ensure that 
the helical region itself resides entirely within the bilayer (Schiffer et al., 1992; 
Reithmeier, 1995; Braun and von Heijne, 1999; Ridder et al., 2000). 
Cytoplasmic loop regions contain a relatively high proportion of charged 
residues to prevent translocation of these regions across the lipid bilayer when 
the protein is inserted into the membrane, giving rise to the so called ‘positive-
inside’ rule (von Heijne and Gavel, 1988; Nilsson et al., 2005). These motifs can 
be used to develop algorithms to predict membrane protein topology (Punta et 
al., 2007). 
One such algorithm is TMHMM (Krogh et al., 2001), which takes hydrophobicity, 
net charge, helix length and topological constraints into consideration when 
predicting presence and topology of transmembrane domains TMHMM 
performs very well in the analysis of the membrane protein content of a given 
dataset, misclassifying less than 1% of soluble proteins as membrane proteins 
whilst correctly identifying 97 – 98% of legitimate transmembrane helices. As an 
aside, SIRP-β-1 and SIRP-β-1 isoform 3 are both predicted to possess a single 
transmembrane helix in exactly the same place by TMHMM, lending further 
weight to the assertion that the latter is also a plasma membrane protein. 
In evaluating the effectiveness of the various membrane enrichment and 
digestion strategies explored here, both GO annotation and the TMHMM 
algorithm have been employed; increasing confidence that any purported 
enrichment in membrane protein identifications are genuine and allowing the 
two software tools to be compared and contrasted. 
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4.1.3. Amine-directed biotinylation reagents 
The interaction of avidin and biotin is among the strongest non-covalent 
interactions known, exhibiting a dissociation constant in the order of 10-15 M 
(Green, 1975). The native structure of avidin is resistant to harsh conditions 
such as extremes of temperature (up to 132ºC), pH (between pH 2 and pH 13) 
and strong denaturants (up to 8 M urea or 3 M guanidine hydrochloride) (Green, 
1963). Interaction with biotin stabilizes the complex further, an avidin-biotin 
complex is stable in 8 M guanidine at pH 5.2, and complete dissociation 
requires at least 6 M guanidine at pH 1.5 (Cuatrecasas and Wilchek, 1968; 
Bodanszky and Bodanszky, 1970). There is also evidence that the complex can 
be formed and maintained in the presence of a wide range of detergents, 
including 1% (w/v) SDS (Waner et al., 2004). 
The properties of this interaction have facilitated its use in a plethora of 
biological applications. Biotinylated molecules will bind streptavidin conjugates 
with high affinity and specificity even in complex mixtures. A vast array of 
reagents are now available for biotinylation of biomolecules of interest, all of 
which are typically composed of a biotin moiety and a reactive group separated 
by a spacer arm. 
A common reactive group used in such reagents is an NHS-ester, which will 
react covalently with primary amines to form a stable amide bond. One such 
reagent is sulfosuccinimidyl-2-(biotinamido)ethyl-1,2-dithiopropionate (EZ-
LinkTM Sulfo-NHS-SS-Biotin, Thermo Fisher) (Fig. 10). This reagent 
incorporates a disulphide bridge in the spacer arm, enabling biotinylated 
biomolecules of interest to be released under reducing conditions without 
employing the harsh reagents required to disrupt the avidin-biotin interaction 
itself. The negative charge imparted to the reagent by the sulfonate group 
counterbalances the poor solubility imparted by the biotin moiety, enabling the 
reagent to be dissolved directly in aqueous buffers (Hermanson, 2008). This 
negative charge character should also prevent it from penetrating the plasma 
membrane of viable cells; indeed it was this property for which it was initially 
employed (Hurley et al., 1985; Cole et al., 1987; Meier et al., 1992; Altin and 
Pagler, 1995). These properties theoretically make EZ-LinkTM Sulfo-NHS-SS-
Biotin ideal for targeting cell surface proteins.        
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Protein NH2 + 
Protein 
Protein 
Protein 
Reduction 
Alkylation 
a) 
b) 
c) 
d) 
Figure 10: Biotinylation of proteins using EZ-LinkTM Sulfo-NHS-SS-Biotin. a)
The OSu ester reacts covalently with primary amines. b) A stable amide bond 
is formed and an NHS leaving group is released. The biotinylated protein can 
then be affinity purified using the avidin-biotin interaction. c) After affinity 
purification, the protein can be liberated through reduction of the disulphide 
bond in the spacer arm of the reagent. This liberates a free thiol d) Alkylation 
converts the thiol to a CAMthiopropanoyl group.     
Avidin 
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From a mass spectrometry-based proteomics perspective, a major shortcoming 
of EZ-LinkTM Sulfo-NHS-SS-Biotin is the residual CAMthiopropanoyl moiety it 
leaves on lysine side chains after affinity purification of the biotinylated 
biomolecules of interest. This chemical group precludes tryptic cleavage at 
modified lysine residues and would be expected to negatively impact upon the 
number and size of peptides produced from a tryptic digest of modified proteins. 
An ‘ideal’ amine-directed biotinylation reagent for mass spectrometry-based 
proteomics would be traceless, that is liberation of biomolecules of interest after 
affinity purification would be concomitant with regeneration of lysine primary 
amines. In recent years, a couple of research groups have incorporated such 
functionality into linkers which are cleaved in response to UV irradiation (Wang 
et al., 2012) and acidic conditions (Maier and Wagner, 2012). 
Our research group has developed RevAmine (Grey et al.; unpublished data), 
an amine-directed biotinylation reagent incorporating a functional group in the 
spacer arm which exploits the beta elimination behaviour of sulfonyl ethanol 
derivatives to enable traceless removal upon treatment with mild base (Fig. 11). 
The reagent has been shown to be soluble in aqueous media and to react with 
peptides in neutral pH, non-amine buffers. Facile cleavage of tagged peptide 
had also been demonstrated in concentrations of dilute ammonia as low as 
0.01% (v/v) and in ammonium bicarbonate at pH 8. These characteristics 
suggested that it would be feasible to incorporate this novel reagent into a cell-
surface biotinylation and affinity purification-based enrichment strategy with the 
aim of circumventing the shortcomings of non-traceless reagents, such as the 
one described above. 
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Protein NH2 + 
Protein 
Protein 
Mild Base Treatment 
NH2 
CO2 
a) 
b) 
c) 
Figure 11: Biotinylation of proteins using RevAmine. a) The OSu ester reacts 
covalently with primary amines. b) A carbamate linkage to lysine on the protein 
is formed and an NHS leaving group is released. The biotinylated protein can 
then be affinity purified using the avidin-biotin interaction. c) After affinity 
purification, treatment with mild base releases the unmodified protein. 
Avidin 
Avidin 
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4.2. Results 
4.2.1. Characterisation of RevAmine - a novel amine-directed 
biotinylation reagent 
4.2.1.1. MALDI-TOF analysis demonstrates facile conjugation of 
RevAmine tag to intact BSA 
The biochemical properties of RevAmine had previously been elucidated with 
peptides. Given that it was intended that RevAmine be used in the context of a 
membrane protein enrichment strategy, the logical progression was to augment 
the peptide-based studies with some whole protein work. With this in mind, 
analogous conjugation and removal experiments were performed using BSA. 
BSA was reconstituted in PBS and a 20-fold molar excess of either EZ-LinkTM 
Sulfo-NHS-SS-Biotin or RevAmine was added. Biotinylation reactions were 
allowed to proceed for 1 hour before quenching. A control reaction was also 
included in which no amine-directed biotinylation reagent was added. All 
reactions were subsequently column-desalted.  Approximately 1 µg protein was 
spotted onto a MALDI plate using sinapinic acid matrix, allowed to dry and 
analysed by MALDI-TOF. 
The extent of biotinylation in unbiotinylated, EZ-LinkTM Sulfo-NHS-SS-Biotin 
labelled and RevAmine-labelled BSA is shown in Fig. 12. These data suggest 
that both reagents can be used for biotinylation of BSA in isolation. On the basis 
of the reported average intact mass measurements, it can be inferred that there 
are approximately 10.46 EZ-LinkTM Sulfo-NHS-SS-Biotin molecules per protein 
and approximately 7.09 RevAmine molecules per protein. These figures are 
slightly higher than those reported by Pierce for modification of Immunoglobulin 
G (IgG) with a 20-fold molar excess of EZ-LinkTM Sulfo-NHS-SS-Biotin.  This 
may be because there are more accessible surface-exposed reactive groups in 
BSA than IgG. The higher number of EZ-LinkTM Sulfo-NHS-SS-Biotin molecules 
per protein suggests slightly greater reactivity for this reagent, which may be 
explained by the improved solubility imparted by the sulfosuccinimide ester. 
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4.2.1.2. LC-MS analysis demonstrates facile conjugation and traceless 
removal of RevAmine tag to and from intact BSA prior to tryptic 
digestion. 
BSA was biotinylated and the reaction quenched as described in section 
4.2.1.1. A control reaction was carried out as before. All biotinylation reactions 
were subsequently divided into two aliquots. The first of the two aliquots for 
each condition were immediately buffer exchanged into 50 mM ammonium 
bicarbonate. The second of the two aliquots for each condition were basified 
through addition of ammonia solution to a final concentration of 0.1% (v/v) and 
incubated at room temperature for 1 hour before being buffer exchanged as 
above. All aliquots were then digested overnight with trypsin, acidified with 1% 
(v/v) TFA, tip desalted and analysed by LC-MS.   
Raw data were processed and searched using Mascot MS/MS search tool with 
mass shifts resulting from modification of N-terminal and lysine side chain 
primary amines with EZ-LinkTM Sulfo-NHS-SS-Biotin and RevAmine reagents 
specified as variable modifications. Peptide reports were exported from Mascot 
MS/MS search as CSV files and imported into Microsoft Excel for further data 
processing. All peptides detected across all runs were examined for presence of 
mass shifts indicative of modification with either reagent. 
Modified and unmodified peptides derived from the BSA biotinylated with EZ-
LinkTM Sulfo-NHS-SS-Biotin and not treated with ammonia are shown in Fig. 13, 
whilst modified and unmodified peptides derived from the BSA biotinylated with 
RevAmine and not treated with ammonia are shown in Fig. 14. No mass shifts 
indicative of modification with either reagent were detected in either replicate for 
the unbiotinylated BSA not treated with ammonia and these data are not shown. 
A total of 288 modified peptides were detected across the two replicates for 
BSA biotinylated with EZ-LinkTM Sulfo-NHS-SS-Biotin, with modifications seen 
at 14 unique residues. In contrast, a total of 54 modified peptides were detected 
across the two replicates for BSA biotinylated with RevAmine, with 
modifications seen at 5 unique residues. This disparity may be due in part to the 
increased reactivity of the commercial reagent owing to the sulfosuccinimide 
ester and in part to the fact that nearly twice as many peptides were detected in 
total across the two replicates where it was used. 
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Modified and unmodified peptides derived from the BSA biotinylated with EZ-
LinkTM Sulfo-NHS-SS-Biotin and treated with ammonia are shown in Fig. 15, 
whilst modified and unmodified peptides derived from the BSA biotinylated with 
RevAmine and treated with ammonia are shown in Fig. 16. No mass shifts 
indicative of modification with either reagent were detected in either replicate for 
the unbiotinylated BSA treated with ammonia and these data are not shown. A 
total of 82 modified peptides were detected across the two replicates for BSA 
biotinylated with EZ-LinkTM Sulfo-NHS-SS-Biotin and then basified with 
modifications seen at 8 unique residues. Whilst this figure is less than the 
number of modified peptides detected in the sample biotinylated with EZ-LinkTM 
Sulfo-NHS-SS-Biotin and not treated with ammonia, the number of total 
peptides detected across the two replicates is also nearly half that here. 
Encouragingly, no modified peptides could be detected across the two 
replicates for BSA biotinylated with RevAmine and then basified. This suggests 
that the RevAmine reagent behaves in the same manner when incubated under 
basic conditions, regardless of whether it is reacted with peptides or proteins.        
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  Total 
365 ± 181 
Unmodified 
221 ± 48.8 
Modified 
144 ± 132.9 
n = 2 
Figure 13: Unmodified and modified BSA peptides detected by LC-MS after 
tryptic digestion of EZ-LinkTM-modified BSA. Data are the average of two 
experimental replicates. 238 MS/MS events corresponded to modified peptides 
in the first replicate and 50 MS/MS events corresponded to modified peptides in 
the second replicate. Modifications were detected on 14 unique peptides 
across the two replicates. 
MS/MS 
Identifications 
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Total 
222 ± 12.73 
Unmodified 
195 ± 16.97 
Modified 
27 ± 29.7 
n = 2 
Figure 14: Unmodified and modified BSA peptides detected by LC-MS after 
tryptic digestion of RevAmine-modified BSA. Data are the average of two 
experimental replicates. 48 MS/MS events corresponded to modified peptides 
in the first replicate and 6 MS/MS events corresponded to modified peptides in 
the second replicate. Modifications were detected on 5 unique peptides across 
the two replicates. 
MS/MS 
Identifications 
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  Total 
185.5 ± 102.5 
Unmodified 
144.5 ± 89.8 
Modified 
41 ± 12.73 
n = 2 
Figure 15: Unmodified and modified BSA peptides detected by LC-MS after 
tryptic digestion followed by treatment with 0.1% (v/v) NH3 of EZ-Link
TM-
modified BSA. Data are the average of two experimental replicates. 32 MS/MS 
events corresponded to modified peptides in the first replicate and 50 MS/MS 
events corresponded to modified peptides in the second replicate. Modifications
were detected on 8 unique peptides across the two replicates. 
MS/MS 
Identifications 
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Total Peptides 
121 ± 63.64 
Unmodified 
121 ± 63.64 
Modified 
0 
n = 2 
Figure 16: Unmodified and modified BSA peptides detected by LC-MS after 
tryptic digestion followed by treatment with 0.1% (v/v) NH3 of RevAmine-
modified BSA. Data are the average of two experimental replicates. No MS/MS 
events corresponding to modified peptides were detected in either replicate, 
suggesting that base treatment completely removes all traces of the RevAmine 
tag from intact proteins as desired. 
MS/MS 
Identifications 
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4.2.1.3. Fluorescence confocal microscopy shows RevAmine and EZ-
LinkTM Sulfo-NHS-SS-Biotin are equally adept at biotinylating 
cell surface proteins in situ. 
Having extended the initial peptide-based studies with RevAmine to an intact 
protein, the final step was to examine whether it could be used to biotinylate 
proteins in situ on the surface of intact cells. 
Jurkat T-cells were incubated in the presence of either EZ-LinkTM Sulfo-NHS-
SS-Biotin or RevAmine. Excess reagent was quenched using Pierce Cell 
Surface Isolation Kit ‘quenching solution’ and removed through extensive 
washing. The cells were then stained with a Streptavidin – Alexa Fluor 568 
conjugate. Stained cells were fixed, cytospun onto microscope slides and 
mounted using a DAPI mounting medium. Unbiotinylated cells were stained and 
processed in the same manner.  Fig. 17 suggests that both reagents can be 
used for cell surface biotinylation, with discernible levels of membrane-localized 
fluorescence which are not present in the unbiotinylated cells. 
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4.2.2. Evaluation of the suitability of amine-directed biotinylation 
reagents as tools for enrichment of cell surface proteins for 
analysis by mass spectrometry. 
The data shown in section 4.2.1. suggested that both EZ-LinkTM Sulfo-NHS-SS-
Biotin and RevAmine could be used to biotinylate surface-exposed primary 
amine residues on intact cells and that the latter of the two reagents could be 
completely removed through treatment with dilute base, regenerating the 
original peptide. It was next investigated whether these biotinylated proteins 
could be captured and enriched before proceeding with tryptic digestion and 
LC-MS analysis. 
All samples processed using a cell surface biotinylation approach were enriched 
broadly in accordance with the protocol supplied with the Pierce Cell Surface 
Isolation Kit, which includes EZ-LinkTM Sulfo-NHS-SS-Biotin and all reagents 
necessary to lyse labelled cells and  capture, enrich and elute biotinylated 
proteins from the lysate. Briefly, after the labelling reaction has been completed, 
cells are lysed and the lysate is loaded into a spin column containing 
NeutrAvidin® Agarose Resin. Biotinylated proteins are allowed to bind the resin 
and non-biotinylated proteins are removed through stringent washing. 
Biotinylated proteins are then liberated from the column through addition of a 
buffer containing DTT and collected as the eluate fraction.    
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4.2.2.1. Filter-Aided Sample Preparation (FASP) performs as effectively 
as standard in-solution digestion for processing of whole cell 
lysates for LC-MS analysis. 
As touched upon in section 4.1., it was desired that FASP be used for digestion 
of membrane-enriched fractions. The suggested buffer for the elution step in the 
Pierce Cell Surface Isolation Kit protocol is PAGE sample buffer (containing 
DTT), which lends itself to a gel-based workflow. For reasons pertaining to the 
digestion and labelling steps of this particular workflow which will be discussed 
more fully in Chapter 6, we wished to avoid gel-based proteomics. 
Nevertheless, it was assumed that the elution buffer should be supplemented 
with a detergent(s) of some description lest the proteins come out of solution in 
the avidin spin column and not be eluted. The presence of detergent in the 
elution buffer would necessitate its removal prior to proceeding with the 
standard in-solution digestion protocol in place in the lab. This could be 
achieved using a precipitation step or a detergent removal resin (indeed, the 
latter is how detergent was removed from whole cell lysates prior to digestion 
for the work presented in Chapter 5. However, precipitations will by definition 
bring all proteins out of solution and even using a detergent removal resin could 
cause the membrane proteins to come out of solution once more. The first step 
of the FASP procedure entails solubilization of proteins in SDS / Tris-HCl and 
reduction with DTT. It was thus reasoned that this solubilization buffer could be 
employed in place of PAGE Buffer to liberate biotinylated proteins from the 
avidin spin column. The resultant eluate could then be processed using FASP. 
Since FASP had never been used in the lab before, we first wished to examine 
whether it could be used in place of in-solution digestion for whole cell lysates. 
This would give an indication as to whether there were any inherent problems 
with the technique itself.  Approximately 100 µg of Jurkat whole cell lysate was 
digested overnight using either FASP or in-solution digestion. Digests were 
acidified with 1% (v/v) TFA, desalted using an SPE cartridge and analysed by 
LC-MS. Raw data were processed and searched using Mascot. Protein 
summary reports were screen scraped and imported into Microsoft Excel. 
Uniprot accession code lists were saved as text files. GO annotation was 
performed using the STRAP software tool (Bhatia et al., 2009). For 
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transmembrane domain prediction, Uniprot accession code lists were converted 
to FASTA format and analysed using a TMHMM batch search. 
The distribution of cellular component GO annotations for all identified proteins 
are shown in Fig. 18a for in-solution digestion and Fig. 18b for FASP. The 
percentage of total proteins identified with ‘plasma membrane’, ‘cytoplasmic’ 
and ‘nuclear’ GO annotations is shown to the right of each pie chart. It is worth 
noting at this point that many proteins have more than one cellular compartment 
GO annotation and hence the percentages reported do not appear to tally with 
the corresponding slice of the pie chart and summate to more than 100%. The 
percentage of proteins predicted to contain transmembrane domains by the 
TMHMM algorithm is also shown.      
The two techniques appear near-equivalent in terms of total protein 
identifications, distribution of subcellular component ontologies across the 
identified proteins and percentage of proteins predicted to contain 
transmembrane helices by TMHMM. This suggested that there were no 
technical issues with FASP as a digestion technique and it was therefore 
adopted for digestion of all membrane fractions for optimization of the 
enrichment aspect of the workflow.   
The disparity between plasma membrane annotations and predicted 
transmembrane proteins also reinforces the need to use multiple methods to 
infer the extent of membrane protein enrichment in a sample. In the first of the 
two FASP runs, 51 proteins were assigned a plasma membrane annotation by 
STRAP. Of these 51 proteins, only 4 were predicted to contain any 
transmembrane helices by TMHMM. Conversely, of the 6 proteins predicted to 
contain any transmembrane helices by TMHMM, only 4 were assigned a 
plasma membrane annotation by STRAP. However, the 2 transmembrane helix-
containing proteins which were not assigned a plasma membrane annotation by 
STRAP were assigned annotations which could be reconciled with some other 
cellular membrane localization. This suggests that GO annotation overestimates 
membrane protein enrichment and sounds a note of caution about the 
automatic annotation of protein lists. 
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Figure 18: Pie charts illustrating the distribution of cellular component 
ontologies of proteins identified from LC-MS analysis of a Jurkat whole cell 
lysate digested using a) in-solution digestion; b) FASP. The number of total 
protein identifications; the percentages of total identifications with ‘plasma 
membrane’, ‘cytoplasmic’ and ‘nuclear’ annotation; and the percentage of 
proteins predicted to contain transmembrane domains by the TMHMM
algorithm are also displayed. The similarities in total identifications and 
comparable distribution of ontologies suggest that both techniques perform 
comparably for digestion of whole cell lysates. N.B. many proteins have more 
than one cellular compartment GO annotation and hence the percentages 
reported here (and in subsequent pie chart figures) do not appear to tally with 
the corresponding slice of the pie chart and summate to more than 100%. 
 
b) Total IDs 
220 ± 18 
Plasma Membrane 
20.36% ± 2.16% 
Cytoplasmic 
51.14% ± 0.10% 
Nuclear 
52.94% ± 0.40% 
 
Contains TMHMM-
predicted Helix 
2.74% ± 0.23% 
n = 2 
a) Total IDs 
232 ± 40 
Plasma Membrane 
21.06% ± 0.67% 
Cytoplasmic 
58.50% ± 1.15% 
Nuclear 
52.57% ± 0.17% 
 
Contains TMHMM-
predicted Helix 
3.11% ± 1.14% 
 
n = 2 
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4.2.2.2. Use of ‘EZ-Link™’ Sulfo-NHS-SS-Biotin and RevAmine to enrich 
for plasma membrane proteins prior to LC-MS analysis 
produces only a small increase in percentage of plasma 
membrane protein IDs 
FASP was designed to allow initial solubilisation of total lysate protein in high 
concentrations of detergent and to then permit quantitative depletion of the 
detergent from the protein solution prior to the introduction of enzyme digestion. 
For this to occur, it is imperative that the detergent is either diluted well below its 
CMC prior to digestion such that the majority of detergent passes through the 
MWCO filter in monomeric form; or that the molecular weight of the micelles is 
sufficiently small to enable their passage through the filter. Different detergents 
have different CMCs and monomeric / micellar molecular weights and 
consequently not all will be quantitatively depleted using the technique. 
The Pierce Cell Surface Protein Isolation Kit contains proprietary detergent-
based lysis and wash buffers, the constituents of which are commercially 
sensitive. It was therefore unclear whether any detergent carryover in the eluate 
fraction from the lysis and wash steps of the procedure would be depleted using 
FASP. In any event, the lysis and wash buffers are not sold separately and to 
purchase the entire kit merely to use the buffers was considered impractical. 
Our initial inclination was thus to substitute these proprietary buffers for SDS-
based buffers.       
Jurkat cells were incubated in the presence of EZ-LinkTM Sulfo-NHS-SS-Biotin. 
Excess reagent was quenched and removed through extensive washing. Cells 
were lysed through addition of 0.1 M TRIS-HCl containing 1% (w/v), 2% (w/v) or 
4% (w/v) SDS and lysates incubated for 1 hour in a spin column containing 
Neutravidin® resin. Wash and elution steps were performed using the buffer 
containing the same concentration of SDS which had been used to lyse the 
cells. Membrane fractions were digested using FASP and digests cleaned up 
and analysed as described in section 4.2.2.1. Data processing, GO annotation 
and transmembrane domain prediction were also performed as previously 
described.    
The distribution of cellular component GO annotations and percentage of 
proteins predicted to contain transmembrane domains by TMHMM for all 
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proteins identified in the membrane fractions processed using 1% (w/v) SDS, 
2% (w/v) SDS and 4% (w/v) SDS are shown in Figs. 19a-c respectively. The 
fraction processed using 1% (w/v) SDS appears to exhibit a modest enrichment 
in membrane proteins, with both plasma membrane GO annotations and 
proteins predicted to contain transmembrane helices increased relative to the 
whole cell lysate data shown in section 4.2.2.1. However, the salient 
observation from this particular set of experiments is the numbers of total 
protein identifications across the three samples. The fraction processed using 
1% (w/v) SDS yields around half the identifications of either whole cell lysate 
digest; the fraction processed using 4% (w/v) SDS yields only a tenth the 
identifications. As detailed in section 4.1.3., there are reports that the avidin-
biotin interaction can be formed and maintained in harsh conditions (including 
1% SDS); though it might be expected that the harsher the conditions, the 
longer it would take for the initial interaction to form. The decreasing protein 
identifications observed with increasing concentrations of SDS is most likely 
due to decreased avidin-biotin binding and suggests increasing incubation times 
in the higher concentrations to allow for this.  
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Given the observations in section 4.2.2.2., the experiment was repeated using 
different conditions. Cells were incubated in the presence of either EZ-LinkTM 
Sulfo-NHS-SS-Biotin or RevAmine. Unbiotinylated cells were also included as a 
control to examine the extent of non-specific binding to the NeutrAvidin® resin. 
Labelled and unlabelled cells were lysed with 0.1 M TRIS-HCl / 4% (w/v) SDS 
and lysates incubated with the resin overnight rather than for an hour. Wash 
and elution steps were also performed using this buffer. For comparison and to 
examine the compatibility of their use with FASP, labelled and unlabelled cells 
were also processed using the lysis and wash buffers included with the Pierce 
Kit as per the supplied protocol and eluted using 0.1 M TRIS-HCl / 4% (w/v) 
SDS. All membrane fractions were digested, cleaned up, analysed and 
annotated as described previously. 
The distributions of cellular component GO annotations and percentage of 
proteins predicted to contain transmembrane domains by TMHMM for all 
identified proteins are shown in Fig. 20 for the samples for which lysis and wash 
steps were performed using Pierce lysis and wash buffers and Fig. 21 for the 
sample for which lysis and wash steps were performed using 4% (w/v) SDS. 
For each figure, data for unlabelled cells, cells labelled with EZ-LinkTM Sulfo-
NHS-SS-Biotin and cells labelled with RevAmine are shown in subfigures (a), 
(b) and (c) respectively.  
The labelled fractions processed using the Pierce lysis and wash buffers both 
yield around a four-fold increase in total protein identification over the unlabelled 
control. Plasma membrane GO annotations and proteins predicted to contain 
transmembrane helices are increased relative to the whole cell lysate data 
shown in section 4.2.2.1., with the latter being increased over four-fold in the 
cells labelled with both EZ-LinkTM Sulfo-NHS-SS-Biotin and RevAmine. 
However, in both labelled fractions, cytoplasmic and nuclear protein annotations 
still dominate. The identification of so many non-membrane proteins in these 
supposedly membrane-enriched fractions was somewhat surprising given the 
design of the experimental technique. 
The fraction labelled using EZ-LinkTM Sulfo-NHS-SS-Biotin and processed using 
4% (w/v) SDS yields around a three-fold increase in total protein identification 
over the unlabelled control. Interestingly, plasma membrane GO annotations 
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here are actually decreased relative to those seen in the whole cell lysates but 
the proportion of proteins predicted to contain transmembrane helices is 
increased over three-fold. Of the 29 proteins assigned a plasma membrane 
annotation here, only 4 are predicted to contain a transmembrane helix; whilst 
of the 16 proteins predicted to contain a transmembrane helix, only 4 are 
assigned a plasma membrane GO annotation. This again suggests that there is 
currently no single method for comprehensive identification of plasma 
membrane proteins using proteomic datasets and so advocates the use of more 
than one means of assessing membrane enrichment. 
The fraction labelled using RevAmine and processed using 4% (w/v) SDS yields 
58 protein identifications, only 8 more than the unlabelled control for this 
particular set of experiments. This is in stark contrast to the RevAmine-labelled 
fraction processed with the Pierce lysis and wash buffers and was a little 
unexpected. The RevAmine tag is cleaved through high pH and presence of 
primary amines. TRIS contains a hindered primary amine and the TRIS-HCl / 
SDS buffer used for lysis and wash steps here is at physiological pH (pH 7.4). 
Nevertheless, it is possible that the longer incubation time with the resin is 
sufficient to cleave the RevAmine linker, causing biotinylated proteins to elute in 
the wash steps. 
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4.2.2.3. The limited enrichment of plasma membrane proteins in 
membrane fractions prepared using cell surface biotinylation-
based approaches is likely due to biotinylation of intracellular 
proteins  
At this stage it was unclear why the majority of proteins detected in the cell 
surface biotinylation and affinity purification strategy being pursued were not of 
membrane origin. Given that biotinylation with EZ-LinkTM Sulfo-NHS-SS-Biotin 
leaves a residual CAMthiopropanoyl moiety even after cleavage of the linker, 
we first mined the data from the EZ-LinkTM-modified membrane fractions for 
peptides detected with this modification and examined the nature of the proteins 
from which they were derived. These data are shown in Table 3. 
 
 
 
This suggested that only a small fraction of the biotinylated proteins detected in 
both fractions were of membrane origin and a substantial number of intracellular 
proteins were also being biotinylated. It is likely that many more proteins were 
biotinylated but modified peptides derived from these proteins were not 
detected. Nevertheless, these data are sufficient to call into question the 
membrane specificity of the labelling. 
To investigate this further; fractions were collected from the affinity purification 
part of the procedure and analysed by SDS-PAGE. Unlabelled and EZ-LinkTM 
Sulfo-NHS-SS-Biotin-labelled cells were processed using Pierce lysis and wash 
buffers, 1% (w/v) SDS and 4% (w/v) SDS. For each sample a fraction was 
collected immediately before affinity purification, immediately after affinity 
purification (the ‘flow-through’) and at the end of the procedure (the ‘eluate’). All 
fractions were subsequently separated on a gel.   
Table 3: Number of unique CAMthiopropanoylated peptides and proteins 
detected from membrane fractions prepared using EZ-LinkTM Sulfo-NHS-SS-
Biotin and processed with Pierce lysis and wash buffers and 4% (w/v) SDS
respectively.  
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Fractions from the unlabelled cells are shown in Fig. 22a, whilst fractions from 
the EZ-LinkTM Sulfo-NHS-SS-Biotin-labelled cells are shown in Fig. 22b. Each 
gel is divided into three segments with three lanes in each segment. The lysates 
in the first segments were generated and processed using the Pierce lysis and 
wash buffers supplied with the kit; the lysates in the second and third segments 
were generated and processed using 1% (w/v) SDS and 4% (w/v) SDS 
respectively. In each segment, lane (1) is unprocessed lysate; lane (2) is the 
‘flow-through’ fraction of the affinity purification; and lane (3) is the ‘eluate 
fraction’ of the affinity purification. The banding patterns in every third lane in 
Fig. 22b bear a striking resemblance to the banding patterns in the 
corresponding first and second lanes; this is particularly notable for the lysates 
processed using SDS. In contrast, no bands are seen in the third lanes in Fig. 
22b. This indicates that the proteins seen in the eluate fractions of the labelled 
lysates are being specifically enriched and are likely biotinylated. The similar 
banding patterns in all lanes of Fig. 22b suggest that biotinylation in the labelled 
cells is not restricted to the cell membranes; rather it is disseminated throughout 
the cell.     
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Figure 22: Polyacrylamide gel electrophoresis of unprocessed, flow-through 
and eluate fractions of a) unlabelled Jurkat cell lysate; b) EZ-LinkTM-labelled 
Jurkat cell lysate processed using the Pierce Cell Surface Isolation Kit as per 
supplied protocol. Each gel is divided into three segments with three lanes in 
each segment. The lysates in the first segments were generated and processed 
using the Pierce buffers supplied with the kit; the lysates in the second and third 
segments were generated and processed using 1% (w/v) SDS and 4% (w/v) 
SDS respectively. In each segment, lane (1) is unprocessed lysate; lane (2) is 
the affinity purification ‘flow-through’ fraction; and lane (3) is the affinity 
purification ‘eluate fraction’. All gels were stained with colloidal Coomassie.  
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The fluorescence confocal microscopy experiments described in section 
1.2.1.3. add further weight to the intracellular biotinylation hypothesis. In 
carrying out these experiments, individual cells labelled with both reagents were 
occasionally observed for which fluorescence was considerably more intense 
than that seen in surrounding cells and not restricted to the plasma membrane 
(Fig. 23). Pierce states that the sulfonate group of EZ-LinkTM NHS-SS-Sulfo-
Biotin prevents it from permeating cell membranes. However, this does not 
preclude the possibility of the reagent being able to cross the membranes of 
cells in which the plasma membrane is already compromised in some way, for 
instance cells in late stages of apoptosis (Arends and Wyllie, 1991).  
As discussed in section 1.1.3.2., transmembrane proteins constitute 20 – 30% 
of all proteins encoded by the genome (Kanapin et al., 2003) but only around 
2% of the total cellular protein content by weight (Rahbar and Fenselau, 2004). 
In contrast, actin alone accounts for 1 – 5% of total cellular protein content (a 
liver cell typically expresses around 20,000 insulin receptors but around half a 
billion actin molecules (Lodish et al., 2000)). The most abundant cytoplasmic, 
cytoskeletal and nuclear proteins are likely present in copy numbers many 
orders of magnitude greater than plasma membrane proteins. For mass 
spectrometric purposes, even intracellular biotinylation of a select few cells in a 
larger population may thus be sufficient to effectively negate any enrichment 
achieved through membrane-specific biotinylation of the rest of the cells. 
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Figure 23: In situ biotinylation of cell surface-exposed primary amine residues 
on Jurkat cells detected through staining with a Streptavidin – Alexa Fluor 568 
conjugate followed by fluorescence confocal microscopy. a) EZ-LinkTM-labelled 
cells. b) RevAmine-labelled cells. All cells were also stained with DAPI prior to 
imaging. The strongly fluorescing cells in both images appear to be biotinylated 
intracellularly, suggesting that both tags can permeate the plasma membrane in 
some instances. 
a) 
b) 
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4.2.3. Evaluation of the suitability of subcellular fractionation protocols 
for enrichment of cell surface proteins for analysis by mass 
spectrometry. 
4.2.3.1. Crude membrane preparations processed using sequential 
extraction in high salt, high pH and urea-containing buffers yield 
a more significant increase in percentage of membrane protein 
IDs 
In spite of the considerable theoretical promise of the RevAmine reagent, it was 
decided given the findings above to pursue alternative means of membrane 
protein enrichment. Intracellular biotinylation appeared to be posing a 
considerable problem in the Jurkat cell line used for the experiments described 
in section 4.2.2. in spite of consistently high viability (> 95%). It was reasoned 
that this problem would only be exacerbated in primary cultures of mature and 
tolerogenic DCs, the viability of which is frequently lower simply as a result of 
the culture conditions. Performing some sort of crude preparation of biotinylated 
membranes prior to affinity purification was considered, but this had previously 
been reported to have little effect over and above simply following the protocol 
supplied with the Pierce kit (Weekes et al., 2010). A further concern in the 
context of the overall workflow was the considerable amount of parallel 
processing required were a cell surface biotinylation-based strategy to be used. 
Membrane proteins are evidently present in a whole cell lysate solubilised in 
SDS. They are merely much harder to detect given the relative complexity of 
the mixture and owing to the presence of more abundant protein species. 
However, with recent advances in the resolving power of chromatographic 
separations and in the accuracy, resolution and speed of modern mass 
spectrometers mean that with state-of-the-art-equipment it is now feasible to 
identify > 5000 proteins (over half the expressed proteome) from a mammalian 
whole cell lysate in a single LC-MS run (Thakur et al., 2011). 
These technological advances are exemplified by the progression of membrane 
enrichment procedures employed by Matthias Mann’s lab from a protracted 
‘classical’ density gradient centrifugation-based procedure (Olsen et al., 2004) 
to a simpler ‘stepwise depletion of non-membrane molecules’ procedure, 
comprising sequential extraction of crude membrane pellets with high salt, high 
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pH and urea-containing buffer (Wisniewski et al., 2009a). Using the latter 
method in conjunction with FASP and peptide fractionation prior to analysis 
enabled the identification of 4206 unique proteins from a single murine 
hippocampus, 64% of which had a membrane annotation (though only 25% of 
which had a plasma membrane annotation). The classical technique enabled 
identification of 355 unique proteins, around 20% of which had a plasma 
membrane annotation. The two studies are not directly comparable. The earlier 
study did not employ any peptide fractionation prior to LC-MS and the peptides 
were isotopically labelled prior to analysis, but the greater than ten-fold increase 
in unique proteins identified in the latter study serves to illustrate that membrane 
preparations need not be extremely pure for identification of appreciable 
numbers of plasma membrane proteins with modern LC-MS instrumentation. 
Using this observation as a starting point, we attempted to recapitulate the 
‘stepwise depletion’ method described by Wisniewski et al. The original method 
was conceived to extract membranous material from whole tissue, and samples 
are completely homogenized in all extraction steps. The first step comprises 
initial homogenization of tissue in high salt buffer. This serves to deplete the 
majority of water-soluble proteins, disrupting even very strong ionic bonds 
between DNA and histones (Burton et al., 1978). This is followed by three 
extractions in high pH buffer, the purpose of which is to convert closed 
membrane vesicles to open membrane sheets and release soluble proteins 
sequestered within these vesicles (Fujiki et al., 1982). A final extraction in 4 M 
urea causes the majority of protein domains to unfold whilst preserving the 
integrity of transmembrane helices, allowing weakly membrane-associated 
proteins to be removed (Wisniewski, 2009). 
Wisniewski et al. place much emphasis upon using a high speed blender to 
facilitate complete sample homogenization at all stages of the procedure, 
though this is likely due to the fact that the starting material is tissue in all 
studies in which it has been employed. We did not have access to a high speed 
blender but intended to apply the method to suspension cell cultures. It was 
originally recommended that cells be lysed with a Dounce homogenizer and 
nuclei pelleted before proceeding with the first extraction step (J. R. Wisniewski, 
personal communication). 
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Therefore, the first iteration of the ‘stepwise depletion’ membrane enrichment 
strategy as applied to Jurkat cells consisted of Dounce homogenisation in 
hypotonic lysis buffer and centrifugation at 1000g to pellet nuclei. The resulting 
supernatant was subsequently rendered hypertonic and stepwise depletion 
carried out as described in section 3.2.4. Cellular component GO annotations 
and percentage of TMHMM-predicted transmembrane proteins for all proteins 
identified using this strategy are shown in Fig. 24a. The percentage of proteins 
predicted to contain transmembrane helices here is enriched over three-fold 
relative to the whole cell lysate data shown in section 4.2.2.1., but the 
percentage of plasma membrane GO annotations does not increase. This is 
perhaps to be expected given that this particular means of membrane 
preparation does not specifically enrich for plasma membranes but rather all 
cellular membranes. Nevertheless, the enrichment figures do not stand up to 
those seen for cell surface biotinylation with EZ-LinkTM Sulfo-NHS-SS-Biotin and 
processing with Pierce lysis and wash buffers in Fig. 20b.  
It was noted during the above experiment that the membranes were not 
pelleting particularly well at the speed suggested by Wisniewski et al. and were 
adhering to the side of the microcentrifuge tubes used, making the high pH and 
urea extraction steps problematic. The second iteration of this strategy thus 
substituted standard microcentrifuge tubes for siliconized microcentrifuge tubes 
and made use of a microcentrifuge with a slightly higher top speed. All other 
aspects of the strategy remained constant. These adjustments allowed the 
membranes to be pelleted and extracted more effectively and yielded an 
increase in percentage of plasma membrane GO annotations from 
approximately 21% to approximately 28% and a small increase in the 
percentage of transmembrane helix- containing proteins (Fig. 24b). However, 
both figures still failed to match those seen in Fig. 20b. 
A possible explanation for the limited enrichment in the first two iterations of the 
stepwise depletion method is the means of homogenization. Douncing lyses 
cells through the shear forces created between the sides of the ‘mortar’ and 
‘pestle’ as the latter is moved in and out within the former. Cells moving past the 
pestle are broken apart by these forces. A pestle is normally selected with 
adequate clearance to lyse cells whilst leaving nuclei intact, ensuring the 
homogenate is not contaminated with DNA and allowing relatively clean 
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separation of nuclear material. The vast majority of publications advocate 
centrifugation for 5 – 10 minutes at 1000g to pellet nuclei. However, there are 
suggestions that spinning at this speed will also pellet plasma membrane 
material (Wolff et al., 1989), an undesirable outcome in this particular instance. 
Research in the Lamond lab encompasses nucleolar proteomics and thus they 
have a vested interest in obtaining pure nuclear pellets. This group uses a 
considerably slower centrifugation to separate nuclei from the rest of the 
homogenate (228g). It is possible that a 1000g nuclear spin may pellet larger 
membrane fragments in addition to nuclei. 
We next explored whether there was any way of replicating the effects of the 
blender used by Wisniewski et al. for sample homogenization without having to 
incur the considerable expense of the instrument itself. The blender utilizes 
rotor-stator homogenization to disrupt samples. The QIAshredder column (used 
principally for clarifying lysates in preparation for RNA extraction) is composed 
of a biopolymer shredding system housed within a microcentrifuge spin column 
and applies similar rotor-stator forces to samples as they pass through. We 
were informed that the columns were not suitable for disruption of intact cell and 
tissue but could be used to homogenize crude lysate (Qiagen, personal 
communication). The third iteration of the stepwise depletion strategy therefore 
substituted Dounce homogenization with a freeze-thaw lysis step followed by 
passage of this lysate through a QIAshredder column, since this eliminated any 
differential centrifugation steps in the initial homogenization where membrane 
material could be lost. 
Cellular component GO annotations and percentage of TMHMM-predicted 
transmembrane proteins for all proteins identified using this third iteration are 
shown in Fig. 24c. Of all the membrane enrichment strategies examined, this 
yielded the highest percentages of plasma membrane GO annotations (two-fold 
enrichment over a whole cell lysate) and predicted transmembrane domain-
containing proteins (twelve-fold enrichment over a whole cell lysate). 
Encouragingly, this is also the only strategy examined where plasma membrane 
GO annotations actually exceed cytoplasmic and nuclear GO annotations. This 
was thus chosen as the preferred membrane enrichment strategy to use in the 
context of the wider workflow.     
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4.2.3.2. Filter-Aided Sample Preparation (FASP) performs more 
effectively than standard in-solution digestion for processing of 
crude membrane fractions prepared using ‘stepwise depletion’ 
for LC-MS analysis 
As detailed in section 4.2.2.1., FASP and in-solution digestion perform 
comparably for digestion of whole cell lysates. With a preferred membrane 
enrichment strategy now in place, the final question was whether FASP was 
indeed a superior means of digesting membrane proteins. This question was 
addressed by digesting membrane fractions prepared via stepwise depletion 
using the standard lab in-solution digestion protocol. Cellular component GO 
annotations and percentage of TMHMM-predicted transmembrane proteins for 
all proteins identified from this in solution digestion are shown in Fig. 25b. The 
in-solution digestion was not carried out concomitantly with the FASP digestion 
described in section 4.2.3.1, but both digests were performed on aliquots of the 
same membrane-enriched fraction. As such, the analogous FASP digestion 
data shown in Fig. 24c is duplicated in Fig. 25a for comparison. 
Though this in-solution digestion does yield a discernible enrichment in plasma 
membrane GO annotations and predicted transmembrane proteins above that 
of a whole cell lysate, it is not as pronounced as that seen for FASP digestion of 
the same material. This could be due to the acetone precipitation step 
employed to deplete lipids from the membrane fraction prior to digestion. Such 
a step is not necessary in FASP as the lipids are quantitatively depleted during 
the urea washes whilst the proteins are kept in solution. It is also possible that 
the membrane protein component does not resolubilize as well as the soluble 
protein complement having been precipitated and is thus less effectively 
digested. 
In conclusion, stepwise depletion (with shredding) followed by FASP was 
chosen as the preferred membrane protein enrichment and digestion strategy to 
incorporate into the wider proteomic workflow.    
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Figure 25: Pie charts illustrating the distribution of cellular component 
ontologies of proteins identified from LC-MS analysis of Jurkat membrane 
fractions prepared using the ‘stepwise depletion’ procedure and digested using 
a) FASP; b) In-solution digestion. 
a) Total IDs 
134 ± 13 
Plasma Membrane 
39.69% ± 0.24% 
Cytoplasmic 
33.32% ± 0.35% 
Nuclear 
28.91% ± 1.32% 
 
Contains TMHMM-
predicted Helix 
35.76% ± 3.82% 
n = 2 
b) Total IDs 
181 ± 0.7 
Plasma Membrane 
28.54% ± 2.07% 
Cytoplasmic 
46.27% ± 3.71% 
Nuclear 
42.94% ± 2.91% 
 
Contains TMHMM-
predicted Helix 
20.5% ± 0.70% 
n = 2 
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4.3. Discussion 
The overall aim of the work presented in this chapter was to optimize a 
membrane enrichment and digestion strategy which could subsequently be 
used as the first stage of a wider proteomics workflow to enable relative 
quantitation of significant numbers of membrane proteins between mature and 
tolerogenic DCs.  
The originally intended endpoint was that the enrichment step of this strategy 
would incorporate RevAmine, a novel and traceless amine-directed biotinylation 
reagent; validating its suitability for use in large scale proteomic applications 
whilst concomitantly addressing issues with comparable commercially available 
reagents which do not exhibit this traceless behaviour. RevAmine has been 
shown to exhibit all the desirable chemical characteristics that it was originally 
conceived to: it covalently modifies primary amine residues on peptides and 
proteins and can be tracelessly removed from both, via treatment with dilute 
base. 
It is less clear whether RevAmine is suitable for enrichment of cell surface 
proteins for mass spectrometry-based proteomic applications. This uncertainty 
is not an indictment of the RevAmine reagent in particular, but appears to be 
symptomatic of a more universal issue affecting amine-directed biotinylation 
reagents when employed for this purpose. RevAmine and the commercially 
available EZ-LinkTM Sulfo-NHS-SS-Biotin have both been shown to specifically 
label surface exposed amine residues on viable Jurkat cells. However, limited 
membrane permeability has also been observed when using both reagents and 
mass spectrometric identification of biotinylated intracellular proteins was 
demonstrated using the latter. This has been reported previously. (Luo et al., 
2009; Weekes et al., 2010) The negatively charged sulfonate group of EZ-
LinkTM Sulfo-NHS-SS-Biotin should preclude its passage through an intact 
plasma membrane, thus the above observations appear to indicate that 
populations of cells labelled using reagents of this kind must be 100% viable to 
preclude intracellular protein labelling.  
Interestingly, there are relatively few published studies which utilize EZ-LinkTM 
Sulfo-NHS-SS-Biotin and/or the Pierce Cell Surface Isolation Kit in the context 
of a mass spectrometry-based membrane proteomic workflow. Of those which 
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do, a couple note comparable contamination of membrane fractions with non-
membrane proteins to that seen here (Faca et al., 2008; Garcia et al., 2009). 
Two of the studies which reported plasma membrane protein IDs as constituting 
the majority of total protein IDs performed a crude membrane preparation prior 
to affinity purification (Peirce et al., 2004; Zhao et al., 2004). However, attempts 
to replicate the enrichment seen in the second of these studies proved 
unsuccessful; with plasma membrane protein IDs making up less than 20% of 
total protein IDs (Weekes et al., 2010). One further study uses the reagent to 
biotinylate cell surface proteins of the protozoan parasite Trichomonas vaginalis 
(de Miguel et al., 2010). Post-labelling, a crude membrane entrapment using 
avidin is performed and biotinylated proteins are digested on the resin, with the 
peptides being collected in the eluate. The authors claim that this approach 
enables the identification of 411 parasite proteins, 35% of which have a putative 
membrane annotation based on homology of conserved domains with 
membrane proteins in other organisms and a further 28% of which are unique to 
T. vaginalis and possess predicted transmembrane domains. However, it is not 
clear why this on-resin digestion strategy was pursued since it somewhat 
negates the reversible properties of the tag. On-resin digestion would likely 
result in significant contamination of peptides from enriched proteins with avidin 
and biotin peptides.  
In summary, novel amine-directed biotinylation reagents such as RevAmine 
theoretically offer considerable promise in facilitating cell surface proteome 
enrichment for mass spectrometry-based proteomic applications; although their 
practical use in this regard is still very much in its infancy. Considerable further 
work is likely necessary to realize this potential and this is presently an area of 
investigation for our lab. 
In order to realize the overall aims of this project, an alternative means of 
membrane protein enrichment was subsequently explored, entailing stepwise 
depletion of non-membrane molecules from crude membrane extract prior to 
digestion. This strategy lacked the novelty of membrane tagging with 
enrichment; and theoretically would not be expected to provide such a specific 
enrichment of plasma membrane proteins; nonetheless it has been shown to 
deliver the enrichment and identification of large numbers of membrane-
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annotated proteins. Another of its appeals was its relative simplicity, an 
important consideration in the context of the wider workflow. 
The final optimized stepwise depletion strategy yielded the most significant 
enrichment of plasma membrane GO annotations and proteins predicted to 
contain transmembrane helices of any strategy explored in this body of work. 
Whilst the total numbers of identified proteins (and thus numbers of proteins 
identified with plasma membrane annotation) do not approach those reported 
by Wisniewski et al., when combined with FASP, the percentage of plasma 
membrane annotations observed actually exceed those reported in the 
published study (approx. 40% vs approx. 26% for a single LC-MS run). The 
disparities in total identifications are likely due to the substantially longer LC 
gradient used in the published study (240 minutes) and differences in 
instrumentation (LTQ-Orbitrap capable of scanning twice as quickly). 
It is difficult to compare the effectiveness of this particular enrichment and 
digestion strategy with the effectiveness of those already published, as there 
are a great many variables at play. In addition to the numerous combinations of 
enrichment, solubilization and digestion strategies which can be assembled as 
a single cohesive workflow, additional variability is imparted through different 
sample types, use of different instrumentation and LC-MS methods and 
different suites of bioinformatics tools used to assess enrichment. In short, there 
exists no recognized standard means of evaluating membrane preparation 
methods for mass spectrometry-based proteomics. It is however not 
unreasonable to posit on the basis of the work presented here that the initial 
enrichment step probably has the greatest influence on the percentages of 
membrane proteins identified by LC-MS. When FASP and in-solution digestion 
were compared for digestion of whole cell lysate in section 4.2.2.1., plasma 
membrane gene annotations and percentages of proteins predicted to contain 
transmembrane helices were essentially identical (and low). When the same 
two techniques were compared for digestion of membrane fractions prepared 
using stepwise depletion in section 4.2.3.2., plasma membrane gene 
annotations and percentages of proteins predicted to contain transmembrane 
helices differed between the two digestion techniques, but both techniques 
allowed for significantly higher membrane protein identification than when either 
was used for digestion of whole cell lysates. 
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Bearing this in mind, a selection of publications covering the main methods 
used for membrane enrichment and reporting high percentages of membrane 
protein identification inferred using various bioinformatics tools were chosen for 
comparison (Durr et al., 2004; Zhao et al., 2004; Cao et al., 2006; Zhang et al., 
2007; Lee et al., 2009; Wisniewski et al., 2009a; de Miguel et al., 2010). Where 
supplementary raw protein identification data was provided with these 
publications, the data were parsed and IDs mapped to Uniprot accession 
numbers where necessary. GO annotation and transmembrane domain 
prediction was then performed on these datasets in exactly the same way as 
before. These comparative data are summarized in Table 4.  
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The disparities between percentages of membrane proteins reported in the 
publications summarised in Table 4 and the percentages reported when the raw 
data are reanalysed using STRAP GO annotation and TMHMM transmembrane 
helix prediction should not be taken at face value. Some discrepancies in the 
data are likely to be introduced by mapping the protein lists to Uniprot 
identifiers. For the majority of studies, some data are lost during this mapping 
but in one of the studies a significant number of additional IDs appear after 
mapping. This imperfect mapping has previously been reported when 
converting international protein index (IPI) numbers to Uniprot identifiers (Griss 
et al., 2011). In addition, different programmes may annotate lists of Uniprot 
identifiers differently. In the original ‘stepwise depletion’ publication, GO 
annotation was performed within MaxQuant and 25% of proteins with a cellular 
compartment GO annotation are reported to have a plasma membrane GO 
annotation. When the same dataset is annotated using STRAP, 32% of proteins 
with a cellular compartment GO annotation are reported to have a plasma 
membrane GO annotation. This discrepancy cannot be explained away by ID 
mapping since the Uniprot identifiers from the original study were fed directly 
into STRAP; though it is possible that more proteins have been assigned 
plasma membrane GO annotations in the interim. 
Nevertheless, this undertaking does reveal some interesting presentation 
‘quirks’. Firstly, many studies report percentages of membrane protein 
annotations as a fraction of total proteins which have a cellular component 
annotation, which often embellishes the final percentage somewhat. One of the 
studies classifies proteins which have a protein-lipid modification motif as 
integral membrane proteins despite these motifs being indicative of 
modifications such as glycosylphosphatidylinositol (GPI)-anchors. However, 
even taking this into account, the percentages of proteins with a STRAP plasma 
membrane GO annotation and at least one TMHMM-predicted transmembrane 
α-helix are frequently lower than the percentages reported in the publications. It 
is not apparent why this is so, and it is particularly perplexing for those studies 
where high percentages of integral membrane proteins are reported but 
analysis of the protein lists with TMHMM generates considerably lower 
percentages. There is a clear imperative to standardise the way in which 
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membrane enrichment is reported to enable unbiased comparison between 
published studies. 
Overall, the membrane enrichment and digestion strategy presented here 
certainly appears to stand up to many previously published strategies when the 
data from these studies are analysed in the same manner as our own data. 
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Chapter 5. Development and validation of an isobaric 
peptide termini labelling-based method to 
facilitate relative quantitative proteomics 
between two samples 
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5.1. Introduction 
5.1.1. Requirement for development and validation of alternative stable 
isotope labelling methods 
As detailed in Chapter 1, there are a wide variety of approaches available to 
facilitate quantitative proteomics analyses. Unfortunately, experimental and 
technical constraints rendered the most widely-used of these approaches 
redundant for this particular project. 
A vital prerequisite for the suitability of any stable isotope labelling-based 
quantitative strategy is complete or near-complete incorporation of the stable 
isotope in the labelled sample. In SILAC, this is dependent on extensive 
turnover of all cellular proteins, a criterion that is generally only met in the 
rapidly-growing proliferative cell lines originally used to develop the technique 
(Ong et al., 2002). The fact that monocytes do not proliferate at all as they 
differentiate into DCs initially suggested that culture in SILAC media would 
result in incomplete labelling.  Spellman et al. had previously demonstrated 
relatively complete SILAC labelling in another non-dividing cell line (primary 
neurons) (Spellman et al., 2008). However, attempts to replicate this in 
monocyte-derived DCs proved unsuccessful (Buck, M. unpublished 
observations). This is likely due to the fact that primary neurons can be kept in 
culture for significantly longer periods of time, allowing for greater protein 
turnover. 
The operational limitations of the mass spectrometer (ion trap-FT hybrid) used 
throughout the project also precluded adoption of alternative tagging and label-
free strategies. CID in ion trap mass spectrometers is subject to a well-
characterized ‘1/3 mass cut-off rule’ which prevents detection of fragment ion 
masses which are less than one third that of the precursor ion mass, so often 
excluding the low mass reporter ions of the iTRAQ and TMT reagents. Label-
free quantitation is performed through comparison of samples which are 
analysed independently of one another and thus requires a stable and 
unfluctuating LC-MS setup. Whilst it is not inconceivable that this could be 
delivered within the core facility in which this work was undertaken, the 
requirement for reproducibility and a lack of appropriate software for analysis 
pose significant obstacles. 
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Given the aforementioned technical issues, it was thus necessary to develop 
and optimize an alternative stable isotope labelling method such that the 
quantitative aspect of the project could be realized. 
5.1.2. Strategy for development and validation of alternative stable 
isotope labelling methods 
Two criteria must be met for a stable isotope labelling method to be suitable for 
use in quantitative proteomic studies. Firstly, as detailed above, label 
incorporation must be complete in the labelled sample/s. Secondly, the reported 
ratios of labelled to unlabelled or of differentially labelled peptide must reflect 
genuine differences in abundance between samples. With this in mind, a two-
step strategy was devised for the development and validation of alternative 
methods. A single model protein (BSA) was used to optimize the labelling 
reaction to ensure that a method for the complete incorporation of the label in 
question could be attained. Quantification of labelling was validated by taking a 
known quantity of complex protein sample (whole cell lysate), dividing it in half, 
labelling one half and leaving the other half unlabelled and then recombining the 
two halves in a number of different ratios and examining the extent to which the 
reported quantitation figures reflected the actual ratios in which the labelled and 
unlabelled samples were combined. 
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5.2. 18O Labelling 
The labelling method initially evaluated was enzymatic labelling of the carboxyl 
termini of peptides using trypsin in H2
18O water. As mentioned in section 
1.1.4.1.2., trypsin digestion in H2
18O water imparts a mass shift to the peptides 
produced relative to trypsin digestion in H2
16O water (Schnolzer et al., 1996). 
However, the question of whether the mass shift imparted to a given peptide is 
2 Da or 4 Da is slightly more complicated and requires an in-depth look at the 
two reactions which occur during trypsin-catalyzed digestion of proteins. These 
reactions are shown in Fig. 26.  
 
 
 
 
 
 
 
 
 
 
 
 
 
a) 
b) 
Figure 26: The two reactions which occur during trypsin-catalysed digestion of 
proteins to peptides in H2
18O water. a) Hydrolysis (adds a single 18O atom to 
the carboxyl termini of each peptide produced). b) Enzyme-catalysed carboxyl 
oxygen exchange (exchanges one of the two carboxyl termini oxygen atoms for 
a free 18O atom). Repeated rounds of carboxyl oxygen exchange in 18O water 
will result in all peptides incorporating two carboxyl termini 18O atoms.  
  = Trypsin 
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The first reaction is hydrolysis, whereby a peptide bond is cleaved to release a 
free carboxylic acid and an amine (Fig. 26a). This reaction occurs only once 
and if it takes place in H2
18O water a single 18O atom will be added to the 
carboxyl termini of each peptide produced. The second of the two reactions is 
the carboxyl oxygen exchange reaction, whereby enzyme covalently binds the 
carboxyl termini of previously cleaved peptides and is then dissociated by water 
(Fig. 26b). This reaction can occur multiple times for any given peptide and in 
any single reaction either of the two oxygen atoms at the carboxyl termini can 
be exchanged. If this reaction takes place in H2
18O water, the number of 
peptides incorporating two 18O atoms will tend towards 100% with repeated 
rounds of carboxyl oxygen exchange (Miyagi and Rao, 2007). Incorporation of 
two 18O atoms will never actually reach 100% since isotopically ‘pure’ H218O 
water is typically 95% – 97% 18O.  
The nature of the carboxyl oxygen exchange reaction means that variable 
incorporation is commonly observed in H2
18O labelled peptides. Multiple 
exchanges must take place for complete incorporation of two 18O atoms, but the 
rate of exchange is very slow under the conditions optimal for hydrolysis and it 
can also vary with size and sequence of peptides (Stewart et al., 2001). In 
practice, this leads to the generation of a mixture of peptide species and results 
in the isotope envelopes of individual peptide species overlapping. This can 
complicate quantitation and skew reported labelled / unlabelled ratios, as 
illustrated in Fig. 27 overleaf. This illustrates the importance of attaining 
complete double labelling in labelled samples when performing 18O-based 
quantitative proteomics. If it were assumed that the sample from which 
spectrum d) was derived was completely labelled and this sample was 
combined in a 1:1 ratio with an unlabelled sample, the reported ratios of 
unlabelled to labelled peptide would be skewed in favour of the former due to 
the incomplete labelling of the latter. 
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  a) 
b) 
c) 
d) 
Figure 27: 18O-labelling of a BSA-derived peptide with sequence 
HLVDEPQNLIK. Spectrum a) shows unlabelled peptide. Spectrum b) shows 
peptide completely labelled with two 18O atoms. Spectrum c) shows the 
unlabelled peptide combined in a 1:1 ratio with the completely labelled peptide. 
Spectrum d) shows peptide from a labelling reaction in which the labelling 
conditions were suboptimal. A mixture of unlabelled, singly 18O-labelled and 
doubly 18O-labelled species are present. 
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5.2.1. ‘Optimal’ 18O Labelling 
There are a good number of 18O-based comparative proteomic publications in 
the literature; however there is a conspicuous lack of agreement on the optimal 
way to perform the 18O-labelling reaction itself prior to combining labelled and 
unlabelled samples. The earliest studies simply performed the trypsin digest in 
18O water, with both studies noting that the rate of incorporation of 18O atoms 
varied from peptide to peptide and was not complete for all peptides examined 
(Stewart et al., 2001; Yao et al., 2001). In 2003, Yao et al. demonstrated the 
value of ‘decoupling’ the digestion step from the labelling step as a way of 
achieving more complete labelling (Yao et al., 2003). There now seems to be a 
general consensus that this decoupling step is beneficial, though the accord 
ends here. A summary of the reaction conditions used by groups which have 
previously published 18O labelling-based proteomic studies is shown overleaf in 
Table 5. (Brown and Fenselau, 2004; Liu et al., 2004b; Staes et al., 2004; Zang 
et al., 2004; Hood et al., 2005; Smith et al., 2007; Wu et al., 2007; Ang et al., 
2008; Kristiansen et al., 2008; Mirza et al., 2008; Lopez-Ferrer et al., 2009; 
Petritis et al., 2009; Bezstarosti et al., 2010; Wang et al., 2010b; Ye et al., 
2010). 
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5.2.2. Results and Discussion 
5.2.2.1. Development of a protocol for optimal C-terminal 18O-labelling of 
peptides 
The various methods reported to date for ‘optimal’ 18O-labelling have been 
evaluated and three conditions which need to be fulfilled in order to efficiently, 
stably and reproducibly label peptides with two 18O atoms have been identified. 
Use of immobilized trypsin over soluble trypsin is advocated in some of the 
studies outlined in Table 5. It is suggested that the much higher enzyme to 
substrate ratio increases labelling efficiency (Mirza et al., 2008); and that it is 
easily removed from the sample via centrifugation or filtration when labelling is 
complete, preventing trypsin-mediated ‘back-exchange’ of 18O atoms for 16O 
atoms when 18O-labelled peptides are resuspended in 16O-based buffers 
(Sevinsky et al., 2007). On the other hand, immobilized trypsin is considerably 
more expensive than soluble trypsin and Petritis et al. report sample losses 
when performing 18O-labelling with immobilized trypsin through peptides binding 
non-specifically to the beads, particularly with small amounts of starting material 
(Petritis et al., 2009). With this in mind, it was deemed that soluble trypsin would 
be used to optimize labelling as opposed to immobilized trypsin. 
5.2.2.2. Decoupling the carboxyl oxygen exchange reaction from 
hydrolysis and performing it at pH4.5 with soluble trypsin 
facilitates labelling of all peptides with two 18O atoms. 
The majority of the studies in Table 5 performed the labelling reaction at pH 8, 
pH 6.75 or pH 4.5. The two most recent studies in which the reaction was 
performed at pH 4.5 specifically state that this is the optimal pH for carboxyl 
oxygen exchange (Bezstarosti et al., 2010; Wang et al., 2010b). One of the 
studies in which the reaction was performed at pH 6.75 suggests that carboxyl 
oxygen exchange proceeds faster in slightly more acidic conditions but neglect 
to investigate pH values lower than 6.75 for fear of significantly reducing trypsin 
activity (Zang et al., 2004). The studies in which the reaction was performed at 
pH8 do not consider the pH of the reaction to be a factor in achieving complete 
labelling.  
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On the basis of these studies, it was decided that labelling efficiency would be 
investigated at pH 8 and pH 4.5. 10 µg aliquots of BSA peptides from an in-
solution overnight digest were dried in vacuo and resuspended in either 50 mM 
18O ammonium bicarbonate (pH 8) or 50 mM 18O ammonium acetate (pH 4.5). 
Labelling reactions were allowed to proceed for either 2 or 24 hours before 
quenching. A zero time point was also included for each pH value. Here, the 
peptides were resuspended in either 50 mM 16O ammonium bicarbonate (pH 8) 
or 50 mM 16O ammonium acetate (pH 4.5) and the reactions were quenched 
immediately. All reactions were subsequently acidified with 1% TFA, tip 
desalted and analysed by LC-MS. The extent of label incorporation for the 
different pH conditions and time points examined was evaluated in 10 BSA 
peptides. 
The extent of label incorporation at 0, 2 and 24 hours when the reaction was 
performed at pH 8 is shown in Fig. 28, whilst the extent of label incorporation at 
the same time points when the reaction was performed at pH 4.5 is shown in 
Fig. 29. These data indicate that the rate of carboxyl oxygen exchange is 
peptide-specific, with each peptide examined exhibiting different levels of 
incorporation of zero, one or two 18O atoms at different time points. However, it 
is also clear that the exchange reaction proceeds much faster at pH 4.5 than pH 
8. The extent of label incorporation observed in all peptides after two hours at 
pH 4.5 is comparable to that observed in all peptides after 24 hours at pH 8. 
After 24 hours at pH 4.5, incorporation of two 18O atoms is at least 90% for all 
peptides examined and considerably more for most of them. 
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   a) 
b) 
c) 
n = 9 
0 × 
18
O 
1 × 
18
O 
2 × 
18
O 
Figure 28: Extent of incorporation of 18O atoms at the carboxyl 
termini of 10 BSA peptides after a) 0 hours; b) 2 hours; c) 24 hours 
when the carboxyl oxygen exchange reaction is carried out in 50
mM ammonium bicarbonate (18O, pH 8). The reaction proceeds 
slowly at pH 8 and a number of peptides remain incompletely 
labelled after 24 hours. The apparent incorporation of one or two 
18O atoms in a small fraction of the peptides at 0 hours is artifactual 
and is due to the intensity of the third and fifth isotope peaks of
each unlabelled peptide. Data are the mean ± mean SD of three 
experimental replicates, which are in turn the mean ± SD of three 
technical replicates. 
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a) 
b) 
c) 
n = 9 
0 × 
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O 
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O 
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O 
Figure 29: Extent of incorporation of 18O atoms at the carboxyl 
termini of 10 BSA peptides after a) 0 hours; b) 2 hours; c) 24 hours 
when the carboxyl oxygen exchange reaction is carried out in 50
mM ammonium bicarbonate (18O, pH 4.5). The reaction proceeds 
far more rapidly at pH 4.5 and at least 90% of all 10 peptides 
examined are labelled with two 18O atoms after 24 hours. Data are 
the mean ± mean SD of three experimental replicates, which are in 
turn the mean ± SD of three technical replicates. 
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5.2.2.3. Reducing and alkylating labelled samples with high 
concentrations of DTT and iodoacetamide prior to resuspension 
in 16O-based buffers completely abrogates trypsin-catalysed 
back exchange in labelled peptides. 
It would be of little use to have optimised reaction conditions for efficient 
labelling of peptides with two 18O atoms if the labelling was not stable. In the 
vast majority of proteomics workflows, 18O labelled peptides have to be 
resuspended in 16O-based buffers further downstream in the process. With this 
in mind, trypsin must either be removed from the sample or its activity 
completely abrogated prior to the addition of this normal water, otherwise it will 
catalyse the ‘back-exchange’ of 18O atoms at the carboxyl termini of peptides for 
16O atoms present in the buffer. 
As aforementioned, one of the purported benefits of labelling with immobilized 
trypsin is that it can be easily removed from the sample when the reaction is 
complete. In contrast, if soluble trypsin is used it must be inactivated. Of the 
studies in Table 5 which utilize soluble trypsin for labelling, the majority include 
a 10 minute boiling step at the end of the reaction for trypsin inactivation (Zang 
et al., 2004; Hood et al., 2005; Petritis et al., 2009; Wang et al., 2010b; Ye et al., 
2010). A further study reports that boiling alone does not suffice and some 
catalytic activity is retained when the sample is returned to room temperature. 
This study instead recommends reduction / alkylation of the reaction upon 
completion to prevent the enzyme from reassuming its native conformation 
(Staes et al., 2004).  
The efficacy of both approaches as a means of preventing trypsin-catalysed 
back-exchange was examined. 10 µg aliquots of BSA peptides from an in-
solution overnight digest were labelled for 24 hours at pH 4.5 as described in 
section 5.2.2.2. Upon completion, labelling reactions were either left untreated; 
boiled for 30 minutes and then rapidly cooled to -20ºC; or reduced at 95ºC with 
20 mM DTT and then alkylated at 60ºC for 30 minutes with 40 mM 
iodoacetamide. The reactions were then dried in vacuo, resuspended in IEF 
buffer made up in 16O water and incubated at room temperature for 24 hours. 
These conditions were chosen to simulate isoelectric focusing, a technique 
which was originally to be used to sub-fractionate proteomic peptides prior to 
LC-MS analysis (see Chapter 6). A control reaction was left untreated in 18O 
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ammonium acetate for the same period of time to verify that the labelling 
reaction itself had gone to completion (data not shown). All reactions were 
subsequently acidified with 1% TFA, tip desalted and analysed by LC-MS. The 
extent to which back exchange had occurred was evaluated in the same 10 
BSA peptides which had previously been examined for labelling efficiency. 
The extent of back exchange in untreated, boiled and reduced / alkylated 
samples is shown in Fig. 30. These data indicate that boiling trypsin alone is 
insufficient to prevent it catalysing carboxyl oxygen back-exchange when 
labelled peptides are resuspended in 16O-based buffers. Indeed, there is very 
little difference in between the boiled sample and the untreated sample in terms 
of the extent of back exchange. However, reduction and alkylation of trypsin is 
shown to be highly effective in completely abolishing all residual catalytic 
activity, with essentially no back exchange observed in this sample even after 
24 hours at room temperature in a 16O-based buffer. 
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Figure 30: Extent of trypsin-catalysed back exchange of 18O atoms 
for 16O atoms at the carboxyl termini of 10 fully 18O-labelled BSA 
peptides when vacuum-dried and resuspended in 50mM 
ammonium bicarbonate (16O, pH 4.5) and left at room temperature 
for 24 hours after a) no treatment; b) incubation at 100ºC for 30 
minutes; c) reduction with 20 mM DTT at 95ºC for 1 hour followed 
by alkylation with 40 mM iodoacetamide for 30 minutes. Data are 
the mean ± mean SD of three experimental replicates, which are in 
turn the mean ± SD of three technical replicates. 
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5.2.2.4. Low pH causes small amounts of acid-catalysed back exchange 
in labelled peptides completely independently of trypsin. 
Trypsin activity is not the only mechanism through which carboxyl oxygen 
exchange can occur. It can also happen completely independently of enzyme 
provided conditions are sufficiently acidic (Niles et al., 2009). Whilst this acid-
catalysed exchange is perhaps not a particularly suitable strategy for labelling 
peptides in itself (it can also occur on the side chains of aspartic and glutamic 
acid residues and the reaction kinetics are orders of magnitude slower than 
trypsin-catalysed exchange) (Niles et al., 2009), it does highlight an important 
point. Peptides are generally reconstituted in acidic buffers immediately prior to 
LC-MS analysis. These buffers are 16O-based and it would prove prohibitively 
costly to make them up using 18O water. The study referenced above suggested 
that some degree of acid-catalysed back exchange may occur in 18O-labelled 
samples stored at low pH for long periods of time prior to LC-MS analysis.   
To investigate the effects of acid-catalysed back exchange on 18O-labelled 
peptides, an identical experiment was performed to that described in section 
5.2.2.3. with the exception that labelled peptides were acidified with 1% TFA 
immediately after being resuspended in IEF buffer. The results are shown in 
Fig. 31.  
Whilst acidification with 1% TFA and storage at room temperature represents 
an ‘extreme’ storage condition, these data suggest that storing labelled peptides 
in more conventional conditions over prolonged periods of time could potentially 
cause small but significant amounts of back exchange. Acidification of the 
untreated and boiled samples resulted in reduced back exchange relative to the 
analogous samples which were not acidified. This is likely due to inhibition of 
trypsin activity at the low pH; however in these samples it is not clear what 
contribution acid-catalysed back exchange makes to the exchange observed 
overall. In contrast, acidification of the reduced / alkylated sample resulted in an 
increase in back-exchange relative to the control sample which was not 
acidified. This increase in exchange can only be explained by an acid-catalysed 
reaction. 
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Figure 31: Extent of trypsin-catalysed back exchange of 18O atoms 
for 16O atoms at the carboxyl termini of 10 fully 18O-labelled BSA 
peptides when vacuum-dried and resuspended in 50 mM 
ammonium bicarbonate (16O, pH 4.5), acidified with 1% TFA and 
left at room temperature for 24 hours after a) no treatment; b)
incubation at 100ºC for 30 minutes; c) reduction with 20mM DTT at 
95ºC for 1 hour followed by alkylation with 40 mM iodoacetamide 
for 30 minutes. Data are the mean ± mean SD of three 
experimental replicates, which are in turn the mean ± SD of three 
technical replicates. 
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5.2.2.5. Optimised protocol for C-terminal 18O labelling of peptides 
The data presented in sections 5.2.2.2. – 5.2.2.4. suggest that complete and 
stable 18O labelling of peptides is dependent on both the pH of the labelling 
reaction itself and the prevention of trypsin- and acid-catalysed back exchange 
when the reaction is complete. The optimised protocol is presented in full in 
section 3.4.2. 
5.2.2.6. Examination of the ability of C-terminal 18O-labelling to quantify 
differences between labelled and unlabelled proteomic peptides 
across a wide dynamic range.  
As aforementioned, a stable isotope labelling method is only of use for 
quantitative proteomic applications if the reported ratios of labelled to unlabelled 
peptide reflect genuine differences in abundance between labelled and 
unlabelled samples when they are combined. With the 18O-labelling reaction 
itself optimised, it was next examined whether this second criterion also held 
true.  
10 µg aliquots of proteomic peptides from an in-solution overnight digest of 
mature DC whole cell lysate were processed using the optimised 18O-labelling 
procedure detailed in section 3.4.2. Half of the aliquots were labelled using 
ammonium acetate and trypsin prepared in 18O water. The other half were 
subjected to exactly the same procedure but the buffers and enzyme used were 
prepared in 16O water. This was done in order to preserve consistency between 
labelled and unlabelled samples. Reduced / alkylated labelling reactions were 
tip desalted and reconstituted in 100 µl 0.2% FA. Labelled and unlabelled 
peptides were then combined according to the scheme shown in Table 6. 
 
 
 
 
Table 6: Scheme for combining labelled and unlabelled 
proteomic peptides to examine whether 18O-labelling is 
suitable for performing quantitative proteomic analyses. 
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Combined samples were analysed using LC-MS. Raw data were processed, 
searched and quantified using Mascot Distiller. Protein and peptide quantitation 
reports were generated and imported into Microsoft Excel for further data 
processing. Box and whisker plots were generated to visualise the distribution 
of reported protein and peptide ratios computed by Distiller for each of the 
combinations. Uncombined samples were not included in the plots but were 
analysed to verify that the labelling reaction had gone to completion.   
The distribution of reported protein ratios computed from the combined 
proteomic samples is shown in Fig. 32. Ideally, these reported ratios would be 
representative of the actual ratios in which the labelled and unlabelled 
proteomic peptides are combined. In actuality, the majority of the reported ratios 
deviate considerably from these expected values. When the peptides are 
combined 1:1, the reported ratios between the first and third quartiles fall very 
close to the expected ratio. However, when 95% of the reported ratios 
surrounding the median ratio are included, the reported ratios span three orders 
of magnitude. This effect is exacerbated the further the ratio deviates from 1:1. 
At five parts labelled to one part unlabelled and vice versa, even the reported 
ratios encompassed within the first and third quartiles span nearly two orders of 
magnitude. 
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Figure 32: Box and whisker plot showing distribution of protein ratios reported 
by Mascot Distiller when 18O-labelled and unlabelled proteomic peptides 
derived from mature DC whole cell lysate are combined in ratios ranging from 5 
parts labelled : 1 part unlabelled through to 1 part labelled : 5 parts unlabelled. 
50% of reported ratios are contained within the boxes and 95% are contained 
within the whiskers. The number of unique proteins detected across 9 
replicates (3 experimental × 3 technical) is shown in brackets on the X-axis.      
n = 9 
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To examine the source of the disparity between expected and reported protein 
ratios, the distribution of reported peptide ratios from the same samples was 
also examined. Mascot Distiller determines peptide ratios through pairing 
precursor peaks which are identified in Mascot as being heavy and light 
isoforms of the same peptide, integrating the areas under the extracted ion 
chromatograms which correspond to each of the paired precursor peaks and 
reporting differences in these areas as a ratio of heavy to light peptide (Fig. 33). 
Finally, the ratios calculated for all peptides derived from a single protein are 
averaged and reported as a single ratio for that protein. It thus stood to reason 
that the protein ratios could be being skewed by a few outlying peptide ratios. 
The distributions of reported peptide ratios are shown in Figs. 34 and 35.  
The distributions shown in Fig. 34 are unfiltered; every peptide ratio computed 
by Mascot Distiller and subsequently assigned to a protein is included. The 
distributions shown in Fig. 35 are ‘filtered’. Each peptide ratio calculation 
computed by Mascot Distiller is subject to three statistical tests to filter out 
‘noisy’ data and ensure that only high quality spectra contribute to the final 
protein ratio reported. Briefly, these are a test on the fraction of peaks versus 
theoretical isotope profile present in the extracted ion chromatogram which 
correspond to the peptide being quantitated; a test on the goodness of fit 
between the predicted and observed isotope envelopes of the peptide being 
quantitated; and finally a test on the standard error of the reported ratio of the 
peptide being quantitated across the elution peak. A peptide will be excluded 
from the protein ratio calculation if it fails one or more of these three tests. 
In addition, three distributions (a, b and c) are shown in each figure. Distribution 
a) includes all ratios, regardless of the MS1 signal intensity of the most 
abundant peptide peak in a pair. Distribution b) includes only ratios where the 
most abundant peak in a pair has MS1 signal intensity greater than 10^4; whilst 
distribution c) includes only ratios where the most abundant peak in a pair has 
MS1 signal intensity greater than 10^5.  
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Figure 33: Relative quantitation of a proteomic peptide with sequence 
SLYASSPGGVYATR derived from unlabelled and 18O-labelled mature DC 
whole cell lysate combined in a 1:1 ratio. Quantitation is performed by 
integrating the areas under the extracted ion chromatograms in a) which 
correspond to the unlabelled and 18O-labelled peptide peaks in b). The red 
profile in b) is the actual isotope profile of the peptide, whilst the black profile is 
the theoretical isotope profile of the peptide. Here, the actual and theoretical
profiles are almost identical and the peptide does not fail any of the statistical 
tests. 
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Figure 34: Box and whisker plot showing distribution of unfiltered peptide ratios 
for a) all peptides assigned to proteins; b) all peptides with MS1 signal intensity 
greater than 104 assigned to proteins; c) all peptides with MS1 signal intensity 
greater than 105 assigned to proteins; reported by Mascot Distiller when 18O-
labelled and unlabelled proteomic peptides derived from mature DC whole cell 
lysate are combined in ratios ranging from 5 parts labelled : 1 part unlabelled 
through to 1 part labelled : 5 parts unlabelled. 50% of reported ratios are 
contained within the boxes and 95% are contained within the whiskers. The 
number of peptides detected across 9 replicates (3 experimental × 3 technical) 
is shown in brackets on the X-axis.     
n = 9 
a) 
b) 
c) 
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Figure 35: Box and whisker plot showing distribution of filtered peptide ratios 
for a) all peptides assigned to proteins; b) all peptides with MS1 signal intensity 
greater than 104 assigned to proteins; c) all peptides with MS1 signal intensity 
greater than 105 assigned to proteins; reported by Mascot Distiller when 18O-
labelled and unlabelled proteomic peptides derived from mature DC whole cell 
lysate are combined in ratios ranging from 5 parts labelled : 1 part unlabelled 
through to 1 part labelled : 5 parts unlabelled. 50% of reported ratios are 
contained within the boxes and 95% are contained within the whiskers. The 
number of peptides detected across 9 replicates (3 experimental × 3 technical) 
is shown in brackets on the X-axis.     
a) 
b) 
c) 
n = 9 
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The six distributions displayed in Figs. 34 and 35 collectively suggest that the 
protein ratios issue is not merely caused by a few outlying peptides but is 
instead symptomatic of a more extensive disparity between expected and 
reported peptide ratios. This disparity is somewhat less severe than that seen 
for the protein ratios plotted in Fig. 32 (a considerably higher number of peptide 
ratios are plotted) but it is still appreciable. However, examining the six 
distributions also sheds light on the factors which contribute to this variability. 
It is immediately apparent that MS1 signal intensity has a significant influence 
on the accuracy of reported ratios. In Figs. 34c and 35c, the reported ratios 
between the first and third quartiles fall very close to the expected ratio for all 
conditions examined. Outliers within the 95% of reported ratios surrounding the 
median ratio in Fig. 35c are not nearly as severe as those seen in Figs. 35a-b. 
For these two distributions, 95% of reported ratios surrounding the median ratio 
are reasonably accurate when peptides are combined 1:1. At two parts labelled 
to one part unlabelled and vice versa, the reported ratios within the first and 
third quartiles remain reasonably accurate, but inclusion of 95% of reported 
ratios surrounding the median ratio begins to introduce more extreme outliers. 
At five parts labelled to one part unlabelled and vice versa, variation around the 
median becomes more significant for all peptides. The same can be said of 
Figs. 34a-b; however outliers within the 95% of reported ratios surrounding the 
median ratio in Fig. 34c are to an extent more severe than those seen in Figs. 
34a-b. This is likely due to the fact that the data is unfiltered and the number of 
peptide ratios plotted in Fig. 34c is considerably lower than in Figs. 34a-b.  
These observations suggest that the accuracy of a reported ratio for a given 
labelled/unlabelled peptide pair is dependent upon accurate measurement of 
the MS1 signal intensity of each peak in the pair. The stronger the intensity of a 
given ion in an MS1 scan, the easier it is to differentiate between signal and 
noise (Karp et al., 2010). This accounts for the significant improvement in 
quantitative accuracy seen when ratios computed from peptides with signal 
intensity lower than 105 are excluded from the dataset in Figs. 34c and 35c. It 
also offers an explanation for the poor dynamic range of quantitation. At ratios 
of five parts labelled to one part unlabelled and vice versa, we would expect the 
signal intensity of the less abundant isoform of a peptide to be five times weaker 
than that of the more abundant isoform. It follows that this less abundant 
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isoform may be difficult to differentiate from noise even if the more abundant 
isoform is well detected, complicating calculation of the ratio. 
Inclusion or exclusion of ratios rejected by Distiller for failing any/all of the three 
statistical tests seems to have considerably less effect on quantitative accuracy. 
Comparing the total numbers of reported ratios in Fig. 34 and Fig. 35, it is clear 
that the majority of ratios rejected by Distiller correspond to peptides with 
weaker MS1 signal intensity. Indeed, around 60% of all reported ratios are 
flagged for rejection, but only around 15% of those corresponding to peptides 
with signal intensity over 105 do not make the cut. Disappointingly, even though 
over half of the raw dataset is excluded in Figs. 35a and 35b, a significant 
number of extreme outliers remain. It is not clear why Distiller fails to reject 
these aberrant ratios. 
With all of the above in mind, one approach to improve the quantitative 
accuracy of the technique would be to only include ratios derived from peptides 
detected with high signal intensity. However, this would entail ignoring the 
majority of the data acquired. Furthermore, the peptides detected with the 
highest signal intensities are likely to have originated from the most abundant 
proteins in the initial digest. Depending on the means of sample preparation 
employed prior to digestion, these proteins may not necessarily be of interest 
from an experimental perspective. The proteomic material used to generate the 
data in Figs. 32, 34 and 35 was whole cell lysate and the peptides with the 
highest signal intensities consequently come from proteins that are largely 
cytoplasmic and cytoskeletal. 
A further point of note is that a quantitative discovery proteomics study is 
usually conceived with the intention of detecting differential protein expression 
in response to differential stimuli applied to an otherwise invariant experimental 
system. One would expect only a small fraction of all expressed proteins to 
exhibit differential expression in response to such a stimulus. It could thus be 
reasonably argued that the majority of proteins identified in such an experiment 
would be equally abundant across all samples and would hence be quantitated 
with reasonable accuracy using 18O labelling. Proteins exhibiting differential 
expression across samples may not necessarily be quantitated accurately but 
would likely still be flagged as being differentially expressed. 
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This point raises a further issue distinct to that pertaining to dynamic range. The 
total number of reported peptide and protein ratios in all six distributions in Figs. 
34 and 35 is rather low considering the data were compiled from three technical 
repeats of three biological replicates. The lowest numbers of reported peptide 
and protein ratios are observed when labelled and unlabelled samples are 
combined in a 1:1 ratio. In an 18O labelling-based quantitative proteomics 
experiment with optimal 18O labelling, peptides will be present in labelled and 
unlabelled isoforms, each with distinct masses. This doubles the complexity of 
every MS1 scan acquired and halves the sensitivity of detection due to the ion 
current being split between the two isoforms of each peptide (Christoforou and 
Lilley, 2012). This is an issue common to all stable isotope labelling-based 
quantitative proteomic methods in which quantitation is performed at the MS1 
level.  Taken together, these factors considerably limit the numbers of unique 
peptides which can be identified in a single experiment of this nature. 
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5.3. Isobaric Peptide Termini Labelling 
Though the data in section 5.2.2.6. appeared to indicate that C-terminal 18O-
labelling would prove suboptimal for an in-depth quantitative proteomics study, 
it was felt that it would be a shame to discard the optimised 18O-labelling 
method itself. The C-terminal localisation of the modification made it possible for 
18O-labelling to be incorporated as the C-terminal labelling step in an isobaric 
peptide termini labelling-based strategy and this approach was thus explored 
further. 
The concept of isobaric peptide termini labelling (IPTL) was originally conceived 
by Koehler et al. for investigating differential protein expression in two samples 
(Koehler et al., 2009). In IPTL, each sample is labelled such that an identical 
mass shift is introduced to both sets of peptides. However, in one of the 
samples the label is incorporated at the N-terminus whilst in the other sample 
the label is incorporated at the C-terminus. When two samples are 
subsequently combined and analysed by LC-MS, differentially labelled peptides 
of identical sequence have the same mass in the precursor ion scan and are 
thus simultaneously isolated and fragmented in the same product ion scan. In 
this regard, the technique is analogous to more widely used isobaric labelling 
approaches such as iTRAQ and TMT.  
The technique differs in the manner in which quantitation is carried out in the 
product ion scan. Co-fragmentation of differentially labelled IPTL peptides 
discriminates the mass differences introduced during labelling. Labelled N- and 
C- terminal fragment ions can thus be distinguished in the product ion scan by 
merit of the mass differences of the respective peptide termini. Quantitation is 
performed by comparing the relative signal intensities of the peaks produced by 
these differentially labelled N- and C-terminal peptide fragment ions. This 
concept is detailed in Fig. 36 overleaf.  
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  a) 
b) 
c) 
d) 
Figure 36: Isobaric peptide termini labelling of a BSA-derived peptide with 
sequence HLVDEPQNLIK. Spectrum a) shows peptide labelled with 13c4
succinic anhydride at the N-terminus and unlabelled at the C-terminus. 
Spectrum b) shows peptide labelled with 12c4 succinic anhydride at the N-
terminus and 18O-labelled at the C-terminus. The peptides in both spectra have 
also been treated with O-Methylisourea to derivatize the C-terminal lysine 
residue.  
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5.3.1. ‘Optimal’ N-Terminal Labelling 
In 18O-labelling, a 4 Da mass shift is introduced to the C-terminus of labelled 
peptides relative to unlabelled peptides. To incorporate this into an IPTL-based 
quantitative strategy, we required a means to introduce a 4 Da mass shift to the 
N-terminus of the peptides which were not 18O-labelled. There is no reagent 
available which will add this 4 Da mass shift to one set of peptides whilst 
leaving the other set unmodified; however there are a number of reagents 
available for modification of amino termini. Stable isotope variants of some of 
these reagents allow the requisite mass shift to be introduced to one set of 
peptides even when both sets are modified. Koehler et al. use normal (C4H4O3) 
and tetradeuterated (C4D4O3) succinic anhydride. 
For an IPTL-based quantitative strategy to be successful, it is vital that the N-
terminal labelling step is as highly specific as the C-terminal labelling step. 
However, reagents which react with N-terminal α-amino groups will also react 
with ε-amino groups on lysine side chains. The reactivity of each group is 
dependent on the pH at which the reaction is performed. The pKa of N-terminal 
α-amino groups (~8.0) is significantly lower than that of lysine (~10.5) side chain 
ε-amino groups (Greenstein and Winitz, 1961; Means and Feeney, 1971) and 
thus N-terminal α-amino groups should theoretically be considerably more 
amenable to modification at pHs of 8 and below. Koehler et al. suggest that 
performing the reaction using 20 mM succinic anhydride in 50 mM sodium 
acetate (pH 7.6) for 5 minutes at room temperature results in largely complete 
N-terminal labelling with minimal side-reactivity at lysine residues. 
Figure 36 (cont.): Spectrum c) is the precursor ion scan of 13c4
16O- and 
12c4
18O- labelled peptides combined in a 1:1 ratio. Note that the two peptides 
are isobaric. Spectrum d) is the product ion scan produced after isolation and 
co-fragmentation of the differentially labelled peptides in spectrum c). This 
produces many pairs of 12c4/
13c4 N-terminal and 
16O/18O C-terminal peptide 
fragments. Quantitation is performed on each of these fragment ion pairs.  
161 
 
5.3.2. Results and Discussion 
5.3.2.1. Development of a protocol for optimal N-terminal succinylation 
of peptides 
Koehler et al. currently perform the N-terminal succinylation reaction as part of a 
two-step, ‘one pot’ procedure in which the C-terminal modification is introduced 
to C-terminal lysine residues through dimethylation with formaldehyde or 
dideuterated formaldehyde immediately after N-terminal modification (Koehler 
et al., 2011). This reaction scheme requires only a single vacuum drying step. 
Combining C-terminal 18O labelling and N-terminal succinylation would require 
both the initial digest to be vacuum dried prior to 18O labelling and the 
completed 18O labelling reaction to be tip desalted (to remove the high 
concentrations of DTT and iodoacetamide) prior to N-terminal succinylation. 
There were concerns with the potential sample losses which may be introduced 
with repeated rounds of desalting, drying and resuspension prior to LC-MS 
analysis and so the feasibility of performing the N-terminal reaction whilst the 
peptides were immobilized on solid phase (having been desalted after 18O-
labelling but prior to elution) was explored. 
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5.3.2.2. Peptides cannot be N-terminally succinylated whilst bound to a 
solid phase extraction column without significant succinylation 
of lysine side chains. 
Problems were encountered in replicating the buffering conditions specified by 
Koehler et al., in which 20 mM succinic anhydride is prepared in 50 mM sodium 
acetate (pH 7.6). These conditions would theoretically be optimal for favouring 
N-terminal modification given the close proximity of the pH to the pKa of α-
amino groups. However, Koehler et al. do not specify whether the sodium 
acetate should be at pH 7.6 before or after addition of succinic anhydride. The 
reagent hydrolyses rapidly in aqueous conditions and addition of 20 mM 
succinic anhydride to 50 mM sodium acetate (pH 7.6) resulted in a near-
immediate and significant drop in the pH of the reaction buffer to ~pH 4.5. It was 
reasoned that these reaction conditions would be suboptimal for N-terminal 
succinylation. This could be countered by preparing the reagent in 200 mM 
sodium acetate (pH 7.6) supplemented with 20 mM sodium hydroxide. The 
initial addition of sodium hydroxide raises the buffer pH significantly but 
subsequent addition of 20 mM succinic anhydride results in a reaction buffer 
which maintains a pH of ~7.6 throughout the reaction. 
30 µg aliquots of BSA peptides from an in-solution overnight digest were dried 
in vacuo and resuspended in 1% TFA. The peptides were captured on a C18-
bonded silica support contained within a commercially available solid phase 
extraction cartridge and desalted but not eluted. The immobilized peptides were 
then reacted with 20 mM succinic anhydride in 200 mM sodium acetate / 20 mM 
sodium hydroxide at room temperature for 5, 10 or 15 minutes. Upon 
completion of the reaction, the peptides were washed for a second time and 
eluted. All reactions were subsequently analysed by LC-MS. The extent of 
succinylation at the three different time points was evaluated in the same 10 
BSA peptides which had been examined during optimization of C-terminal 18O-
labelling. This is shown in Fig. 37.   
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a) 
b) 
c) 
n = 9 
Unmodified 
1 × Succinyl 
2 × Succinyl  
Figure 37: Succinylation of 10 BSA peptides when reacted 
with 20 mM succinic anhydride in 200 mM sodium acetate / 
20 mM sodium hydroxide (pH 7.6) for a) 5 minutes; b) 10 
minutes; c) 15 minutes. Given the pKa of N-terminal α-amino 
groups is significantly lower than the pKa of lysine side chain 
ε-amino groups, it is assumed that single modifications are 
N-terminal directed. A mixture of unsuccinylated, singly 
succinylated and doubly succinylated isoforms are observed 
for all 10 peptides examined. Data are the mean ± mean SD 
of three experimental replicates, which are in turn the mean 
± SD of three technical replicates. 
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These data indicate that, as with carboxyl oxygen exchange, the rate of 
succinylation is peptide-specific. Each peptide examined exhibits varying 
degrees of single and double succinylation. There is no way to differentiate 
between N-terminal and side chain succinylation on the basis of precursor ion 
mass alone. However, given the reaction conditions, a singly succinylated 
peptide was assumed to have been N-terminally modified whilst a doubly 
succinylated peptide was assumed to also carry a lysine side chain 
modification. The validity of this assumption was confirmed by examining 
MS/MS sequence data using Mascot. 
The variable succinylation seen in the 10 peptides across the three time points 
suggests that exclusive N-terminal modification of peptides whilst they are 
bound to solid phase is not feasible. The nature of the required modification 
state here contrasts with that required for C-terminal 18O-labelling. With the 
latter it is necessary to drive the reaction to completion; here it is necessary to 
avoid doing so. All 10 peptides examined exhibit some degree of double 
succinylation even after 5 minutes. On the other hand, an appreciable fraction 
of 3 of the 10 peptides examined remained unmodified after 15 minutes, in spite 
of similar fractions of the same peptides also exhibiting double succinylation. 
Reducing the reaction time below 5 minutes may reduce the incidence of 
double succinylation but will likely also result in increased incidences of non-
modification. 
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5.3.2.3. Peptides can be specifically guanidinated on lysine side chains 
whilst bound to a solid phase extraction column 
If the ε-amino groups of lysine side chains could be blocked in some way prior 
to succinylation then N-terminal α-amino labelling could be driven to completion 
without having to worry about side reactions. One possible means of 
accomplishing this would be to derivatize lysine residues to homoarginine 
through guanidination with O-Methylisourea. This modification has previously 
been reported to be highly specific for the ε-amino group of lysine (Kimmel, 
1967). More recently, Beardsley and Reilly have optimised the procedure for the 
reaction to the extent that it proceeds to completion in a matter of minutes 
(Beardsley and Reilly, 2002). This optimised procedure now forms the basis of 
a number of commercially available guanidination kits.  
30µg aliquots of BSA peptides from an in-solution overnight digest were 
captured and desalted without elution on an SPE cartridge as described in 
section 5.3.2.2. The immobilized peptides were then reacted with 1 M O-
Methylisourea in 6.67% ammonia solution at 65ºC for 10, 20 or 30 minutes. 
Continuous flow of reagent through the SPE cartridge was facilitated through 
the vapour pressure generated by the ammonia when the top end of the 
cartridge was capped. Upon completion of the reaction, excess reaction buffer 
was aspirated from the cartridge and the peptides were washed for a second 
time and finally eluted. All reactions were subsequently analysed by LC-MS and 
the extent of guanidination at the three different time points evaluated as 
described in section 5.3.3.2. A summary of the results is shown in Fig. 38. 
  
166 
 
 a) 
b) 
c) 
n = 9 
Unmodified 
1 × Guanidinyl 
2 × Guanidinyl  
Figure 38: Guanidination of 10 BSA peptides when reacted 
with ~1 M O-Methylisourea in 6.67% ammonia (pH ~11) at 
65ºC for a) 10 minutes; b) 20 minutes; c) 30 minutes. The 
reaction has previously been reported to be highly specific 
for the ε-amino group of lysine and thus it is assumed that 
single modifications are lysine-directed. 8 of the 9 lysine-
containing peptides examined are at least 85% derivatized 
after 30 minutes whilst the non-lysine containing peptide 
remains largely unmodified. Data are the mean ± mean SD 
of three experimental replicates, which are in turn the mean 
± SD of three technical replicates. 
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These results support the reported literature that the guanidination reaction 
catalysed by O-Methylisourea is highly specific for lysine. The potential for N-
terminal side-reactivity was taken into account but none of the peptides 
examined by MS/MS exhibited any double guanidination. After 30 minutes, all 8 
lysine-containing peptides are at least 85% guanidinated whilst the non-lysine-
containing peptide remains unmodified. Interestingly, the peptide with sequence 
‘RPCFSALTPDETYVPK’ could not be detected at all in any of the biological or 
technical replicates at any of the time points. It is not clear why this is the case 
since guanidination is widely accepted to enhance the detection of lysine-
containing peptides (Beardsley et al., 2000). 
5.3.2.4. Guanidination of lysine side chains renders subsequent 
succinylation N-terminal specific 
The final step in optimising N-terminal succinylation of peptides was to perform 
the reactions described in sections 5.3.2.3. and 5.3.2.2. sequentially. 30µg 
aliquots of BSA peptides from an in-solution overnight digest were captured and 
desalted as previously described. Desalted peptides were guanidinated for 30 
minutes; desalted a second time; succinylated for 15 minutes; and desalted a 
final time before elution. All reactions were subsequently analysed by LC-MS.  
All potential modification states of the 10 BSA peptides examined throughout 
were taken into account when evaluating the N-terminal specificity of labelling. 
Results are shown in Fig. 39. 
These data suggest that guanidination of lysine residues prior to succinylation is 
an effective means of ensuring that the second of the two reactions remains N-
terminal specific. Of the 10 BSA peptides examined, the majority of those which 
contain lysine are detected with a mass consistent with both lysine 
derivatization and N-terminal succinylation. The majority of peptides examined 
which do not contain lysine are detected with a mass consistent with N-terminal 
succinylation alone.  
It is worth noting that a significant fraction of this latter one peptide (‘YLYEIAR’) 
was also detected with a mass consistent with two succinyl groups. This was 
puzzling given the peptide does not contain a lysine residue. Scrutiny of the b-
ion series in the product ion scan of this doubly succinylated peptide revealed 
that both succinylation events were localized to the N-terminus (Fig. 40). 
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Succinic anhydride side-reactions with tyrosine phenolate side-chains have 
previously been reported (Hermanson, 2008) and it may be that this particular 
residue on this particular peptide is more reactive than usual in this regard. 
Tyrosine is one of the less common amino acids (with an occurrence in proteins 
of just 3% (http://www.ncbi.nlm.nih.gov/Class/Structure/aa/aa_explorer.cgi)) and 
the other N-terminal tyrosine peptide examined does not exhibit the same 
behaviour; thus this is unlikely to present a significant caveat to quantitation. 
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n = 9 
Unmodified 
1 × Guanidinyl 
2 × Guanidinyl  
1 × Succinyl  
1 × Guanidinyl, 1 × Succinyl  
2 × Succinyl  
Figure 39: Modification states of 10 BSA 
peptides when reacted with ~1 M O-
Methylisourea in 6.67% ammonia (pH ~11) at 
65ºC for 30 minutes and subsequently reacted 
with 20 mM succinic anhydride in 200 mM 
sodium acetate / 20 mM sodium hydroxide (pH
7.6) for 15 minutes. At least 82% of all 9 lysine-
containing peptides examined exhibit a mass 
consistent with lysine derivatization and N-
terminal succinylation. A significant proportion of 
the peptide with sequence YLYEIAR exhibits a 
mass consistent with double succinylation in 
spite of not having any lysine residues. Data are 
the mean ± mean SD of three experimental 
replicates, which are in turn the mean ± SD of 
three technical replicates. 
Figure 40: Mascot 
fragmentation data of the 
peptide with sequence 
YLYEIAR and a mass 
consistent with a) single 
succinylation; b) double 
succinylation. The b-series 
ions (highlighted) confirm 
that both modifications in 
the doubly succinylated 
peptide are localized to the 
N-terminus. 
 
 
b) 
a) 
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5.3.2.5. Optimised protocol for N-terminal succinylation of peptides 
The data presented in section 5.3.2.4. suggest that N-terminal specific 
modification of peptides with succinic anhydride can be achieved through first 
derivitizing lysine residues to homoarginine. This prevents concomitant lysine 
side chain modification during the succinylation reaction itself. The optimised 
protocol is presented in full in section 3.4.3. 
5.3.2.6. Examination of the ability of isobaric peptide termini labelling 
employing both N-terminal succinylation and C-terminal 18O 
labelling to quantify differences between labelled and unlabelled 
BSA and proteomic peptides across a wide dynamic range 
It was next necessary to combine the newly optimised N-terminal succinylation 
method with the previously optimised C-terminal 18O labelling method and 
examine whether using the two in tandem addressed the issues with accuracy 
and dynamic range of quantitation observed when using 18O labelling alone.  
30µg aliquots of proteomic peptides from an in-solution overnight digest of 
Jurkat whole cell lysate were 18O labelled as described in section 3.4.2. 
Reduced/alkylated labelling reactions were acidified with 1/10th volume 10% 
TFA and processed using the optimised N-terminal succinylation procedure 
detailed in section 3.4.3. Peptides which had been 18O-labelled were 
succinylated using normal succinic anhydride whilst peptides which had not 
been 18O labelled were succinylated using 13C4 succinic anhydride. These 
isobarically labelled peptides were reconstituted in 200 µl 0.2% FA. Labelled 
and unlabelled peptides were then combined according to the scheme shown in 
Table 7. 
  
Table 7: Scheme for combining 
differentially labelled proteomic 
peptides to examine whether isobaric 
peptide termini labelling is suitable 
for performing quantitative proteomic 
analyses. 
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Combined samples were analysed using LC-MS. Raw data were processed, 
searched and quantified within Mascot itself. Protein quantitation reports were 
screen scraped directly from Mascot protein summary reports. Peptide 
quantitation reports were exported from Mascot MS/MS search as CSV files. 
Both sets of reports were imported into Microsoft Excel for further data 
processing and Box and whisker plots generated as described in section 
5.2.2.6. Uncombined samples were not included in the plots but were analysed 
to verify that both labelling reactions had gone to completion.   
The distribution of reported protein ratios computed from the combined 
proteomic samples is shown in Fig. 41a, whilst the distribution of reported 
peptide ratios is shown in Fig. 41b. In comparison with the data shown in Figs. 
32, 34 and 35, these reported protein and peptide ratios approximate much 
more closely to the actual ratios in which the differentially labelled samples were 
combined. In both cases, the reported ratios within the first and third quartiles 
fall very close to the expected ratio when the samples are combined in ratios 
ranging from 5:1 to 1:5. In contrast to the 18O-labelling data, inclusion of 95% of 
reported ratios surrounding the median for these combinations does not 
introduce any extreme outliers. At combination ratios of 10:1 and 1:10, the 
accuracy of reported ratios begins to diminish slightly and there is a general 
‘ratio compression’ effect where reported ratios tend to underestimate the true 
combination ratio. This effect becomes more pronounced at combination ratios 
of 20:1 and 1:20, with neither median reported ratio here being more than 10:1 
or 1:10. Nevertheless, this is still a considerable improvement in accuracy and 
dynamic range of quantitation. 
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a) 
b) 
n = 1 
Figure 41: Box and whisker plot showing distribution of a) protein ratios; b)
peptide ratios reported by Mascot when 13C4-succinylated and 
12C4-
succinylated / 18O-labelled proteomic peptides derived from Jurkat whole cell 
lysate are combined in ratios ranging from 20:1 through to 1:20. 50% of 
reported ratios are contained within the boxes and 95% are contained within 
the whiskers. The number of peptides detected across 1 replicate is shown in 
brackets on the X-axis.     
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In conclusion, the IPTL-based quantitative strategy presented here is well-
suited for quantitative proteomics applications. First and foremost, it conforms to 
the two criteria specified at the beginning of the chapter. Label incorporation 
has been optimised for both C-terminal 18O labelling and N-terminal-specific 
succinylation and differences in abundance between differentially labelled 
samples are accurately reported up to around one order of magnitude in each 
direction. Labelling is carried out at the peptide level, enabling scrutiny of 
samples which could not be analysed using metabolic labelling approaches. 
The collective cost of all labelling reagents is also relatively inexpensive in 
comparison to commercially available alternatives; the total cost of differentially 
labelling two 30 µg samples for comparison should not exceed £10.     
IPTL is akin to more widely used isobaric peptide labelling methods such as 
iTRAQ and TMT where quantitation is performed in the product ion scan, 
circumventing the issues detailed in section 5.2.2.6. pertaining to precursor 
scan quantitation. This is seen not only in the increased dynamic range of 
quantitation relative to 18O-labelling, but also in the considerable increase in 
protein and peptide identifications. The isobaric nature of the differentially 
labelled peptides does not result in increased precursor scan complexity and 
the ion current is not negatively affected because peptides of identical 
sequence in each sample have (effectively) identical masses. 
However, IPTL-based quantitation also possesses novel characteristics which 
set it apart from iTRAQ and TMT. Quantitation is performed on pairs of 
differentially labelled N- and C- terminal peptide fragments spanning the entire 
MS2 spectrum rather than on single reporter ions detected in the low mass 
region of the spectrum (see Fig. 36 above). The technique is thus compatible 
with ion trap mass spectrometers in which the ‘1/3 parent mass cut-off rule’ 
precludes use of the iTRAQ and TMT reagents and therefore is more generally 
applicable. In addition, reported peptide ratios are composites of relative 
quantitation of many pairs of peptide fragments, increasing the confidence in 
the accuracy of the ratio. Finally, the ratio calculations are by definition peptide-
specific and therefore less likely to be skewed by the mixed ‘MS/MS’ 
phenomenon seen in iTRAQ and TMT, where isobarically tagged peptides with 
different sequences but commensurate mass and retention times are 
fragmented simultaneously (Ow et al., 2009).  
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This particular IPTL-based method possesses further features which set it apart 
from the original method. Koehler et al. introduce their C-terminal modification 
through dimethylation after N-terminal succinylation. Consequently, only C-
terminal lysine residues are modified and peptides with a C-terminal arginine 
residue cannot be used for quantitation. The fact that this method utilizes 
trypsin-catalysed C-terminal 18O labelling enables all tryptic peptides (other than 
C-terminal peptides) to be labelled and contribute to quantitation. Just recently 
Yang et al. published a further IPTL-based method in which 18O-labelling is 
used to introduce the C-terminal modification and peptides are subsequently 
guanidinated prior to N-terminal dimethylation with formaldehyde or 
dideuterated formaldehyde (Yang et al., 2012). However, this reaction scheme 
does not allow for the use of a 13C isotope of formaldehyde and (as discussed in 
section 1.1.4.1.1.) deuterium is known to affect retention time in RPLC, 
potentially complicating quantitation (Zhang et al., 2001). 
An addition novel feature of this method is that the N-terminal labelling step is 
performed whilst peptides are immobilized on C18 reversed phase as opposed 
to in solution. Stable isotope labelling of peptides generally requires the sample 
to be desalted and dried in vacuo prior to the labelling step. This drying step is 
known to be responsible for substantial sample losses through adsorption of 
peptides to laboratory plastics (Speicher et al., 2000). If C-terminal 18O labelling, 
lysine derivatization and N-terminal succinylation were all to be carried out in 
solution, this would require three separate rounds of desalting and drying. 
Performing the N-terminal modifications on a single reversed phase ‘mini-
reactor’ reduces this to just one desalting and drying cycle. Peptide modification 
on C18 had previously been reported for applications outside the field of 
quantitative proteomics (Conrotto and Hellman, 2005; Cindric et al., 2006; Nika 
et al., 2012; Nika et al., 2013a; Nika et al., 2013b), however to our knowledge it 
has not previously been employed in a stable isotope labelling-based relative 
quantitative proteomics workflow. 
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Chapter 6. Evaluation of the suitability of OFFGEL 
fractionation and StageTip-based SAX 
fractionation as the first dimension of separation 
for analysis of complex mixtures of proteomic 
peptides 
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6.1. Introduction 
The rate of development of liquid chromatography and mass spectrometry 
instrumentation over the past decade has resulted in shotgun-based proteomics 
far surpassing 2D electrophoresis as the approach of choice for discovery 
experiments (Lopez, 2007). However, proteomic samples processed using 
shotgun approaches are frequently too complex to analyse comprehensively in 
one LC-MS run incorporating a single dimension of reversed phase peptide 
separation. Reduction in complexity therefore necessitates pre-fractionation of 
proteomic peptides on the basis of some physicochemical property other than 
the hydrophobicity relied upon for RP-HPLC. 
Pre-fractionation was initially achieved using GeLC-MS (Blagoev et al., 2004), a 
workflow in which proteins are first separated by size on a 1D-PAGE gel. The 
gel itself is then sliced into fractions and each fraction subjected to in-gel 
digestion. Pre-fractionation can also be performed on-line at the peptide level 
using Multi-Dimensional Protein Identification Technology (MuDPIT) (Wolters et 
al., 2001) In the wider context of this particular project, using GeLC-MS would 
necessitate the proteins in each slice being digested then differentially N- and 
C- terminally labelled individually before being recombined, substantially 
increasing both the time taken to perform the labelling steps of the workflow and 
the quantity of labelling reagents required. The LC setup required to perform 
MuDPIT online was not in routine use in the lab at the time of onset of the 
project. 
Two alternatives which were investigated given the nature of the overall 
workflow were liquid-phase isoelectric focussing (Horth et al., 2006) and 
StageTip-based offline anion-exchange chromatography (Wisniewski et al., 
2009a). Both techniques have been employed in recent years as the first 
dimension of multidimensional peptide separation schemes by the highly 
regarded Mann lab at Max Planck Institute in Martinsried. In evaluating the 
suitability of each technique for fractionation in practice, it is important to 
consider three criteria: the number of peptides identified in each fraction, the 
uniformity of peptide identification frequency across all fractions and the 
efficiency of the fractionation itself (i.e. the number of fractions in which discrete 
peptides are identified). 
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6.2. OFFGEL Fractionation 
Liquid-phase isoelectric focussing was first established in 2006 with the 
introduction of the Agilent OFFGEL Fractionator (Horth et al., 2006). Optimal 
conditions for peptide focussing using the fractionator have since been 
comprehensively evaluated by Hubner et al. (Hubner et al., 2008). The results 
from this study were: - 
1. OFFGEL fractionation compares favourably to (the de-facto) GeLC-MS in 
terms of numbers of peptides and proteins identified from the same quantity 
of starting material.              
 
2. Sampling rate and peptide identification decrease with decreased peptide 
loading, whilst fractionation efficiency decreases with increased peptide 
loading. A good compromise is to load 50-100 µg of peptide for 12-well 
separations and 100-250 µg of peptide for 24-well separations. 
 
3. The doubling of starting material and LC-MS analysis time necessitated by 
24-well separations is not reflected in a concomitant doubling of peptide and 
protein IDs, yielding around 40% additional peptide IDs but less than 20% 
additional protein IDs. 12-well separations are thus recommended over 24-
well separations. 
At the time of onset of this project, OFFGEL fractionation was routinely used in 
the lab as the first dimension of separation for proteomic studies and it was 
initially intended that it be used in this project as well.  
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6.2.1. Results 
6.2.1.1. OFFGEL Fractionation can be used as the first dimension of 
separation for 18O-based quantitative proteomic experiments. 
The first instance in which OFFGEL fractionation was utilised in this project was 
after optimization of 18O-labelling reaction conditions but before the limitations of 
18O-based quantitative proteomics discussed in the previous chapter were fully 
appreciated. 18O-labelling of a given peptide should not alter its isoelectric point. 
Thus OFFGEL fractionation was employed as the first dimension of separation 
in an 18O-based quantitative proteomic comparison of the whole proteomes of 
mature and tolerogenic DCs. Approximately 50 µg of unlabelled mature DC 
proteomic peptides were combined with approximately 50 µg of 18O-labelled 
tolerogenic DC proteomic peptides and fractionated into 12 wells across a pH 3 
– 10 IPG strip. Upon completion, individual fractions were recovered from the 
wells, acidified with 1% (v/v) TFA, tip desalted and analysed by LC-MS. Raw 
data files were concatenated, processed, searched and quantified using Mascot 
Distiller. Peptide quantitation reports were generated and imported into 
Microsoft Excel for further data analysis.  
The numbers of total peptides and unique peptides (i.e. total number of 
peptides of unique sequence) identified per well is shown in Fig. 42a, whilst the 
redundancy of unique peptide identification across all 12 wells is shown in Fig. 
42b & Fig. 42c. In terms of uniformity and efficiency of fractionation, these data 
are comparable to those reported by Hubner et al. The variability in total 
number of peptides per well is somewhat similar. The two wells ranked 1st and 
2nd in terms of total number of peptides detected in this study (wells 5 and 2) 
were ranked 2nd and 3rd in the published study, whilst the two wells ranked 11th 
and 12th (wells 9 and 10) were the same for both studies. However, notably 
fewer peptides were detected in wells 1, 4 and 7 in this study. This disparity is 
particularly pronounced for well 1, which ranked 9th here but 1st in the published 
study. This may be because very little liquid was recovered from well 1 in my 
experiments. The fractionation efficiency in this study is significantly higher than 
that reported by Hubner et al., with 89% of unique peptides identified detected 
in a single well in the former and 56% in the latter. The two experiments are not 
directly comparable in this respect as blanks were run between every fraction in 
this LC-MS experiment whilst Hubner et al. appear to have run all 12 fractions 
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consecutively. The numbers of peptides identified in each fraction is significantly 
higher in the published study and the total number of peptides is around five 
times as high. The column lengths and gradient times are similar (20 cm vs. 15 
cm; 85 minutes vs. 105 minutes). However, on the basis of their methods (and 
assuming equal peptide recovery post-fractionation in both studies), Hubner et 
al. appear to have injected around 4 times as much material per LC-MS run as 
was injected here; and different LC-MS instrumentation and software was used 
for data acquisition and analysis. Both of these factors may go some way to 
explaining this disparity. Nevertheless, overall the data suggests that OFFGEL 
fractionation is a suitable means of pre-fractionation for 18O-based quantitative 
proteomic workflows.   
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Total Peptides 
(6875 ± 1977) 
Unique Peptides 
(2702 ± 216)  
n = 3 
n = 3 
a) 
b) 
Figure 42: OFFGEL fractionation 
of ~50 µg peptides derived from an 
unlabelled mature DC whole cell 
lysate combined 1:1 with ~50 µg 
peptides from an 18O-labelled 
tolerogenic DC whole cell lysate 
and fractionated on a pH 3-10 IEF 
strip. a) Total and total unique 
peptides identified in each well; b) 
& c) Redundancy of unique peptide 
identification across all 12 wells 
represented as a bar graph and a 
pie chart respectively.  Error bars 
are calculated from three technical 
replicates. The peptides fractionate 
across the entire pH gradient 
(though some wells contain 
considerably more peptides than 
others) and ~89% of all unique 
peptides are detected in one well
only.  
c) n = 3 
% Peptides Identified In 
Wells 1 2 3 
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6.2.1.2. OFFGEL Fractionation is less effective when used as the first 
dimension of separation for IPTL-based quantitative proteomic 
experiments. 
As aforementioned, the limitations of 18O-based quantitative proteomics were 
only fully appreciated after acquisition of the data discussed in the previous 
chapter. The subsequent addition of the N-terminal labelling step to the stable 
isotope labelling strategy resulted in the introduction of two further peptide 
modifications. Lysine derivatization should not change the net charge of a 
peptide. However, in converting the α-amino group from basic to acidic, N-
terminal succinylation will do so (Klapper and Klotz, 1972). This might be 
expected to affect the uniformity of fractionation across a pH 3 – 10 IPG strip 
and cause peptides to focus in a more narrow range, migrating towards the 
acidic end of the strip. 
The extent of this effect was revealed when first using OFFGEL fractionation to 
separate approximately 50 µg of differentially IPTL-labelled and combined 
mature and tolerogenic DC proteomic peptides. The numbers of total and 
unique peptides identified per well and the redundancy of unique peptide 
identification across all 12 wells are shown in Figs. 43a – 43c. Uniformity of 
fractionation is markedly compromised in comparison to the fractionation 
described in section 6.2.1.1., with negligible peptide identifications reported in 
the wells corresponding to the neutral and basic areas of the strip (wells 5 – 12). 
In addition, very few peptides are identified in well 3. It is not clear why this is 
the case given approximately 80% of the peptides identified across all twelve 
wells are found in the two neighbouring wells The issue may be related to 
downstream processing and analysis of this particular fraction rather than a 
peculiarity of the focussing procedure, though there have previously been 
anecdotal reports of batch-to-batch variation in IPG strips and ampholytes. 
Fractionation efficiency remains high, with 90% of unique peptides identified 
detected in a single well. However, given the relative paucity of wells in which 
significant numbers of peptides are detected at all, this is perhaps a trivial 
observation.    
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Figure 43: OFFGEL fractionation 
of peptides derived from a 13C4-
succinylated mature DC whole cell 
lysate combined 1:1 with a 12C4-
succinylated / 18O-labelled 
tolerogenic DC whole cell lysate 
and fractionated on a pH 3-10 IEF 
strip. a) Total and total unique 
peptides identified in each well; b) 
& c) Redundancy of unique peptide 
identification across all 12 wells 
represented as a bar graph and a 
pie chart respectively. Once again, 
~90% of all unique peptides are 
detected in one well only. However, 
the peptides seem to preferentially 
fractionate to the acidic end of the 
IPG strip. This is likely due to the 
fact that the peptides have been 
succinylated.     
c) n = 1 
% Peptides Identified In 
Wells 1 2 3 
n = 1 
n = 1 
a) 
b) 
Total Peptides 
(3369) 
Unique Peptides 
(1269)  
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In light of these data, it was clear that OFFGEL fractionation with full range pH 3 
– 10 IPG strips would be inadequate for effective pre-fractionation of IPTL-
labelled peptides prior to LC-MS analysis. One potential means of counteracting 
the more acidic focussing range of succinylated peptides would be to use an 
IPG strip with a narrower pH range. At the time, the principle supplier of IPG 
strips for use with the OFFGEL instrument (GE Healthcare) did not offer strips 
with the desired pH range. However, another supplier (Bio-Rad) offered strips 
with a suitable pH range (pH 3 – 10) together with a published workaround 
(Berkelman et al., 2011) which consisted of the removal of a single well from the 
end of an OFFGEL 12 well frame assembly to enable these strips to be used 
with the OFFGEL device in spite of being slightly too short. 
The fractionation described in section 6.2.1.2. was thus repeated using the Bio-
Rad IPG strips and the aforementioned workaround. Numbers of total and 
unique peptides and redundancy of unique peptide identification across all wells 
are plotted as previously in Figs. 44a – 44c. After fractionation, no liquid was 
recovered from the 11th well; the data shown are therefore for wells 1 – 10 only.  
Uniformity of fractionation is only slightly improved relative to the separation 
described in section 6.2.1.2. Over 16000 total peptides are identified in wells 1 – 
5 (corresponding to the acidic half of the strip). However, very few peptides are 
identified in wells 6 – 10 (corresponding to the basic half of the strip). IPTL 
peptides fractionated on a pH 3 – 10 strip (Fig. 43) appeared to focus in wells 1 
– 4 (save for well 3), which corresponds to a pH range of 3 – 5.33. With this in 
mind, we might expect IPTL peptides fractionated on a pH 3 – 6 strip to focus in 
the first eight or nine of the eleven wells rather than just five. One possible 
explanation for this is that whilst the IPG strip used here had a pH range of 3 – 
6, the ampholytes used in the focussing buffer had a broader range of 3 – 10. It 
has since been suggested that uniformity of fractionation could be further 
improved through using ampholytes with a narrower and more acidic pH range 
(Bio-Rad, personal communication). However, an ampholyte solution 
corresponding precisely to the pH range of the strip itself is not available.   
In addition, fractionation efficiency is substantially reduced in comparison to the 
separations shown in Fig. 42 & Fig. 43. Only 60% of unique peptides identified 
are detected in a single well, with 16%, 8%, 8% and 6% of unique peptides 
being detected in 2, 3, 4 and 5 wells respectively, Whilst these figures are 
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comparable to those reported by Hubner et al., it is worth noting that the latter 
study reports identification of significant numbers of peptides in every fraction 
and (as previously discussed) all twelve LC-MS fractions were run 
consecutively; neither of which can be said of this particular separation. The 
reasons for this poorer focussing are unclear, but may be due to incompatibility 
issues between the OFFGEL instrument and the Bio-Rad IPG strips and 
ampholytes. 
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Figure 44: OFFGEL fractionation 
of peptides derived from a 13C4-
succinylated mature DC whole cell 
lysate combined 1:1 with a 12C4-
succinylated / 18O-labelled 
tolerogenic DC whole cell lysate 
and fractionated on a pH 3-6 IEF 
strip. a) Total and total unique 
peptides identified in each well; b) 
& c) Redundancy of unique peptide 
identification across all 10 wells 
represented as a bar graph and a 
pie chart respectively. The acidic 
IEF strip slightly improves 
focussing range of succinylated 
peptides. However, fractionation 
efficiency is significantly lower, with 
~60% of unique peptides detected 
in one well only. This may be due 
to incompatibility of this IEF strip 
with the OFFGEL fractionator.   
1 2 3 4 5 6 
% Peptides Identified In 
Wells 
c) n = 1 
n = 1 
n = 1 
a) 
b) 
Total Peptides 
(16237) 
Unique Peptides 
(2938)  
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6.3. StageTip-based SAX Fractionation 
In spite of the recommendation to use ampholytes with a complimentary pH 
range to that of the pH 3 – 6 IPG strip to focus IPTL peptides, it was decided at 
this point to explore alternative means of fractionation. An additional impetus for 
doing so was the lengthy and unpredictable run times observed for each 
OFFGEL separation (nearly two days in one instance). 
A year after the publication of the Hubner et al. OFFGEL paper, Wisniewski et 
al. published a further paper (Wisniewski et al., 2009a) in which they described 
a novel MuDPIT-type offline anion-exchange method for peptide fractionation 
based on the StageTip method originally conceived for sample desalting prior to 
LC-MS analysis (Rappsilber et al., 2003). In this method, peptides are 
resuspended in pH 11 Britton-Robinson (BR) buffer, bound to anion exchange 
resin housed within a pipette tip and eluted stepwise with BR buffers of 
decreasing pH values. Wisniewski et al. report that whilst this separation 
scheme is slightly inferior to OFFGEL fractionation in terms of redundancy 
across fractions; its speed, simplicity and reproducibility make it a desirable 
alternative. 
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6.3.1. Results 
6.3.1.1. Evaluation of StageTip-based SAX fractionation as an 
alternative to OFFGEL Fractionation for first-dimensional 
separation of succinylated peptides 
Though isoelectric focussing and ion exchange chromatography are distinct 
separation strategies, both share a common mode in separating molecules on 
the basis of charge state. With this in mind, it was not clear whether the same 
difficulties experienced with OFFGEL fractionation of IPTL-labelled peptides 
would also be seen when using StageTip-based SAX fractionation, particularly 
since peptides are loaded at high pH and the first couple of elutions are at 
neutral pH or above. The technique was thus evaluated using unlabelled and 
succinylated proteomic peptides from a Jurkat whole cell lysate as opposed to 
material derived from mature and tolerogenic dendritic cells. 
6.3.1.2. StageTip-based SAX fractionation is an effective alternative to 
OFFGEL Fractionation for the first dimension of separation of 
unmodified and succinylated peptides 
Approximately 25 µg of unmodified Jurkat proteomic peptides and a similar 
quantity of succinylated Jurkat proteomic peptides were fractionated as 
described by Wisniewski et al. with a couple of notable exceptions. In the 
published study, the first elution is performed at pH 8 whereas we performed 
our first elution at pH 7, based on our experiences with IPG strips. Additionally, 
the last elution in the published study is performed at pH 3 whereas we included 
an addition elution step at pH2. All fractions and the pH 11 flow-through were 
acidified with 1% (v/v) TFA, tip desalted and analysed by LC-MS. Raw data 
were processed and searched within Mascot itself. Peptide reports were 
exported from Mascot as CSV files and imported into Microsoft Excel for further 
data processing. 
The numbers of total and unique unmodified peptides identified per fraction is 
shown in Fig. 45a; whilst the redundancy of unique unmodified peptide 
identification across all seven fractions is shown in Figs. 45b & 45c. 
Corresponding data for succinylated peptides is shown in Figs. 46a – 46c. 
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The data for unmodified peptides are comparable to those reported by 
Wisniewski et al. and also compare favourably with the data shown in section 
6.2.1.1. for OFFGEL fractionation of a combination of unlabelled and 18O-
labelled peptides. The separation is considerably more uniform than the 
corresponding OFFGEL fractionation, with approximately 11000 peptides 
identified in the highest yielding fraction (pH 6) and approximately 6000 
peptides identified in the lowest yielding fraction (pH 3). This uniformity and 
peptide identification frequency is also seen in the published study. As 
previously acknowledged, Wisniewski et al. suggest that fractionation efficiency 
may be slightly compromised in comparison to OFFGEL fractionation. However, 
approximately 77% of unique peptides identified here are only detected in a 
single fraction in spite of blanks not being run between the LC-MS fractions. 
This value is higher than that reported in the published study, where less than 
50% of unique peptides identified were detected in a single fraction.  
The data for succinylated peptides also compares favourably to those shown in 
section 6.2.1.2. for OFFGEL fractionation of IPTL-labelled peptides. The 
separation is not as uniform as that seen for unmodified peptides, with notably 
fewer total peptide identifications from the pH4 and pH3 fractions. However, 
appreciable numbers of peptides are identified in every fraction and there are 
no fractions for which analysis would be deemed counterproductive on the basis 
of wasted instrument time. Total peptide identifications are markedly reduced in 
every fraction in comparison with the analogous unmodified fractions. This may 
be because peptides carrying an additional ~100 Da succinyl group (potentially 
two succinyl groups for many peptides since lysine residues were not 
derivatized in this particular experiment) are less likely to fly well than their 
unmodified counterparts. As with unmodified peptides, fractionation efficiency 
remains favourably high (approximately 81% of unique peptides detected in a 
single fraction). 
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Figure 45: First StageTip-based 
SAX fractionation of 25 µg 
unlabelled peptides derived from a 
Jurkat whole-cell lysate. a) Total 
and total unique peptides identified 
in each fraction; b) & c)
Redundancy of unique peptide 
identification across all 7 fractions 
represented as a bar graph and a 
pie chart respectively. The data 
suggest that StageTip-based SAX 
fractionation is an effective 
alternative to OFFGEL 
fractionation for unlabelled 
peptides. High numbers of 
peptides are identified in each 
fraction and ~77% of all unique 
peptides are detected in one well 
only in spite of blanks not being run 
between SAX fractions.   
c) 
1 2 3 4 5 6 
% Peptides Identified In 
Wells 
n = 1 
n = 1 
n = 1 
a) 
b) 
Total Peptides 
(59943) 
Unique Peptides 
(16661)  
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Figure 46: First StageTip-based 
SAX fractionation of 25 µg 
succinylated peptides derived from 
a Jurkat whole-cell lysate. a) Total 
and total unique peptides identified 
in each fraction; b) & c)
Redundancy of unique peptide 
identification across all 7 fractions 
represented as a bar graph and a 
pie chart respectively. The data 
suggest that StageTip-based SAX 
fractionation can alleviate the 
pitfalls observed with OFFGEL 
fractionation for succinylated 
peptides. Appreciable numbers of 
peptides are identified in each 
fraction and ~81% of all unique 
peptides are detected in one well 
only in spite of blanks not being run 
between SAX fractions. 
c) n = 1 
1 2 3 4 5 6 
% Peptides Identified In 
Wells 
n = 1 
n = 1 
a) 
b) 
Total Peptides 
(14147) 
Unique Peptides 
(4398)  
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6.3.1.3. Peptides bound to anion exchange resin in StageTip-based SAX 
fractionation appear to interact with the polystyrene sorbent of 
the resin in addition to the quaternary ammonium functional 
groups 
One of the two alterations made to the published StageTip-based SAX 
fractionation procedure adhered to in section 6.3.1.2. was the inclusion of an 
additional elution step at pH 2. The data in Figs. 45 and 46 suggest that 
substantial amounts of peptide remain bound to the anion exchange resin after 
the pH 3 elution step (the final elution step in the published study). This residual 
material is particularly marked when separating succinylated peptides, with 
more total peptide identifications in the pH 2 fraction than in the pH 3 and pH 4 
fraction combined. Taking the possibility of non-specific binding into 
consideration, the fractionation described in section 6.3.1.2. was repeated with 
the inclusion of a further elution step with a buffer composed of 50% (v/v) BR 
buffer (pH 2) and 50% (v/v) acetonitrile. A corresponding amount of 
unfractionated peptide (assuming fractionation resulted in identical amounts of 
material in each fraction, therefore 1/9th of total material) was also analysed for 
both unmodified and succinylated samples to assess the increase in peptide 
identifications attained through performing the procedure. 
Fractions and flow-through were processed as described previously. The 
number of total and unique unmodified peptides identified per fraction is shown 
in Fig. 47a, whilst the redundancy of unique peptide identification across all 
eight fractions is shown in Figs. 47b & 47c. Corresponding data for 
succinylated peptides is shown in Figs. 48a – 48c. 
These data clearly demonstrate the advantages of performing an additional 
dimension of peptide separation upstream of LC-MS analysis. Separation into 
eight fractions allows for 82559 total (20713 unique) unmodified peptides and 
39269 total (8619 unique) succinylated peptides to be identified across all eight 
runs. In contrast 13718 total (5366 unique) unmodified peptides and 6407 total 
(2523 unique) succinylated peptides are identified when the material is not 
fractionated and analysed in a single run. Fractionation will thus result in the 
identification of more proteins (detection of more unique peptides) with greater 
confidence (unique peptides detected more frequently).     
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Interestingly, the elution step incorporating 50% acetonitrile liberates significant 
amounts of unmodified and succinylated peptide material even after the elution 
step at pH 2. This is particularly notable for the succinylated separation, where 
the highest number of total protein identifications was observed in this fraction. 
Furthermore, the total amount of peptide material released with this final elution 
step is around four times that released in the preceding step as inferred through 
signal intensity across the total ion chromatograms (data not shown). The 
majority of peptides identified in the final elution are unique to this fraction for 
both unmodified and succinylated samples (approx. 84% and approx. 78% 
respectively, data not shown). This suggests that there are non-specific 
hydrophobic interactions occurring between the peptides and the polystyrene 
sorbent in addition to the ionic interactions taking place between the peptides 
and the quaternary ammonium functional groups of the resin. The unique 
peptides identified in the final elution probably interact more strongly with the 
polystyrene than the quaternary ammonium. 
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Figure 47: Second StageTip-
based SAX fractionation of 25 µg 
unlabelled peptides derived from a 
Jurkat whole-cell lysate. a) Total 
and total unique peptides identified 
in each fraction and in an 
equivalent amount of 
unfractionated material; b) & c)
Redundancy of unique peptide 
identification across all 8 fractions 
represented as a bar graph and a 
pie chart respectively. The number 
of unique peptides detected 
exclusively in the final elution step 
implies that some peptides may 
interact more strongly with the 
polystyrene sorbent of the resin 
than the quaternary ammonium 
groups. ~74% of all unique 
peptides are detected in one well 
only in spite of blanks not being run 
between SAX fractions.  
c) n = 1 
1 2 3 4 5 6 
% Peptides Identified In 
Wells 
n = 1 
n = 1 
a) 
b) 
Total Peptides 
(82559) 
Unique Peptides 
(20713)  
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Figure 48: Second StageTip-
based SAX fractionation of 25 µg 
succinylated peptides derived from 
a Jurkat whole-cell lysate. a) Total 
and total unique peptides identified 
in each fraction and in an 
equivalent amount of 
unfractionated material; b) & c)
Redundancy of unique peptide 
identification across all 8 fractions 
represented as a bar graph and a 
pie chart respectively.  As with the 
unmodified peptide data shown in 
(Fig. 6), a large number of unique 
peptides are detected exclusively 
in the final fraction and 
fractionation efficiency remains 
high (~75% of all unique peptides 
detected in one well only). 
c) n = 1 
1 2 3 4 5 6 
% Peptides Identified In 
Wells 
n = 1 
n = 1 
a) 
b) 
Total Peptides 
(39269) 
Unique Peptides 
(8619)  
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6.3.1.4. The ionic interactions of peptides with the resin in StageTip-
based SAX fractionation that appears to vary with successive 
decreases in pH is strongly affected by the presence of 
acetonitrile in the buffer 
Given the substantial amount of material present in the final fraction in the 
experiment described in section 1.3.1.3., a further fractionation was performed 
in which elutions with BR buffer at every pH step were followed by an elution 
with a buffer composed of 50% (v/v) BR buffer and 50% (v/v) acetonitrile before 
moving down to the next pH step. It was reasoned that if both ionic and 
hydrophobic interactions were playing a role in determining whether peptides 
were retained or released from the resin in any given elution step, this alteration 
to the procedure might aid in distributing the peptide material more evenly 
across the fractions. Fractions and flow-through were processed as described 
previously and data for unmodified and succinylated peptides are plotted as in 
previous figures in Fig. 49 and Fig. 50 respectively.    
For both unmodified and succinylated separations, these additional elution 
steps do not impart the desired effect. Instead, a large amount of peptide 
material is liberated in the pH 7 acetonitrile elution in comparison to the 
preceding pH 7 or subsequent pH 6 elutions (around five times as much for the 
succinylated sample and around ten times as much for the unmodified sample 
as inferred through signal intensity across the total ion chromatograms, data not 
shown). All subsequent elutions for both sets of samples contain considerably 
less peptide material and yield considerably less total peptide identifications 
than in the corresponding fractionations described in sections 6.3.1.2. and 
6.3.1.3., where acetonitrile was either not used at all or only introduced at the 
final elution step.  
Interestingly, peptide yield and identifications recover somewhat at the lowest 
pH elutions. This is only really seen in the pH 2 BR and pH 2 acetonitrile elution 
with the unmodified peptides, but is also seen in the pH 3 and pH 4 acetonitrile 
elutions with the succinylated peptides. This observation may offer some insight 
into what is happening. Acetonitrile has a powerful elutrophic effect on peptides 
bound to this solid-phase support, disrupting hydrophobic interactions which 
may still endure in the absence of ionic interactions. Thus many basic peptides 
(pH 7 – pH 11) which are retained at pH 7 owing to hydrophobic interactions are 
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released in the pH 7 acetonitrile elution. Acidic peptides retained on the basis of 
ionic interactions rather than or in addition to hydrophobic interactions are 
retained until the pH of the elution buffer is sufficiently low to disrupt these ionic 
interactions. Addition of acetonitrile to low pH buffers enhances release of these 
acidic peptides in the same manner. Succinylated peptides are more acidic, 
which would explain why we see peptide yield and identifications begin to 
recover in the pH 4 acetonitrile elution in the succinylated separation. The 
equivalent unmodified (less acidic) peptides would likely have already been 
eluted in an earlier fraction. 
In conclusion, the cons of this particular elution scheme probably outweigh the 
pros. It does not seem to be of detriment to fractionation efficiency with 
succinylated peptides (approx. 77% of unique peptides detected in a single 
fraction), though unmodified peptide fractions do appear to be slightly more 
diffuse (approx. 68% of unique peptides detected in a single fraction). However, 
the abundance of peptide material liberated in the pH 7 acetonitrile elution 
results in a number of subsequent weakly acidic elutions containing 
comparatively little material and yielding relatively few peptide identifications. It 
may be that there is an optimal concentration of acetonitrile to add to each 
elution buffer in order to obtain a more homogeneous distribution of peptide 
material across the thirteen fractions; however this would likely require 
considerable further experimental work. However, it is now obvious that binding 
and elution to and from this SAX material involves a ‘mixed-mode’ of action. 
This phenomenon has previously been reported for MuDPIT separations, where 
application of a 10% - 30% acetonitrile gradient at the end of the conventional 
salt step gradient resulted in an increase in peptide identifications of around 
23% (Liu et al., 2006).  
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Figure 49: Third StageTip-based 
SAX fractionation of 25 µg 
unlabelled peptides derived from a 
Jurkat whole-cell lysate. a) Total 
and total unique peptides identified 
in each fraction and in an 
equivalent amount of 
unfractionated material; b) & c)
Redundancy of unique peptide 
identification across all 13 fractions 
represented as a bar graph and a 
pie chart respectively. The 
inclusion of elution steps 
incorporating 50% acetonitrile 
across the entire pH range of the 
procedure releases a 
disproportionately large amount of 
peptide material from the resin in 
the pH 7 acetonitrile fraction. Later 
fractions contain considerably less 
material and yield fewer IDs than 
the corresponding fractions shown 
in (Figs. 4 and 6).  
c) n = 1 
1 2 3 4 5 6 
% Peptides Identified In 
Wells 
n = 1 
n = 1 
a) 
b) 
Total Peptides 
(52302) 
Unique Peptides 
(13392)  
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Figure 50: Third StageTip-based 
SAX fractionation of 25 µg 
succinylated peptides derived from 
a Jurkat whole-cell lysate. a) Total 
and total unique peptides identified 
in each fraction and in an 
equivalent amount of 
unfractionated material; b) & c)
Redundancy of unique peptide 
identification across all 13 fractions 
represented as a bar graph and a 
pie chart respectively. As with the 
unmodified peptide data shown in 
(Fig. 8), there is a spike in peptide 
material released from the resin in 
the pH 7 acetonitrile fraction, with 
less material contained in later 
fractions in comparison to the 
corresponding fractions shown in 
(Figs. 5 & 7).  
c) n = 1 
1 2 3 4 5 6 
% Peptides Identified In 
Wells 
n = 1 
n = 1 
a) 
b) 
Total Peptides 
(29017) 
Unique Peptides 
(9619)  
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6.4. Discussion 
As previously touched upon, the OFFGEL and SAX fractionation data presented 
in this chapter are not directly comparable: the latter was explored as an 
alternative when it became clear that the former might not be well-suited to 
separating IPTL-labelled peptides as opposed to all experiments being 
performed as a cohesive body of work. The fractionation efficiency figures 
reported for OFFGEL fractionation appear superior to those reported to SAX 
fractionation because OFFGEL fractionation is a more effective technique in this 
regard, but also because blanks were run between all OFFGEL fractions whilst 
all SAX fractions were analysed consecutively. The majority of residual peptide 
material retained on the LC column after a given sample fraction will therefore 
be liberated in the blank fraction as opposed to the following sample fraction. 
On the other hand, the numbers of total and unique peptide identifications 
reported for SAX fractionation were consistently higher than those reported for 
OFFGEL fractionation because SAX fractionation enables greater recovery of 
starting material, but also because the SAX fractions were analysed using a 
considerably longer LC column, affording greater peptide loading capacity and 
enhanced peak resolving power. In much the same way, neither dataset is 
directly comparable to the data published by Hubner et al. and Wisniewski et al. 
as these studies employed entirely different experimental systems from which to 
derive their starting material and performed all analysis using different 
instruments and set-ups. The primary objective here is thus not to draw any 
absolute parallels between the techniques but merely to weigh the relative 
merits of the two. 
Taking the above into account, these data strongly advocate employing 
StageTip-based anion exchange chromatography as the first dimension of 
separation in the context of this particular proteomics workflow. Firstly, the 
StageTip-based format of the SAX procedure renders it considerably quicker 
and simpler to perform than OFFGEL electrophoresis. Secondly, the 
separations described in section 6.2.1.2. would suggest that there are inherent 
issues in using liquid phase isoelectric focussing to fractionate peptides with 
modifications which alter charge state. These issues may not necessarily be 
insurmountable, but also appear to be largely circumvented when using SAX 
fractionation. 
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Of the three elution schemes explored for StageTip-based SAX fractionation, 
the second of the three (incorporating a final elution step with 50% (v/v) BR 
buffer (pH 2) and 50% (v/v) acetonitrile) appears to be the most favourable 
compromise in terms of the trade-off between the numbers of total and unique 
peptides identified across all of the fractions and the instrument time required to 
analyse all of these fractions. As previously discussed, it is likely that this 
second scheme is not completely optimised and more peptide identifications 
could be gleaned if the material released from the anion exchange resin with 
the addition of acetonitrile could be separated more uniformly across all of the 
preceding elutions. However, of all peptide fractionation experiments performed 
over the course of this project, this particular methodology proved most 
successful in terms of meeting the criteria set out at the beginning of the 
chapter. The next logical step would be to apply this methodology to fractionate 
a mixture of differentially labelled, membrane enriched dendritic cell proteomic 
peptides.  
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Chapter 7. Application of optimized quantitative and 
membrane proteomics methods to mature and 
tolerogenic dendritic cells 
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7.1. Introduction 
At various intervals throughout the course of this body of work, the methods 
developed and heretofore described were applied to perform proteomic 
analyses on mature and tolerogenic dendritic cells. More specifically, 
development of the IPTL-based quantitation strategy described in Chapter 5 
and the StageTip-based SAX fractionation procedure described in Chapter 6 
were in part informed by quantitative proteomic comparisons of the whole cell 
proteomes of mature and tolerogenic DCs using both 18O labelling and IPTL in 
combination with OFFGEL fractionation. Whilst these latter two workflows were 
subsequently found to be suboptimal from a technical viewpoint, this did not 
preclude the possibility that the experiments themselves yielded information that 
was of biological interest. The optimized membrane enrichment and digestion 
strategy described in Chapter 4 was also latterly applied successfully for 
qualitative profiling of the membrane proteomes of mature and tolerogenic DC. 
The results of these quantitative and qualitative experiments are described 
herein. 
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7.2. 18O-based quantitative profiling of the whole cell proteomes of 
mature and tolerogenic DC 
Mature and tolerogenic DC whole cell lysates were prepared using the whole 
cell lysate preparation for the in-solution digestion procedure described in 
section 3.2.1. Detergent removal was performed as described in section 3.3.1. 
and digestion as described in section 3.3.2. Mature DC peptides were 18O 
labelled, whilst tolerogenic DC peptides remained unlabelled. A small quantity 
of mature DC peptides were analysed to verify that labelling had run to 
completion. Approximately 50 µg each of labelled and unlabelled peptides were 
then combined in a 1:1 ratio and focused into 12 fractions by OFFGEL 
electrophoresis. Focused fractions were recovered, cleaned-up and analysed 
as described in section 3.5.1. Two biological replicates were performed and 
three technical replicates carried out for each fraction, giving a total of 36 raw 
data files for each biological replicate. 
The 36 files were concatenated, searched and quantitated using Mascot 
Distiller (Matrix Science). 10678 peptides corresponding to 1008 proteins were 
identified in the first biological replicate (false discovery rate: 4.31%) and 7060 
peptides corresponding to 779 proteins were identified in the second biological 
replicate (false discovery rate: 4.09%). Protein quantitation ratios were reported 
if a minimum of two peptides were detected that passed all three of the 
statistical tests described in section 5.2.2.6. Refining using these criteria, 416 
proteins were quantitated in the first biological replicate and 296 proteins were 
quantitated in the second biological replicate. Quantitation ratios were 
normalized on the median reported ratio and a labelled to unlabelled ratio of ≥ 2 
or ≤ 0.5 (twofold change) was taken as the minimum criteria for differential 
expression. It was noted that Distiller frequently reports ratios for C-terminal 
peptides (which do not 18O label and should thus be exempt from ratio 
calculations) and occasionally calls the fifth isotope peak of particularly intense 
unlabelled peptides as the first isotope peak of equivalent labelled peptides, 
skewing the resultant protein ratios. With this in mind, the spectra of the 
individual peptides identified in differentially expressed proteins were manually 
examined in order to remove spurious results. This left 15 proteins of twofold or 
greater abundance in mature DCs than in tolerogenic DCs and 9 proteins of 
twofold or greater abundance in tolerogenic DCs than in mature DCs for the first 
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biological replicate; and 17 proteins of twofold or greater abundance in mature 
DCs than in tolerogenic DCs and 13 proteins of twofold or greater abundance in 
tolerogenic DCs than in mature DCs for the second biological replicate.  
Proteins detected in either or both biological replicates with twofold or greater 
expression in mature DCs than in tolerogenic DCs are shown in Table 8. 
Proteins detected in either or both biological replicates with twofold or greater 
expression in tolerogenic DCs than in mature DCs are shown in Table 9. Ratios 
are reported as the product of abundance of labelled peptide divided by 
abundance of unlabelled peptide. Identification of a protein as having twofold or 
greater expression in one cell type relative to the other does not permit 
inference of whether the protein is upregulated in the first cell type or 
downregulated in the second, merely that the protein is differentially expressed. 
To further increase confidence in results, the quantitation ratios of differentially 
expressed proteins in the first biological replicate were examined in the second 
biological replicate and vice versa. In instances where a protein had been 
quantitated in both biological replicates and the ratios conflicted, the spectra of 
individual peptides of that protein were manually examined in both replicates 
and the replicate with the best quality data (in terms of number and / or intensity 
of peptides quantitated) was assumed to be more representative of the true 
ratio. These ratios are shaded in grey in the tables. For both tables, proteins 
detected with twofold or greater expression in both biological replicates, 
proteins detected in both biological replicates with twofold or greater expression 
in the replicate with the best quality data and proteins detected with twofold or 
greater expression in one biological replicate but not detected in the other are 
listed in the top section of the table. Proteins detected in both biological 
replicates with less than twofold expression in the replicate with the best quality 
data are listed separately in the bottom section of table. 
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Table 8: Proteins identified in 18O-based quantitative profiling of whole cell 
proteomes of mature and tolerogenic DCs with twofold or greater expression in 
mature DCs. In instances where a protein had been quantitated in both 
biological replicates and the ratios conflicted, the spectra of individual peptides 
of that protein were manually examined in both replicates and the replicate with 
the best quality data (in terms of number and / or intensity of peptides 
quantitated) was assumed to be more representative of the true ratio. These 
ratios are shaded in grey in the tables. 
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Table 9: Proteins identified in 18O-based quantitative profiling of whole cell 
proteomes of mature and tolerogenic DCs with twofold or greater expression in 
tolerogenic DCs. In instances where a protein had been quantitated in both 
biological replicates and the ratios conflicted, the spectra of individual peptides 
of that protein were manually examined in both replicates and the replicate with 
the best quality data (in terms of number and / or intensity of peptides 
quantitated) was assumed to be more representative of the true ratio. These 
ratios are shaded in grey in the tables. 
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7.3. IPTL-based quantitative profiling of the whole cell proteomes of 
mature and tolerogenic DC 
Mature and tolerogenic DC whole cell lysates were prepared and digested as 
described in section 7.2. Mature DC peptides were labelled with 13C4-succinic 
anhydride only and tolerogenic DC peptides were labelled with 18O water and 
12C4-succinic anhydride. A small quantity of mature and tolerogenic DC peptides 
were individually analysed to verify that labelling had run to completion. 
Approximately 50 µg of differentially labelled peptides were then combined in a 
1:1 ratio and focused into 10 fractions by modified OFFGEL electrophoresis 
using a Bio-Rad pH 3 – 6 IPG strip. Focused fractions were recovered, cleaned-
up and analysed as described in section 7.2. 
The 10 files were concatenated using Mascot Daemon and then searched and 
quantitated within Mascot. A total of 5765 peptides corresponding to 478 
proteins were identified (false discovery rate: 3.73%). Whilst this is less than 
either of the two 18O-labelling experiments, it is worth noting that the majority of 
peptides fractionated into the first five wells (see section 6.2.1.2.) and no 
technical replicates were performed for this reason. Protein quantitation ratios 
were reported if a minimum of two peptides were detected and quantified. 
Applying these criteria, 351 of the 478 proteins were quantitated. Quantitation 
ratios were normalized on the median reported ratio and a labelled to unlabelled 
ratio of ≥ 2 or ≤ 0.5 (twofold change) was taken as the minimum criteria for 
differential expression. Just 7 proteins were identified with twofold or greater 
abundance in mature DCs than in tolerogenic DCs, while only 2 proteins were 
identified with twofold or greater abundance in tolerogenic DCs than in mature 
DCs. Manual examination of the spectra of the individual peptides identified in 
differentially expressed proteins confirmed that all results appeared genuine. 
The identities of these proteins are shown in Table 10.  
Whilst treatment of tolerogenic DCs with dexamethasone and vitamin D3 would 
be expected to result in differential expression in a small subset of proteins 
relative to mature DCs, the cells differentiate from a common precursor (CD14+ 
monocytes) and the culture protocol is broadly similar, thus global protein 
expression should by and large remain equivalent across the two cell types. 
The distribution of all reported protein ratios computed from the combined 
mature and tolerogenic DC samples is shown in Fig. 51. These data suggest 
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that this is indeed the case and reinforce the quantitative accuracy of the IPTL 
method in lieu of a biological replicate for the experiment described in section 
5.3.2.6. 
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Table 10: Proteins identified in IPTL-based quantitative profiling of whole cell 
proteomes of mature and tolerogenic DCs with twofold or greater expression in 
one cell type relative to the other. 
Figure 51: Box and whisker plot showing distribution of a) protein ratios; b)
peptide ratios reported by Mascot when 13C4-succinylated mature DC 
proteomic peptides and 12C4-succinylated / 
18O-labelled tolerogenic DC 
proteomic peptides are combined in a 1:1 ratio. 50% of reported ratios are 
contained within the boxes and 95% are contained within the whiskers. 
a) b) 
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7.4. Discussion (whole cell proteomes) 
Many of the proteins identified as being of two-fold or greater abundance in 
mature DCs over tolerogenic DCs in these whole proteome quantitative 
comparisons have previously been reported to be induced upon and/or have 
functions reconcilable with DC maturation and immune activation. 
Fascin (Table 8, protein 1) is an actin-bundling protein which has been shown to 
be essential in mature DC dendrite formation (Ross et al., 2000), and there is 
evidence that increased expression of Fascin is linked with concomitantly 
increased expression of MHC class II and co-stimulatory molecules (Al-Alwan et 
al., 2001). It has been suggested that HLA class II histocompatibility antigen 
gamma chain (CD74) (Table 8, protein 4) is transiently induced in the early 
stages of LPS-induced DC maturation, temporarily inhibiting migration and 
facilitating maximal antigen uptake (Faure-Andre et al., 2008); though it is not 
clear whether this increased expression would persist a full 24 hours after LPS 
stimulation (the time-point at which our mature and tolerogenic DCs are 
harvested). Thioredoxin (Table 8, protein 5) is important in generating the 
reducing extracellular microenvironment necessary for T cell activation (Angelini 
et al., 2002) and has been shown to be highly upregulated in LPS-matured 
monocyte-derived DCs relative to immature DCs in a previous proteomics study 
(Pereira et al., 2005). Levels of rho GDP-dissociation inhibitor 2 (Table 10, 
protein 6) were similarly increased in the same study. Ubiquitin-like protein 
ISG15 (Table 8, protein 7) mRNA and protein levels have been shown to be 
induced during LPS-induced DC maturation using microarray analysis, RT-PCR 
and immunoblotting (Ebstein et al., 2009). β2-microglobulin (Table 8, protein 17) 
is a subunit of MHC Class I molecules, which are highly upregulated on the 
surface of mature DCs to enable cross presentation (Ackerman and Cresswell, 
2003). Transferrin receptor protein 1 (Table 8, protein 19) mediates iron uptake 
in mature DCs (Brinkmann et al., 2007), and iron depletion has been shown to 
inhibit DC maturation (Kramer et al., 2002). Serpin B9 (Table 10, protein 4) 
inhibits granzyme B and enables mature DC to cross present to CD8+ T cells 
without succumbing to contact-mediated cytotoxicity themselves (Lovo et al., 
2012). Finally, protein-glutamine gamma glutamyltransferase 2 (Table 10, 
protein 7) has been postulated to play an important role in the maturation 
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process itself, with DCs from knockout mice exhibiting impaired maturation and 
reduced response to LPS stimulation (Matic et al., 2010). 
In contrast, it is less easy to ascribe roles from the literature in immune 
tolerance to many of the proteins identified as being of twofold or greater 
abundance in tolerogenic DCs than in mature DCs. This is not to say that the 
proteins do not play a role in the process: DC-mediated T cell tolerance is a less 
well characterized phenomenon than DC-mediated T cell activation and some 
of the proteins are not characterised at all. Nevertheless, a few proteins do 
stand out.  
The cathepsins are a family of lysosomal proteases known to be important in 
antigen processing and MHC class II loading (Honey and Rudensky, 2003). The 
precise roles of individual members of the family in this process is yet to be 
completely delineated but evidence suggests that they are not redundant 
(Honey and Rudensky, 2003). Treatment of DCs with ZLRL (a highly-specific 
inhibitor of Cathepsin B) enhanced their ability to present tetanus toxin C-
fragment peptides and induce a pro-inflammatory response (Reich et al., 2009). 
In contrast, treatment of DCs with CLIK-60 (an inhibitor of Cathepsin S) impairs 
their ability to present alpha-fodrin peptides in Sjogren’s syndrome and 
suppresses the pro-inflammatory response (Katunuma et al., 2003). These data 
suggest that Cathepsin B (Table 9, protein 3) is significantly more abundant in 
tolerogenic DCs whilst Cathepsin S (Table 9, protein, 21) expression is more 
equivocal, with the more compelling of the two biological replicates suggesting 
little difference in abundance between the two cell types.  
Additionally, adipocyte fatty acid-binding protein (Table 9, protein 12) is a target 
gene of the transcription factor PPARγ (Szanto et al., 2010), which our group 
has previously shown is upregulated in tolerogenic DCs relative to mature DCs 
(unpublished observations). The conversion of biliverdin to bilirubin by surface 
expressed biliverdin reductase (BVR) (Table 9, protein 17) induces BVR 
phosphorylation and downstream activation of protein kinase B signalling, 
leading to enhanced IL-10 production in macrophages (Wegiel et al., 2009). 
Finally, whilst these data suggest that expression levels of Galectin-3 (Table 9, 
protein 19) in tolerogenic DCs fall just below the threshold for differential 
expression, it merits consideration as there is evidence that siRNA knockdown 
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of the protein in immature and mature DCs results in enhanced T cell activation 
(Mobergslien and Sioud, 2012).     
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7.5. Qualitative profiling of the membrane proteomes of mature and 
tolerogenic DC 
Enriched mature and tolerogenic DC membrane fractions were prepared and 
digested using the optimized stepwise depletion and FASP procedure described 
in section 4.2.3.1. Digests were cleaned up and analysed as described in 
section 3.6. – 3.7. Data processing, GO annotation and transmembrane domain 
prediction were also performed as previously described. A total of 1134 
peptides corresponding to 351 proteins were identified in the mature DC 
membrane fraction (false discovery rate: 8.99%) and a total of 1232 peptides 
corresponding to 429 proteins were identified in the tolerogenic DC membrane 
fraction (false discovery rate: 9.50%). 
The distribution of cellular component GO annotations and percentage of 
proteins predicted to contain transmembrane domains by TMHMM for all 
proteins identified in the mature and tolerogenic DC membrane fractions are 
shown in Fig. 52a and Fig. 52b respectively. Both fractions exhibit comparable 
membrane protein enrichment to the Jurkat membrane fraction shown in Fig. 
24c, with plasma membrane GO annotations once again exceeding cytoplasmic 
and nuclear GO annotations in both instances. Interestingly, whilst similar total 
numbers of plasma membrane-annotated proteins and proteins predicted to 
possess transmembrane domains are identified in both mature and tolerogenic 
DC membrane fractions, the percentages are notably higher for the mature DC 
fraction by merit of the larger number of total proteins identified in the 
tolerogenic DC fraction. The aim was to inject identical amounts of peptide from 
both fractions and the total ion chromatograms (TICs) from the LC-MS runs 
seem to suggest that this was the case Fig. 53, with marginally more material in 
the mature DC fraction if anything. 
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  Total IDs 
351 
Plasma Membrane 
46.44% 
Cytoplasmic 
30.20% 
Nuclear 
27.07% 
 
 
Contains TMHMM-
predicted Helix 
33.33% 
 
Total IDs 
429 
Plasma Membrane 
36.83% 
Cytoplasmic 
34.50% 
Nuclear 
30.30% 
 
Contains TMHMM-
predicted Helix 
27.51% 
 
a) 
b) 
Figure 52: Pie charts illustrating the distribution of cellular component 
ontologies of proteins identified from LC-MS analysis of a) mature DC 
membranes and b) tolerogenic DC membranes prepared using the optimized 
stepwise depletion enrichment method described in Chapter 4 and digested 
using FASP. The number of total protein identifications; the percentages of total 
identifications with ‘plasma membrane’, ‘cytoplasmic’ and ‘nuclear’ annotation; 
and the percentage of proteins predicted to contain transmembrane domains by 
the TMHMM algorithm are also displayed.  
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Given the similar amounts of material contained in each fraction, it was 
reasoned that it would not be entirely unwarranted to make some very basic 
quantitative inferences in the absence of stable isotope labelling through 
comparison of the protein content of the two fractions. The identities of plasma 
membrane proteins identified exclusively in the mature fraction are shown in 
Table 11 and the identities of plasma membrane proteins identified exclusively 
in the tolerogenic fraction are shown in Table 12. Where a plasma membrane 
protein was detected in both fractions, emPAI scores were used to infer whether 
it appeared to be differentially expressed in one fraction relative to the other. 
The emPAI score of a protein is calculated by taking the exponent of the 
number of observed peptides over the number of theoretically observable 
peptides and subtracting one (Ishishama et al., 2005). It is proportional to 
protein content in a sample over around two orders of magnitude but it is worth 
noting that this relationship does not hold for emPAI values less than 0.1 (Kim 
et al., 2012). Plasma membrane proteins potentially exhibiting differential 
Figure 53: Total ion chromatograms from LC-MS analysis of a) mature DC 
membranes and b) tolerogenic DC membranes.  
a) 
b) 
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expression are shown in Table 13, whilst plasma membrane proteins appearing 
to be equally abundant in both fractions are shown in Table 14. For the sake of 
stringency, a protein was only taken as being a plasma membrane protein if it 
was assigned a plasma membrane GO annotation and had at least one 
TMHMM-predicted transmembrane helix. 
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Table 11: Proteins identified exclusively in mature DC membrane-enriched 
fraction. 
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Table 12: Proteins identified exclusively in tolerogenic DC membrane-enriched 
fraction. 
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Table 13: Proteins identified in both mature and tolerogenic DC membrane-
enriched fractions with emPAI scores suggesting differential expression. 
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Table 14: Proteins identified in both mature and tolerogenic DC membrane-
enriched fractions with emPAI scores suggesting commensurate expression. 
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7.6. Discussion (membrane proteomes) 
The case for making quantitative inferences in the absence of stable isotope 
labelling is strengthened somewhat by the fact that the majority of HLA Class II 
antigens have emPAI values which suggest that they are equally abundant in 
both mature and tolerogenic DCs, which is supported by cell surface profiling 
data from our group obtained using a pan-HLA-DR stain (Anderson et al., 
2008). In addition, the majority of HLA Class I antigens are detected exclusively 
in the mature DC fraction, which tallies with the observations of Ackerman et al. 
described above (Ackerman and Cresswell, 2003). 
Of the other proteins detected exclusively in the mature DC fraction or detected 
in both fractions with emPAI values suggesting greater abundance in the 
mature DC fraction, many can once again be reconciled with roles in DC 
maturation and immune activation. Interactions between Integrin beta-1 (CD29) 
(Table 11, protein 17) and fibronectin present in the extracellular matrix have 
been shown to be important in dendrite formation (Swetman Andersen et al., 
2006) and CD29 had been shown to be upregulated in murine DCs upon LPS 
stimulation in a previous proteomics study (Ferret-Bernard et al., 2012). Bone 
marrow stromal antigen 2 (CD317) (Table 11, protein 23) expression is induced 
in LPS-stimulated myeloid and monocyte-derived DCs and is thought to play a 
role in sequestration of viruses such as HIV-1 at the cell surface to prevent their 
dissemination to T cells (Blanchet et al., 2013). Intercellular adhesion molecule 
3 (CD50) (Table 11, protein 24) is the most abundantly expressed co-
stimulatory ligand for T cell lymphocyte function-associated antigen 1 on blood 
DCs (Starling et al., 1995) and integrin alpha-5 (CD49e) (Table 11, protein 28) 
expression is increased in lung DCs relative to peripheral blood monocytes 
(Nicod and el Habre, 1992). LPS-stimulated DCs from receptor-type tyrosine 
protein phosphatase C (CD45) (Table 13, protein 4) knockout mice exhibit a 
decreased capacity to elicit Th1 responses (Cross et al., 2008). Finally, CD44 
(Table 13, protein 11) expression appears to be important in conferring 
migratory properties to mature DCs (Weiss et al., 1997). 
Encouragingly, a number of the proteins detected exclusively in the tolerogenic 
DC fraction or detected in both fractions with emPAI values suggesting greater 
abundance in the tolerogenic DC fraction have been reported as having 
established or putative roles in tolerance induction. shRNA-mediated 
222 
 
knockdown of CD63 (Table 13, protein 17) in Epstein-Barr virus-transformed B 
lymphoblastoid cells has been shown to lead to increased CD4+ T cell activation 
through increased formation of MHC Class II-containing exosomes (Petersen et 
al., 2011). It has been suggested that high affinity immunoglobulin epsilon 
receptor subunit gamma (FcεRIγ) (Table 12, protein 2) forms a signalling 
complex with C-type lectin domain family 4 member C (CD303) which 
suppresses inflammatory cytokine production in plasmacytoid dendritic cells 
(Cao et al., 2007). Signalling lymphocyte activation molecule (CD150) (Table 
12, protein 3) is upregulated on monocyte-derived DCs treated with IL-10 
(McBride et al., 2002) and Taenia solium cysticerci (Adalid-Peralta et al., 2013), 
the latter being proposed as a parasite immune evasion strategy. Scavenger 
receptor cysteine-rich type protein M130 (CD163) (Table 12, protein 7) is known 
to be highly expressed and play a role in the anti-inflammatory properties of 
alternatively-activated macrophages (Moestrup and Moller, 2004); and has also 
previously been reported to be upregulated on dexamethasone-treated blood 
DCs (Maniecki et al., 2006). The haemoglobin-scavenging properties of CD163 
may provide more heme for degradation by heme oxygenase 1 (Table 12, 
protein 12), another protein detected exclusively in the tolerogenic DC 
membrane fraction. Heme oxygenase 1 expression by murine DCs has been 
shown to be essential for the suppression of effector T cell function by CD4+ 
CD25+ Tregs (George et al., 2008). Increased expression of these two proteins in 
tolerogenic DCs also ties in with the increased expression of biliverdin 
reductase observed in the quantitative profiling of the whole cell proteomes of 
mature and tolerogenic DCs, as biliverdin is a degradation product of heme. 
In murine XS106 cells (a DC cell line), co-stimulation of C-type lectin domain 
family 4 member M (CD299) (Table 12, protein 6) and TLR-2 with 
lipoarabinomannan and FSL-1 respectively suppresses NF-κB activation and 
pro-inflammatory cytokine production compared with FSL-1 stimulation alone 
(Ohtani et al., 2012). TLR-2 (Table 12, protein 16) itself has previously been 
shown to be upregulated on monocyte-derived tolerogenic DCs generated using 
dexamethasone and vitamin D3, both alone and in synergy, by our group (Harry 
et al., 2010) and others (Chamorro et al., 2009). A recent study also 
demonstrated that TLR-2 signalling in murine macrophages upregulates cell 
surface expression of the inhibitory Fc receptor FcγRIIB (CD32b) (Abdollahi-
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Roodsaz et al., 2013) (Table 12, protein 20). CD32 has previously been 
reported to be upregulated on monocyte-derived dendritic cells in response to 
treatment with both dexamethasone (Piemonti et al., 1999) and vitamin D3 
(Piemonti et al., 2000), though the antibody used in the studies did not 
differentiate between CD32a (activating Fc receptor FcγRIIA) and CD32b. 
CD32a is reported as being detected exclusively in the tolerogenic DC 
membrane fraction, although the peptide detected is shared with CD32b. 
Manual inspection of the total ion chromatograms for the peptide in question 
across the two fractions suggest it is relatively strongly detected in the 
tolerogenic DC fraction (approx. 1.5 × 104 counts) but completely absent in the 
mature DC fraction (Fig. 54). CD32b has previously been identified by our 
group as highly expressed on tolerogenic DCs but absent on mature DCs in a 
low density array (data not shown). This raises the exciting prospect that CD32b 
could be used as the much sought-after quality control marker of tolerogenic 
phenotype discussed in section 1.2.7. 
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Chapter 8. General Discussion 
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There is little doubt that tolerogenic dendritic cells represent a promising and 
innovative avenue for amelioration of autoimmune pathologies. They offer the 
prospect of specific and enduring suppression of autoreactive T cells whilst 
circumventing the side effects frequently observed when using global 
immunosuppressive agents. Tolerogenic DC therapy for rheumatoid arthritis at 
Newcastle University has shown promise in preclinical studies and has just 
recently entered the clinic. Further progression would be both facilitated and 
expedited through a more thorough understanding of the mechanisms through 
which the cells exert their effects and the establishment of a means to positively 
distinguish cells as being tolerogenic (thus safeguarding against undesirable 
immune reactivity upon reinoculation into patients). 
The overall aim of this body of work was to develop a mass spectrometry-based 
quantitative proteomics workflow in order to compare and contrast the plasma 
membrane proteomes of mature and tolerogenic DCs. Plasma membrane 
proteins are of paramount importance in determining the way in which a given 
cell responds to and interacts with its extracellular environment and other cells 
within it. It was envisaged that examining differential expression of plasma 
membrane proteins present on mature and tolerogenic DCs would enable the 
identification of cell surface markers of the tolerogenic phenotype and also 
identify proteins with a role in the induction and propagation of tolerance, 
thereby shedding light on some of the ambiguities in our understanding of the 
nature of tolerogenic DCs.   
The comprehensive realization of this aim required optimization and validation 
of various aspects of the bottom-up proteomic workflow described in section 
1.1.2. Specifically, it was necessary to develop methods to enable extraction 
and isolation of plasma membrane proteins prior to proteolytic digestion, 
thereby favouring their detection over the more abundant cytoplasmic and 
nuclear proteins also present in cell lysates without any enrichment. It was also 
important to provide a robust means of performing relative quantitation of 
proteins derived from two distinct biological samples (in this case mature and 
tolerogenic DCs). The non-replicative nature of monocyte-derived DCs and the 
LC-MS instrumentation employed throughout (ion trap) precluded the use of 
both metabolic labelling (SILAC) and reporter ion-based MS2 quantitation 
(iTRAQ / TMT) respectively and consequently necessitated the development 
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and optimization of a different method of stable isotope labelling distinct from 
these more commonly employed techniques. 
Herein we report that these two requirements have both been successfully met. 
Initial efforts to specifically isolate plasma membrane proteins using cell surface 
biotinylation and affinity purification did not turn out to be nearly as effective in 
practice as might have been anticipated. However, adaptation of a previously 
reported crude membrane extraction procedure (Wisniewski et al., 2009a) in 
which non-membrane molecules are sequentially depleted prior to proteome 
solubilization proved considerably more fruitful; outperforming the affinity 
purification strategy examined here and also yielding comparable plasma 
membrane proteome enrichment to that reported in a wide variety of previously 
published strategies, in spite of its relative technical simplicity and not 
exclusively enriching for plasma membrane proteins. The need to employ an 
alternative means of stable isotope labelling to SILAC and iTRAQ / TMT was 
initially explored through optimization of 18O-labelling such that all labelled 
peptides incorporated two 18O atoms at their C-termini. When limitations were 
subsequently identified pertaining to the quantitative accuracy and dynamic 
range of 18O-based quantitation (as detailed in Chapter 5), the optimized 18O-
labelling procedure was then further developed by coupling it with an N-terminal 
labelling procedure. This then enabled differential stable isotope labelling of 
peptide N- and C- termini and established what was, at the time, a novel means 
of MS2-level quantitation. This ‘isobaric peptide termini labelling’-based strategy 
(Koehler et al., 2009) exhibits a dynamic range of quantitation of around an 
order of magnitude in either direction; is compatible with both samples from any 
biological origin and a wide range of mass spectrometers; and is not subject to 
ratio compression effects owing to mixed MS/MS (Ow et al., 2009). 
In order to attain maximum proteome coverage, it was always our intention to 
perform peptide fractionation immediately prior to LC-MS analysis, although it 
was not anticipated that this stage of the bottom-up workflow would require 
optimization to the same extent. However, our experiments showed that peptide 
fractionation performed using OFFGEL electrophoresis (IEF) was negatively 
affected by the presence of N-terminal succinylation inherent to the IPTL 
methodology. This led to the exploration of alternative means of fractionation, 
culminating in the adoption and adaptation of a previously reported offline SAX 
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fractionation procedure (Wisniewski et al., 2009a). We incorporated two 
additional productive elution steps, the first at pH 2 and the second at pH 2 in 
combination with 50% acetonitrile. This procedure both fractionates unmodified 
peptides as effectively as that described in the published study and additionally 
fractionates succinylated peptides in a considerably more uniform manner than 
OFFGEL electrophoresis. In addition, use of the final two elution steps have not 
previously been reported in a mass spectrometry-based proteomics context. 
Whilst development  and optimisation of the steps of the overall workflow 
described above were carried out using both BSA (as a model protein) and a 
Jurkat cell line (as model cells); efforts were made throughout to apply aspects 
of this workflow to mature and tolerogenic DCs themselves. Quantitative 
analyses of the mature and tolerogenic DC whole cell proteomes were 
performed using both 18O-labelling and IPTL in combination with OFFGEL 
electrophoresis and qualitative profiling of the mature and tolerogenic DC 
membrane proteomes was performed with the aid of the optimized membrane 
extraction procedure. A number of the proteins identified as being differentially 
expressed in the quantitative analyses and inferred as being differentially 
expressed in the qualitative profiling have previously been reported as having 
roles in both immune activation and immune tolerance (see Chapter 7). Many 
others are less easily explained in the above context and it is also difficult to 
delineate those which may play roles in previously unreported aspects of the 
tolerogenic phenotype, especially in the absence of significant numbers of 
biological replicates. Nevertheless, as discussed in section 1.2.7., there is not a 
great deal known of the mechanisms by which our tolerogenic DCs induce 
tolerance and this profiling and comparison of the mature and tolerogenic DC 
membrane proteomes has putatively identified both a number of proteins which 
may potentially stimulate further inquiry and also a candidate quality control 
marker for tolerogenic cells in the form of CD32b. 
Much is made of the matchup between mass spectrometry-based proteomics 
and the more mature technology of transcriptomics, with some suggesting that 
the former is well placed to usurp the latter as the go-to means of scrutinizing 
biological systems from a panoptic perspective (Cox and Mann, 2007). There is 
little doubt that proteome analysis possesses a number of conceptual and 
material advantages over transcriptome analysis. Proteins are the principle 
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executors of biological function and proteomics provides a direct readout of their 
presence or abundance in a sample as opposed to the mRNA-based proxy 
readout produced by transcriptomics. mRNA abundance measurements cannot 
account for the effects of protein synthesis and decay rates on the protein 
complement of a cell and the most comprehensive study carried out to date to 
address the correlation between the two sets of biological macromolecules by 
Schwanhäusser et al. suggests that only around 40% of variation in protein 
abundance can be attributed to variation in mRNA abundance (Schwanhausser 
et al., 2011). Proteomics also allows for the identification and quantitation of 
post-translational modification isoforms, a further dimension of regulation 
imperceptible at the transcriptome level. On the other hand, transcriptomics 
continues to advance at a comparable pace to proteomics such that it is 
commonplace today for transcriptome data to document all transcribed gene 
products (Lundberg et al., 2010). Powerful technologies such as RNA-Seq and 
RT-PCR-Seq can provide an encyclopaedic snapshot of mRNA presence and 
abundance at any given point in time (Howald et al., 2012). Whilst it was 
determined at the outset that we would attempt to address the questions posed 
with regard to differential expression of mature and tolerogenic DC plasma 
membrane proteins using proteomics, they could equally have been tackled 
using transcriptomics. A transcriptomics approach may have given a faster 
readout of differential expression between the two cell types, enabling more 
time to be dedicated to functional follow-up studies of candidate proteins of 
interest for putative roles in tolerance induction. However, given the limitations 
described above, a proteomics approach was chosen on the basis that it was 
expected to deliver a more representative cell surface profile. In truth, 
transcriptomics and proteomics should not be seen as at odds with one another 
but rather as two complementary techniques which, when performed in tandem, 
have the potential to provide a more comprehensive picture of global protein 
expression than either is able to do in isolation.     
Given more time and with a little further work to bring all elements of this 
particular proteomics workflow together would have enabled a more expansive 
and comprehensive quantitative comparison of the membrane proteomes of 
mature and tolerogenic DCs to be undertaken. This is no mean feat in itself; 
indeed the vast majority of in-depth membrane proteome studies published to 
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date have been qualitative in nature (Vuckovic et al., 2013). One notable study 
utilized SILAC labelling, an ultracentrifugation / carbonate extraction membrane 
preparation method and GeLC-MS for relative quantitation of the membrane 
proteomes of self-renewing and differentiating human embryonic stem cells 
(hESCs) (Prokhorova et al., 2009). 1556 proteins were identified in total, of 
which 811 had a membrane GO annotation (although only 438 of these 811 
proteins also possessed at least one predicted transmembrane domain). Of the 
811 proteins, 702 were relatively quantified using at least two peptides and a 
number of candidate biomarkers of the hESC differentiation state were 
identified.  
It is not unreasonable to posit that a crucial consideration for the overall 
success of a membrane-directed quantitative proteomics study is the amount of 
peptide material that one has for LC-MS analysis having proceeded through the 
bottom-up workflow. Constraints can present in the form of limiting amounts of 
starting material and be compounded through sample losses as the workflow 
progresses. Such losses may be concurrent with specific steps of the workflow 
(for instance, around 50% of loaded material is typically recovered from the 
FASP procedure (Wisniewski et al., 2011)) or losses may simply occur through 
non-specific adsorption of proteins and peptides to laboratory plastics (Bark and 
Hook, 2007) and glassware (Stejskal et al., 2013). In the study by Prokhorova et 
al. outlined above, starting material was not limiting as replicative cell lines were 
used and SILAC labelling precluded the potential for sample losses during 
peptide-level stable isotope labelling. In our workflow, starting material is 
necessarily limited to the number of monocytes which can be isolated from a 
single component donation cone. In addition the proteomics workflow is 
somewhat more protracted when membrane isolation, digestion, C- and N- 
terminal labelling and peptide fractionation steps are considered collectively. It 
is unclear at present whether sufficient peptide material from our isolates can 
carry through the entire procedure to permit the thorough proteome coverage 
desired. This may represent a notable limitation of the workflow as a whole. On 
the other hand, if peptide material does not prove limiting, there is ample 
evidence in advocacy of the methods presented herein to suggest that a 
detailed and accurate quantitative comparison of the mature and tolerogenic DC 
membrane proteomes is certainly within reach. 
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As discussed at the very beginning of this thesis, mass spectrometry-based 
proteomics has come a long way since the turn of the century and has 
continued to develop at an unprecedented rate even within the period in which 
the work presented here was undertaken. Today, with the aid of long 
chromatography columns and gradients, ‘ultra’ performance LC instruments, 
and the latest mass spectrometers endowed with increased scanning speed, 
attomole sensitivity and ≥ 100 K resolving power; it is now feasible to identify 
thousands more distinct proteins in a single LC-MS run than was possible only 
5 years ago (Thakur et al., 2011). The performance of the instrumentation used 
throughout this body of work cannot match this latest high-end equipment in 
terms of scan speed and sensitivity but it can still be considered adequate in 
comparison to the present installed user base at most UK universities. For 
example, the second replicate of the SAX fractionation experiment for 
unmodified peptides shown in section 6.3.1.3. yielded 82559 total and 20713 
unique peptide identifications, equating to 4407 unique protein identifications; 
the largest number of identifications from a set of fractionated proteomic 
peptides during the course of this work by some distance and an impressive 
figure even by today’s standards. Notably, these LC-MS runs were carried out 
with a 50 cm column, suggesting that our current LC-MS setup is adequately 
equipped to benefit from the movement towards long columns currently taking 
place. Any future attempts to consolidate the findings herein into a finalised 
quantitative membrane proteomics workflow would undoubtedly benefit from the 
use of these longer columns. Although less immediately practicable, it would 
also be very interesting to see how the optimised workflow and its individual 
components would perform were analysis carried out using cutting-edge 
instrumentation.  
Of course, the identification of any potential biomarker is only the first phase in 
the protracted process which culminates in it becoming valuable from a clinical 
perspective, and differential expression of CD32b (and any future biomarkers) 
will have to be further validated using distinct approaches. Clinical biomarkers 
are commonly sought in biofluids (most frequently blood), in which case 
validation can be carried out through serum immunoassay (e.g. enzyme-linked 
immunosorbent assay (ELISA)). However, the nature of what is desired in this 
particular instance (quality control markers which conclusively define cells as 
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being tolerogenic ex vivo prior to intra-articular injection) means that the 
validation phase could be accomplished equally effectively using flow 
cytometry.  
Application of either of the above techniques requires the existence of good 
quality antibodies against the candidate biomarker of interest. Monoclonal 
antibodies are already available which differentiate between the various 
isoforms of CD32 (Veri et al., 2007) but it is possible that good quality 
antibodies against further biomarkers of the tolerogenic phenotype will not be 
available, particularly if they are less well characterized. If this proves to be the 
case, antibodies may be raised against molecules of interest using a technique 
such as selected lymphocyte antibody method (SLAM), which entails 
immunization of animals and subsequent isolation of B-cells specific to said 
molecules through haemolytic plaque assays (Babcook et al., 1996) or high-
throughput ELISA-based antigen binding assays. (Tickle et al., 2009). 
Alternatively, targeted mass spectrometry-based strategies using selected 
reaction monitoring coupled with stable isotope dilution of labelled standards 
(e.g. AQUA / QconCAT peptides) allows simultaneous monitoring of 30 – 100 
candidate biomarkers at detection thresholds up to 100 times lower than would 
be possible in an untargeted experiment (Keshishian et al., 2007). Sensitivity 
may be further increased using stable isotope standards and capture by anti-
peptide antibodies (SISCAPA), in which the peptides to be monitored are first 
enriched using anti-peptide antibodies (Anderson et al., 2004). These targeted 
strategies have the potential to circumvent the often protracted process of 
raising and validating novel protein antibodies entirely.                            
In conclusion, the proteomic methods developed and described herein are now 
well poised both to facilitate the potential identification and validation of further 
putative markers of the tolerogenic dendritic cell phenotype and beyond that, for 
possible future applications in the wider field of general proteomics. 
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